busulfan has been researched along with Graft-Versus-Host Disease in 731 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we explored in 121 patients, mostly with advanced stage diseases, a sirolimus-based, calcineurin-inhibitor-free prophylaxis of graft-versus-host disease (GvHD) to allow the infusion of unmanipulated peripheral blood stem cell (PBSC) grafts from partially HLA-matched family donors (TrRaMM study, Eudract 2007-5477-54)." | 9.20 | Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. ( Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M, 2015) |
| "For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective." | 9.20 | 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. ( Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S, 2015) |
| " Patients with hematologic malignancies for whom limited long-term survival was expected with standard therapy were administered an outpatient conditioning regimen of busulfan 3." | 9.20 | Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. ( Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N, 2015) |
| "The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies." | 9.19 | Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. ( Andersson, BS; Champlin, RE; de Lima, MJ; Furlong, T; Jones, RJ; Kanakry, CG; Luznik, L; Medeot, M; Mielcarek, M; O'Donnell, PV; Thall, PF; Wei, W, 2014) |
| "We aimed to evaluate the safety and efficacy of fludarabine (FLU) and pharmacokinetic-targeted busulfan (BU) as conditioning regimen for hematopoietic cell transplantation (HCT) in adult patients with acute lymphoid leukemia (ALL)." | 9.15 | Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. ( Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S, 2011) |
| "A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation." | 9.15 | Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. ( Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011) |
| "We assessed the combination of sirolimus, tacrolimus, and low-dose methotrexate as acute graft-versus-host disease (aGVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation from matched related (MRD, n = 46) and unrelated (URD, n = 45) donors." | 9.13 | Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. ( Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ, 2008) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 9.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| " The preparative therapy consisted of busulfan, melphalan, and antithymocyte globulin, with cyclosporine and corticosteroids for graft-versus-host disease (GVHD) prophylaxis." | 9.11 | Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. ( Brochstein, JA; Carter, SL; Frangoul, H; Goyal, RK; Horan, JT; Kamani, NR; Kapoor, N; Kernan, NA; Kurtzberg, J; Pietryga, D; Wagner, JE; Wall, DA, 2005) |
| "Decitabine is a hypomethylating agent that has activity in patients with leukemia." | 9.10 | Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. ( Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 9.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| "To study the toxicity and potential efficacy of busulfan (BU) and cyclophosphamide (CY) as a conditioning regimen before allogeneic bone marrow transplantation (ABMT) in patients with multiple myeloma (MM)." | 9.07 | Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. ( Appelbaum, FR; Beatty, P; Bensinger, WI; Bianco, JA; Buckner, CD; Clift, RA; Dalton, W; Fefer, A; Petersen, FB; Singer, JW, 1992) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 9.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML)." | 9.06 | Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. ( Copelan, EA; Klein, JP; Tutschka, PJ, 1987) |
| "Cyclophosphamide plus total body irradiation (CYTBI) and oral busulfan plus cyclophosphamide (BUCY) are commonly used conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in patients with leukemia." | 8.87 | Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. ( Dantkale, V; Gupta, T; Kannan, S; Laskar, S, 2011) |
| "Twenty-four children with beta-thalassemia major received abatacept at a dose of 10 mg/kg intravenously on days -1, +5, +14, and +28 after HSCT in addition to calcineurin inhibitors and methylprednisolone." | 8.02 | Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. ( Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L, 2021) |
| "The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID)." | 8.02 | Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. ( Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M, 2021) |
| " busulfan (Bu) has been the main conditioning regimens for allogeneic hematopoietic cell transplantation (alloHCT) for young patients with acute myelogenous leukemia (AML) eligible for a myeloablative conditioning (MAC) regimen." | 7.96 | Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up fro ( Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Armenian, S; Budde, E; Dadwal, S; Dandapani, S; Forman, SJ; Hui, S; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Murata-Collins, J; Nakamura, R; Peng, K; Pullarkat, V; Salhotra, A; Sandhu, KS; Snyder, D; Spielberger, R; Stein, A; Teh, JB; Wong, J; Yang, D, 2020) |
| " We retrospectively analyzed in a population of 670 children receiving allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body irradiation (TBI) and busulfan, as part of the preparative regimen." | 7.96 | Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec ( Balduzzi, A; Calore, E; Fagioli, F; Faraci, M; Favre, C; Giorgiani, G; Locatelli, F; Pagliara, D; Prete, A; Quarello, P; Saglio, F; Tambaro, FP; Zecca, M, 2020) |
| "In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results." | 7.96 | Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. ( Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G, 2020) |
| "Fludarabine and melphalan (Flu/Mel) has emerged as a more tolerable chemotherapy-based conditioning regimen compared with busulfan and cyclophosphamide (Bu/Cy) for allogeneic stem cell transplant (allo-hematopoietic stem cell transplantation (HSCT)) patients with acute myelogenous leukemia (AML)." | 7.88 | Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. ( Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK, 2018) |
| "To develop a stable mouse model of acute graft-versus-host disease (aGVHD) by preconditioning with busulfan (BS)-cyclophospha mide (CP)." | 7.81 | [Establishment of a mouse model of acute graft-versus-host disease by busulfan combined with cyclophosphamide]. ( Guo, K; He, X; Huang, Y; Wang, J; Xu, X; Ye, Y; Yi, W, 2015) |
| "We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies." | 7.80 | Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. ( Liu, W; Mao, XF; Wan, DM; Zhao, XF, 2014) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 7.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| " busulfan (Bu) is well tolerated and effective in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML)." | 7.76 | The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N, 2010) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 7.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| " We did a retrospective, multicenter analysis to assess the feasibility of conditioning with fludarabine and treosulfan before allogeneic SCT in multiple myeloma patients." | 7.74 | Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. ( Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L, 2007) |
| "The present clinical trial was undertaken to investigate the toxicity and antimyeloma activity of busulfan (BU) and cyclophosphamide (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive patients with multiple myeloma (MM)." | 7.70 | High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. ( Bandini, G; Belardinelli, A; Benni, M; Bonini, A; Cavo, M; Gozzetti, A; Lemoli, RM; Motta, MR; Rizzi, S; Ronconi, S; Rosti, G; Tura, S; Zamagni, E, 1998) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 7.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS)." | 7.68 | Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. ( Cronin, S; Dan, ME; de Planque, MM; Hussein, M; Karanes, C; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J, 1993) |
| "Cutaneous graft-versus-host disease (GVHD) has been reported after administration of cyclosporine (CSP) after autologous bone marrow transplantation (ABMT) with unpurged marrow in patients with lymphoma." | 7.68 | Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. ( Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM, 1992) |
| "Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide." | 7.66 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. ( Beschorner, WE; Bias, WB; Braine, HG; Brookmeyer, R; Burns, WH; Elfenbein, GJ; Kaizer, H; Santos, GW; Saral, R; Tutschka, PJ, 1983) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 6.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "Complete bioavailability of i." | 6.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 6.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| "Myalgia was reported in 37 patients; 34 patients in the treosulfan group and 3 patients in the busulfan group (p = 0." | 5.62 | Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool. ( Berghuis, D; Bredius, RGM; Buddingh, EP; Guchelaar, HJ; Lankester, AC; Mohseny, AB; Smiers, FJW; van der Stoep, MYEC; Zwaveling, J, 2021) |
| "Busulfan (Bu) is an alkylating agent routinely used for conditioning regimens before allogeneic stem cell transplantation (allo-SCT)." | 5.62 | Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie ( Bartoli, A; Bramanti, S; Castagna, L; De Gregori, S; De Philippis, C; Giordano, L; Mannina, D; Mariotti, J; Pieri, G; Roperti, M; Sarina, B; Valli, V, 2021) |
| "Factors independently associated with delayed puberty were extensive chronic GVHD (P = ." | 5.56 | Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. ( Dalle, JH; Lebon Labich, B; Leheup, B; Pochon, C; Weinhard, S; Wiedemann, A, 2020) |
| " Prophylactic T cell depletion via antithymocyte globulin (ATG) during ASCT conditioning is one of the standards of care for GVHD prophylaxis, although the optimal dosing strategy is still unclear." | 5.56 | Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ( Bene, MC; Blin, N; Chevallier, P; Debord, C; Dubruille, V; Duquesne, A; Eveillard, M; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Bris, Y; Le Gouill, S; Mahe, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Wuilleme, S, 2020) |
| "Busulfan is a major component of chemotherapy conditioning in hematopoietic cell transplantation (HCT)." | 5.51 | Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient. ( Bezinelli, LM; Carvalho, DLC; Corrêa, L; da Silva, CC; Eduardo, FP; Ferreira, MH; Gobbi, M; Hamerschlak, N; Rosin, FCP, 2019) |
| "Thirty-four patients had thalassemia major and 4 had SCA." | 5.43 | Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. ( Ben-Arush, M; Elhasid, R; Khalil, A; Rowe, JM; Zaidman, I, 2016) |
| " The responses and adverse events of the 2 groups were assessed." | 5.34 | [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia]. ( Li, J; Luo, SK; Peng, AH; Tong, XZ; Xu, DR; Zhang, GC; Zheng, D; Zou, WY, 2007) |
| "Busulfan was given once daily." | 5.32 | Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. ( Chan, KW; Gomez Almaguer, D; Gordon, N; Mullen, CA; Tran, H; Worth, L, 2003) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate for all patients, associated with ATG in 39 patients (76." | 5.30 | Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. ( Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A, 2019) |
| "Twenty-five consecutive patients with acute myelogenous leukemia (AML) underwent 26 allogeneic bone marrow transplants at Hahnemann University Hospital." | 5.28 | Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia. ( Bigler, R; Brodsky, I; Bulova, S; Crilley, P; Topolsky, D, 1990) |
| " For graft-versus-host disease (GVHD) prophylaxis, cyclosporine and methotrexate were administered." | 5.24 | Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. ( Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC, 2017) |
| " Here we explored in 121 patients, mostly with advanced stage diseases, a sirolimus-based, calcineurin-inhibitor-free prophylaxis of graft-versus-host disease (GvHD) to allow the infusion of unmanipulated peripheral blood stem cell (PBSC) grafts from partially HLA-matched family donors (TrRaMM study, Eudract 2007-5477-54)." | 5.20 | Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. ( Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M, 2015) |
| "For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective." | 5.20 | 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. ( Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S, 2015) |
| " Patients with hematologic malignancies for whom limited long-term survival was expected with standard therapy were administered an outpatient conditioning regimen of busulfan 3." | 5.20 | Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. ( Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N, 2015) |
| " AlloSCT was composed of RIC with busulfan/fludarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host disease (GVHD) prophylaxis." | 5.20 | Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. ( Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R, 2015) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate." | 5.19 | Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. ( Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE, 2014) |
| "The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies." | 5.19 | Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. ( Andersson, BS; Champlin, RE; de Lima, MJ; Furlong, T; Jones, RJ; Kanakry, CG; Luznik, L; Medeot, M; Mielcarek, M; O'Donnell, PV; Thall, PF; Wei, W, 2014) |
| "Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15)." | 5.17 | Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. ( Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R, 2013) |
| "We evaluated the incidence of GVHD, risk factors and the impact of graft composition on acute GVHD (aGVHD) in 92 children who underwent BMT for thalassemia following busulfan/cyclophosphamide (BUCY)-based conditioning regimens and GVHD prophylaxis with CSA/short-MTX and methylprednisolone." | 5.16 | Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia. ( Adorno, G; Alfieri, C; Andreani, M; Daniele, N; De Angelis, G; Del Proposto, G; Gallucci, C; Gaziev, J; Isgrò, A; Lanti, A; Lucarelli, G; Marziali, M; Paciaroni, K; Roveda, A; Saltarelli, F; Simone, MD; Sodani, P; Testi, M, 2012) |
| "Sixteen patients diagnosed with various hematologic malignancies participated in a phase II study evaluating the addition of rabbit antithymocyte globulin (rATG, Thymoglobulin(®)) to the hematopoietic cell transplant (HCT) conditioning regimen of IV fludarabine monophosphate (fludarabine) and targeted intravenous (IV) busulfan (fludarabine/(T)busulfan)." | 5.16 | A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. ( Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL, 2012) |
| " busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous leukemia/myelodysplastic syndromes (AML/MDS), recurrent leukemia posttransplantation remains a problem." | 5.15 | Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. ( Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL, 2011) |
| "We aimed to evaluate the safety and efficacy of fludarabine (FLU) and pharmacokinetic-targeted busulfan (BU) as conditioning regimen for hematopoietic cell transplantation (HCT) in adult patients with acute lymphoid leukemia (ALL)." | 5.15 | Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. ( Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S, 2011) |
| "A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation." | 5.15 | Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. ( Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011) |
| "From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70)." | 5.14 | Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR, 2009) |
| "Combination tacrolimus and sirolimus graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant in patients conditioned with a fractionated total body irradiation-based regimen has shown encouraging results." | 5.14 | A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. ( Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D, 2010) |
| "We report long-term results after a median follow-up of 105 months in 18 patients with multiple myeloma who received an intensified myeloablative conditioning regimen regimen consisting of modified total body irradiation, busulfan, cyclophosphamide, and antithymocyte globulin, followed by allogeneic stem cell transplantation (SCT)." | 5.14 | Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. ( Derigs, G; Einsele, H; Kröger, N; Krüll, A; Wandt, H; Zander, A, 2010) |
| "We assessed the combination of sirolimus, tacrolimus, and low-dose methotrexate as acute graft-versus-host disease (aGVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation from matched related (MRD, n = 46) and unrelated (URD, n = 45) donors." | 5.13 | Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. ( Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ, 2008) |
| "In the current study, we have analyzed the efficacy of cyclosporine A (CSA) plus mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis in the fludarabine plus melphalan or busulfan reduced intensity regimen (RIC) setting in a series of 44 patients receiving allogeneic transplantation from an unrelated donor." | 5.13 | Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ( Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D, 2008) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 5.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "This prospective study evaluated the outcomes of 75 successive patients receiving a FBC (fludarabine, busulphan, alemtuzumab) reduced-intensity conditioning (RIC) regimen for myelodysplastic syndromes (MDS) using volunteer unrelated donors(VUD)." | 5.12 | Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. ( Czepulkowski, B; Devereux, S; Duarte, RF; Ho, AY; Ingram, W; Kenyon, M; Lim, ZY; Mufti, GJ; Pagliuca, A; Pearce, L, 2006) |
| " Using conditioning consisting of fludarabine, busulfan, and anti-T-lymphocyte globulin and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients who had hematologic malignancies in an advanced stage or with a poor prognosis underwent transplantation using peripheral blood stem cells from an HLA-haploidentical donor (2-3 antigen mismatches in the graft-versus-host [GVH] direction) without T-cell depletion." | 5.12 | Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. ( Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S, 2006) |
| " Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-versus-host disease prophylaxis." | 5.12 | Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. ( Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T, 2007) |
| " Methotrexate only was given for graft-versus-host disease (GVHD) prophylaxis." | 5.11 | Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. ( Alonzo, TA; Barnard, DR; Buxton, AB; Gold, S; Kalousek, D; Kobrinsky, N; Lange, BJ; Neudorf, S; Sanders, J; Wallace, JD; Woods, WG, 2004) |
| " We report the results of allografting following conditioning with fludarabine, busulphan, and alemtuzumab in 62 patients with myelodysplastic syndromes (MDSs) (matched sibling donors [24] or volunteer unrelated donors [VUDs, 38])." | 5.11 | Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. ( Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE, 2004) |
| " Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD." | 5.11 | CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. ( Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R, 2005) |
| " The preparative therapy consisted of busulfan, melphalan, and antithymocyte globulin, with cyclosporine and corticosteroids for graft-versus-host disease (GVHD) prophylaxis." | 5.11 | Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. ( Brochstein, JA; Carter, SL; Frangoul, H; Goyal, RK; Horan, JT; Kamani, NR; Kapoor, N; Kernan, NA; Kurtzberg, J; Pietryga, D; Wagner, JE; Wall, DA, 2005) |
| "Decitabine is a hypomethylating agent that has activity in patients with leukemia." | 5.10 | Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. ( Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003) |
| " The conditioning regimen was cyclophosphamide (160 mg/kg) and busulfan (10-14 mg/kg), followed by unmanipulated bone marrow (median of 5&10(8) cells/kg) and CyA (+MTX in two patients) for prophylaxis of graft-versus-host disease (GvHD)." | 5.09 | Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. ( Bacigalupo, A; Benvenuto, F; Berisso, G; Bregante, S; Figari, O; Frassoni, F; Gualandi, F; Lamparelli, T; Mordini, N; Raiola, AM; Van Lint, MT, 2000) |
| " Cyclosporin A and short methotrexate were used for graft-versus-host disease (GVHD) prophylaxis." | 5.08 | Combined transplantation of allogeneic bone marrow and CD34+ blood cells. ( Arseniev, L; Bähre, O; Battmer, K; Berenson, RJ; Casper, J; Diedrich, H; Jacobs, R; Kadar, JG; Kühl, J; Link, H; Poliwoda, H; Schubert, J, 1995) |
| "67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease." | 5.08 | Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. ( Allerton, JP; Callander, N; Essell, JH; Halvorson, R; Harman, GS; Lew, V; Lewis, SK; Schroeder, MT; Snyder, M; Thompson, JM, 1998) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 5.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| " Cyclosporine, methotrexate and prednisone were used for graft-versus-host disease (GVHD) prophylaxis." | 5.07 | Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. ( Angelucci, E; Baronciani, D; Erer, B; Galimberti, M; Gaziev, D; Giardini, C; Lucarelli, G; Polchi, P; Rapa, S; Ripalti, M, 1994) |
| "To study the toxicity and potential efficacy of busulfan (BU) and cyclophosphamide (CY) as a conditioning regimen before allogeneic bone marrow transplantation (ABMT) in patients with multiple myeloma (MM)." | 5.07 | Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. ( Appelbaum, FR; Beatty, P; Bensinger, WI; Bianco, JA; Buckner, CD; Clift, RA; Dalton, W; Fefer, A; Petersen, FB; Singer, JW, 1992) |
| " Based on this concept, 17 patients with refractory or relapsed leukemia or lymphoma undergoing either autologous or allogeneic bone marrow transplantation (BMT) were treated on a Phase I protocol using high doses of busulfan (16 mg/kg, days -10, -9, -8, -7) and cyclophosphamide (120 mg/kg, days -6, -5) followed by escalating doses of a 48-h continuous infusion of cytarabine (starting dose 1000 mg/m2/48 h, days -3, -2)." | 5.07 | Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. ( Chandler, C; Devine, S; Geller, RB; Larson, RA; Myers, S; O'Toole, K; Park, CL; Topper, RL; Williams, SF, 1992) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 5.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML)." | 5.06 | Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. ( Copelan, EA; Klein, JP; Tutschka, PJ, 1987) |
| "Cyclophosphamide plus total body irradiation (CYTBI) and oral busulfan plus cyclophosphamide (BUCY) are commonly used conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in patients with leukemia." | 4.87 | Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. ( Dantkale, V; Gupta, T; Kannan, S; Laskar, S, 2011) |
| "We retrospectively reviewed 17 consecutive bone marrow failure patients who underwent unrelated umbilical cord blood transplantation in our center and received conditioning regimens of Total Body Irradiation (TBI) or Busulfan (BU) + Fludarabine (FLU) + Cyclophosphamide (CY)." | 4.84 | Outcome of first or second transplantation using unrelated umbilical cord blood without ATG conditioning regimen for pediatric bone marrow failure disorders. ( Chen, X; Chen, Y; Guo, Y; Liu, F; Ren, Y; Wan, Y; Yang, W; Zhang, L; Zhu, X; Zou, Y, 2024) |
| " Cyclosporine- cyclophosphamide-mycophenolate mofetil was the most widely used graft-versus-host disease prophylaxis regimen." | 4.31 | A single-center experience of haploidentical stem cell transplantation in hematological malignancies. ( Akdemir, NB; Büyükaşık, Y; Demiroğlu, H; Göker, H; Haznedaroğlu, İC; Karakulak, EA; Malkan, ÜY; Özcebe, Oİ; Sayınalp, N; Tekin, F, 2023) |
| " We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis." | 4.31 | Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. ( Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA, 2023) |
| "We report three adult patients with primary immunodeficiency (PID) treated with reduced-intensity allogenic hematopoietic cell transplantation (HCT) with fludarabine/treosulfan conditioning and graft-versus-host disease (GvHD) prophylaxis with alemtuzumab and a calcineurin inhibitor." | 4.12 | Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series. ( Arranto, C; Dalla Via, V; Heim, D; Junker, T; Matteazzi, F; Medinger, M; Passweg, JR; Recher, M; Stelmes, A; van den Berg, J, 2022) |
| " The graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate." | 4.12 | Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. ( Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI, 2022) |
| " Cyclosporine gave as preferred graft-versus-host disease prophylaxis with a short course of methotrexate." | 4.12 | Successful Allogeneic Peripheral Blood Stem Cell Transplantation in 4 Wiskott-Aldrich Syndrome Patients. ( Ahmed Nacer, R; Ait Ouali, D; Baazizi, M; Benakli, M; Bouarab, H; Hamladji, RM; Harieche, F; Mehdid, F; Rahmoune, N; Zerkout, S, 2022) |
| "Twenty-four children with beta-thalassemia major received abatacept at a dose of 10 mg/kg intravenously on days -1, +5, +14, and +28 after HSCT in addition to calcineurin inhibitors and methylprednisolone." | 4.02 | Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. ( Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L, 2021) |
| "The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID)." | 4.02 | Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. ( Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M, 2021) |
| "One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis." | 4.02 | Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. ( Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A, 2021) |
| " busulfan (Bu) has been the main conditioning regimens for allogeneic hematopoietic cell transplantation (alloHCT) for young patients with acute myelogenous leukemia (AML) eligible for a myeloablative conditioning (MAC) regimen." | 3.96 | Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up fro ( Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Armenian, S; Budde, E; Dadwal, S; Dandapani, S; Forman, SJ; Hui, S; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Murata-Collins, J; Nakamura, R; Peng, K; Pullarkat, V; Salhotra, A; Sandhu, KS; Snyder, D; Spielberger, R; Stein, A; Teh, JB; Wong, J; Yang, D, 2020) |
| "30) versus busulfan-based myeloablative regimens; were diagnosed with acute graft-versus-host disease (GVHD) with stage 2+ skin involvement (OR = 1." | 3.96 | Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. ( Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA, 2020) |
| " busulfan and post-transplant graft-versus-host disease (GVHD) prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil." | 3.96 | Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen. ( Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Iamsirirak, P; Jetsrisuparb, A; Lektrakul, Y; Meekaewkunchorn, A; Pakakasama, S; Pongphitcha, P; Rujkijyanont, P; Sanpakit, K; Sirachainan, N; Sirireung, S; Songdej, D; Sruamsiri, R; Surapolchai, P; Wahidiyat, PA, 2020) |
| " We retrospectively analyzed in a population of 670 children receiving allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body irradiation (TBI) and busulfan, as part of the preparative regimen." | 3.96 | Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec ( Balduzzi, A; Calore, E; Fagioli, F; Faraci, M; Favre, C; Giorgiani, G; Locatelli, F; Pagliara, D; Prete, A; Quarello, P; Saglio, F; Tambaro, FP; Zecca, M, 2020) |
| "In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results." | 3.96 | Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. ( Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G, 2020) |
| "Fludarabine and melphalan (Flu/Mel) has emerged as a more tolerable chemotherapy-based conditioning regimen compared with busulfan and cyclophosphamide (Bu/Cy) for allogeneic stem cell transplant (allo-hematopoietic stem cell transplantation (HSCT)) patients with acute myelogenous leukemia (AML)." | 3.88 | Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. ( Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK, 2018) |
| "We successfully used a haploidentical transplantation protocol with posttransplant cyclophosphamide (CY) (50 mg/kg/d on days +3 and +4) for in vivo T-cell depletion in patients with mucopolysaccharidosis using reduced-intensive conditioning regimens, followed by a busulfan-based conditioning regimen, which included busulfan (12 to 16 mg/kg) and fludarabine(150 to 200 mg/m)+rabbit antihuman thymocyte globulin (7." | 3.88 | Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis. ( Feng, S; Li, J; Liu, R; Shi, X; Song, Z; Yue, Y, 2018) |
| "To further investigate the role of treosulfan conditioning in children, the EBMT Pediatric diseases working party performed a retrospective analysis of 193 children with hematological malignancies (ALL n = 71, AML n = 47, MDS/MPS n = 40, other leukemia/lymphoma n = 25) undergoing allogeneic HSCT following treosulfan between January 2005 and July 2010." | 3.83 | European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. ( Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M, 2016) |
| " Of these, 33 received RIC with fludarabine, cyclophosphamide, and rituximab (FCR) and graft-versus-host disease (GVHD) prophylaxis with a calcineurin inhibitor and mini-methotrexate, and 61 received RIC with fludarabine and busulfan (FluBu) and GVHD prophylaxis with a calcineurin inhibitor and mycophenolate mofetil." | 3.83 | Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. ( Chinratanalab, W; Engelhardt, BG; Goodman, SA; Greer, JP; Jagasia, M; Kassim, AA; Kennedy, VE; Savani, BN; Sengsayadeth, S, 2016) |
| "The clinical data of 190 patients with hematological malignancies undergoing sUCBT between April 2000 and December 2013 at Department of Hematology, Anhui Provincial Hospital were retrospectively analyzed, of whom 156 received IMCR without ATG (IMCR group), including 79 patient receiving total body irradiation (TBI)/cytosine arabinoside (Ara-C)/cyclophosphamide (CY) regime, 47 receiving fludarabine (Flu)/busulfan (Bu)/CY regime, and 30 receiving Ara-C/Bu/CY regime, and all of the 156 received a combination of cyclosporine A (CsA) and mycophelonate mofetil (MMF) for the prophylaxis of graft-versus-host disease (GVHD); the remaining 34 patients received MCR (MCR group), 30 patients receiving Bu/CY regime, and 4 receiving TBI/CY regime, all using CsA/MMF±ATG or methotrexate (MTX) for the prophylaxis of GVHD." | 3.83 | [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. ( Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY, 2016) |
| "25 mg/kg/day on days -4 to -1) and graft-versus-host disease (GVHD) prophylaxis with tacrolimus and methotrexate were used in all patients." | 3.81 | A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH, 2015) |
| "To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and secondary acute myelogenous leukemia (MDS-AML) using conditioning regimen with busulfan (Bu) and increased-dose of fludarabine (ID-Flu)." | 3.81 | [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. ( Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J, 2015) |
| "To develop a stable mouse model of acute graft-versus-host disease (aGVHD) by preconditioning with busulfan (BS)-cyclophospha mide (CP)." | 3.81 | [Establishment of a mouse model of acute graft-versus-host disease by busulfan combined with cyclophosphamide]. ( Guo, K; He, X; Huang, Y; Wang, J; Xu, X; Ye, Y; Yi, W, 2015) |
| "Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD)." | 3.80 | A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. ( Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Coso, D; Crocchiolo, R; D'Incan, E; Devillier, R; El-Cheikh, J; Etienne, A; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Picard, C; Schiano, JM; Stoppa, AM; Vey, N, 2014) |
| "We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies." | 3.80 | Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. ( Liu, W; Mao, XF; Wan, DM; Zhao, XF, 2014) |
| " To prevent from graft-versus-host disease (GVHD), cyclosporin A and short term methotrexate (MTX) were used." | 3.80 | [The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation]. ( Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B, 2014) |
| "Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML)." | 3.79 | Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia worki ( Aljurf, M; Ben Othman, T; Campos, A; Labopin, M; Masszi, T; Michallet, M; Mohty, M; Nagler, A; Passweg, J; Poire, X; Rocha, V; Sengelov, H; Shimoni, A; Socie, G; Unal, A; Veelken, H; Volin, L; Yakoub-Agha, I, 2013) |
| " All the patients were conditioned with cyclophosphamide and busulfan, and treated with cyclosporin (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis." | 3.77 | Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. ( Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y, 2011) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine A and, for unrelated donors, short course of methotrexate and anti-T-lymphocyte globulin." | 3.77 | Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience. ( Baran, J; Czogała, W; Goździk, J; Krasowska-Kwiecień, A; Pituch-Noworolska, A; Skoczeń, S; Wędrychowicz, A; Wiecha, O; Zembala, M, 2011) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 3.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| " busulfan (Bu) is well tolerated and effective in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML)." | 3.76 | The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N, 2010) |
| " Conditioning regimen consisted of busulfan (16 mg/kg) and cyclophosphamide (160 mg/kg) followed by cyclosporine and methotrexate as graft-versus-host disease prophylaxes." | 3.76 | Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. ( Ashouri, A; Babaie, MH; Ghavamzadeh, A; Iravani, M; Khatami, F; Tavakoli, E, 2010) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A (CsA) alone (n = 3) or in addition to methotrexate (MTX; n = 132) or mycophenolate mofetil (MMF; n = 51)." | 3.75 | Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. ( Barba, P; Briones, J; Brunet, S; Delgado, J; Martino, R; Moreno, E; Piñana, JL; Sierra, J; Sureda, A; Valcárcel, D; Vega, M, 2009) |
| " The addition of melphalan was an independent risk factor; melphalan use combined with high busulfan exposure (AUC >74 mg x h/L) was associated with high incidences of aGVHD (58%), veno-occlusive disease (66%), and mucositis grade III-IV (26%)." | 3.75 | Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. ( Bartelink, IH; Belitser, SV; Bierings, M; Boelens, JJ; Bredius, RG; Egberts, AC; Egeler, M; Knibbe, CA; Lankester, AC; Suttorp, MM; Zwaveling, J, 2009) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 3.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG)." | 3.74 | Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. ( Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ, 2008) |
| " We did a retrospective, multicenter analysis to assess the feasibility of conditioning with fludarabine and treosulfan before allogeneic SCT in multiple myeloma patients." | 3.74 | Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. ( Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L, 2007) |
| " Graft-versus-host disease (GVHD) prophylaxis included methotrexate, cyclosporine A, and rabbit antithymocyte globulin (Thymoglobulin)." | 3.74 | Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR, 2007) |
| " Conditioning regimens consisted of busulfan and cyclophosphamide, followed by cyclosporine +/- methotrexate for graft-versus-host disease (GVHD) prophylaxis." | 3.74 | Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. ( Alimoghaddam, K; Ashouri, A; Ghaffari, H; Ghavamzadeh, A; Hadjibabaie, M; Iravani, M; Mahdavi, N; Mousavi, SA; Namdar, R; Nedaeifard, L; Shamshiri, A, 2008) |
| " Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and methotrexate." | 3.73 | Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. ( Furst, DE; Georges, GE; Henstorf, G; Langston, AA; Lee, J; McSweeney, PA; Nash, RA; Nelson, JL; Shulman, H; Storb, R; Sullivan, KM; Wener, M, 2006) |
| " In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)." | 3.72 | Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003) |
| " Group A (n=5) received metronidazole as graft-versus-host disease prophylaxis during Bu treatment." | 3.72 | The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ( Aschan, J; Hassan, M; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O, 2003) |
| "All patients were transplanted between 1992 and 1999, were >or= 18 years of age, received either cyclophosphamide/total-body irradiation (TBI) or busulfan/cyclophosphamide conditioning regimens, and received four doses of methotrexate for graft-versus-host disease prophylaxis post-transplant." | 3.72 | Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. ( Bruemmer, B; Lloid, ME; Potter, JD; Robien, K; Schubert, MM; Ulrich, CM, 2004) |
| "Postulating favorable antileukemic effect with improved safety, we used intravenous busulfan and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 3.72 | Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X, 2004) |
| "The results showed that the intravenous busulfan-based regimen had better compliance and less adverse effects including mucositis, hepatic toxicity, transplant-related hepatic veno-occlusive disease, and acute graft-versus-host disease than oral busulfan-based treatment." | 3.72 | Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: the preliminary experience in Taiwan. ( Bai, LY; Chang, CY; Chen, PM; Chiou, TJ; Hsiao, LT; Hung, GY; Lee, MY, 2004) |
| "Twelve patients with leukemia, including 4 in complete remission, whose HLAs were full matched with donors, and 8 with refractory leukemia, whose HLAs were mismatched, were transplanted with G-CSF mobilized allogeneic peripheral blood stem cells after conditioned with a regimen consisting of fludarabine (30 mg/m(2) x 6 days), busulfan (4 mg/kg x 2 days) and cyclophosphamide (30 approximately 60 mg/kg x 2 days) (FBC)." | 3.71 | [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation]. ( Guo, K; Song, Z; Wu, B; Xiao, L; Yan, D; Yang, Y, 2002) |
| "Using nonmyeloablative, immunosuppressive, fludarabine (FLU)-based conditioning regimens, we have performed allogeneic peripheral blood stem cell transplants in 26 patients (8 with chronic myelogenous leukemia, 6 with acute myelogenous leukemia, 10 with acute lymphoblastic leukemia, 1 with myelodysplasia, and 1 with thalassemia major)." | 3.71 | Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. ( Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ, 2001) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine and a short course of methotrexate." | 3.71 | A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. ( Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR, 2001) |
| " Graft-versus-host disease (GVHD) prophylaxis was attempted with cyclosporine A (CYA) and methotrexate." | 3.70 | [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. ( Hirabayashi, N; Ikeda, Y; Ishida, A; Matsuoka, S; Moriki, T; Okamoto, S; Wakui, M; Watanabe, R, 1998) |
| "The present clinical trial was undertaken to investigate the toxicity and antimyeloma activity of busulfan (BU) and cyclophosphamide (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive patients with multiple myeloma (MM)." | 3.70 | High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. ( Bandini, G; Belardinelli, A; Benni, M; Bonini, A; Cavo, M; Gozzetti, A; Lemoli, RM; Motta, MR; Rizzi, S; Ronconi, S; Rosti, G; Tura, S; Zamagni, E, 1998) |
| " Graft-versus-host disease (GVHD) prophylaxis was cyclosporin, prednisolone and low-dose antithymocyte globulin." | 3.70 | Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin. ( Haghshenas, M; Khojasteh, HN; Ramzi, M; Zakerinia, M, 1999) |
| "The purpose of this study was to evaluate the influence of busulfan (BU) pharmacokinetics on survival, grades II-IV acute graft-versus-host disease (GVHD), non-relapse mortality (NRM) and relapse in a group composed of 45 children (<18 years) and seven adults with acute myeloid leukemia (AML) in first complete remission and undergoing hematopoietic stem cell transplantation (SCT)." | 3.70 | Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. ( Baker, KS; Blazar, BR; Bostrom, B; DeFor, T; Ramsay, NK; Woods, WG, 2000) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion with IgM monoclonal antibody T10B9 plus complement and posttransplant cyclosporine-A." | 3.69 | Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. ( Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R, 1995) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 3.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| " For graft-versus-host disease prophylaxis patients received cyclosporin A (CSA) and methotrexate (MTX) (n=32), MTX alone (n=12), CSA and methylprednisone (n=5), or CSA alone (n=13)." | 3.69 | Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. ( Brugger, SA; Dieckmann, KU; Fischer, G; Geissler, K; Greinix, HT; Haas, O; Hinterberger, W; Hocker, P; Jager, U; Kalhs, P; Keil, F; Lechner, K; Linkesch, W; Mannhalter, C; Reiter, E; Schneider, B; Schwarzinger, I, 1996) |
| "Twenty-five patients with hematologic malignancies were treated with busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg x 3 days) as conditioning for bone marrow transplantation using marrow from serologically matched, DR locus genotypically identical unrelated donors." | 3.69 | Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. ( Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D, 1996) |
| "Between September 1987 and December 1994, 80 patients with multiple myeloma (MM) received high-dose busulfan and cyclophosphamide without (n = 57) or with modified total body irradiation (n = 23) followed by marrow from allogeneic donors." | 3.69 | Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. ( Anasetti, C; Appelbaum, FR; Barnett, T; Bensinger, WI; Buckner, CD; Chauncey, T; Clift, R; Shulman, H; Storb, R, 1996) |
| "Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS)." | 3.68 | Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. ( Cronin, S; Dan, ME; de Planque, MM; Hussein, M; Karanes, C; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J, 1993) |
| "Cutaneous graft-versus-host disease (GVHD) has been reported after administration of cyclosporine (CSP) after autologous bone marrow transplantation (ABMT) with unpurged marrow in patients with lymphoma." | 3.68 | Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. ( Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM, 1992) |
| "Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide." | 3.66 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. ( Beschorner, WE; Bias, WB; Braine, HG; Brookmeyer, R; Burns, WH; Elfenbein, GJ; Kaizer, H; Santos, GW; Saral, R; Tutschka, PJ, 1983) |
| "Strategies to reduce recurrence are urgently required." | 3.01 | Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021) |
| "Most patients with juvenile myelomonocytic leukemia (JMML) are curable only with allogeneic hematopoietic cell transplantation (HCT)." | 2.87 | Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. ( Cairo, MS; Cooper, T; Dang, H; Dvorak, CC; Gao, Y; Grupp, SA; Hirsch, B; Kahwash, S; Loh, ML; Mazor, T; Mehta, PA; Olshen, AB; Parker, JS; Patel, N; Pei, Q; Raimondi, S; Satwani, P; Skeens, M; Stieglitz, E; Wall, D, 2018) |
| "Busulfan levels were monitored to avoid excess toxicity." | 2.84 | Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. ( Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA, 2017) |
| " The efficacy and safety of both dosing strategies were compared using a systematic review and meta-analysis." | 2.82 | Fixed-dose administration and pharmacokinetically guided adjustment of busulfan dose for patients undergoing hematopoietic stem cell transplantation: a meta-analysis and cost-effectiveness analysis. ( Chen, C; Chen, T; Guo, J; He, X; Liu, M; Zheng, B, 2022) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 2.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "Forty-three patients with high-risk hematologic malignancies (median age, 43 years) were enrolled between December 2011 and September 2013." | 2.82 | Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. ( Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE, 2016) |
| " Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab." | 2.80 | Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. ( Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G, 2015) |
| "Fifty-four patients with advanced hematologic malignancies were enrolled on this study." | 2.80 | Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. ( Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W, 2015) |
| "Busulfan was administered mainly intravenously and exceptionally orally from days -5 to -3." | 2.79 | Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. ( Ahmad, I; Albert, MH; Belohradsky, BH; Bredius, R; Fasth, A; Fernandes, JF; Fischer, A; Gaspar, HB; Gennery, A; Gruhn, B; Güngör, T; Haddad, E; Hassan, M; Hough, R; Kentouche, K; Lachance, S; Moshous, D; Rentsch, K; Resnick, IB; Schanz, U; Schlegel, PG; Seger, R; Shaw, PJ; Slatter, M; Stepensky, P; Stussi, G; Teira, P; Telles da Cunha, JM; Vermont, C; Veys, P, 2014) |
| "Secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/sAML) are the most serious secondary events occurring after immunosuppressive therapy in patients with aplastic anemia." | 2.79 | Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. ( Baumann, I; Führer, M; Furlan, I; Göhring, G; Niemeyer, CM; Nöllke, P; Schlegelberger, B; Schwarz, S; Strahm, B; Teigler-Schlegel, A; Walther, JU; Yoshimi, A, 2014) |
| "In AML patients, minimal residual disease (MRD; n = 10) at the time of HCT predicted higher relapse incidence (70% versus 18%) and lower OS (41% versus 79%) at 2 years, when compared with patients without MRD." | 2.79 | Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. ( Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B, 2014) |
| " We conducted a phase I/II controlled, adoptive, randomized study to determine the optimal dosing schedule of i." | 2.78 | Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. ( Anderlini, P; Bassett, R; Champlin, R; de Lima, M; Ganesan, P; Giralt, S; Kebriaei, P; Khouri, I; Parmar, S; Rondon, G; Thall, P, 2013) |
| " We sought to determine the safety of GO in combination with busulfan/cyclophosphamide (Bu/Cy) conditioning before allogeneic hematopoietic stem cell transplantation (alloSCT)." | 2.77 | A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regim ( Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Dela Cruz, F; Duffy, D; Foley, S; Garvin, JH; George, D; Hawks, R; Jin, Z; Le Gall, J; Morris, E; Satwani, P; Schwartz, J; van de Ven, C, 2012) |
| "Busulfan has a narrow therapeutic range, and in children, pharmacokinetic variability has been found to be high even after the use of intravenous (i." | 2.77 | Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ( Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ, 2012) |
| "Busulfan (1." | 2.77 | Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. ( Atsuta, Y; Fukumoto, M; Inamoto, Y; Karasuno, T; Kohno, A; Kuwatsuka, Y; Miyamura, K; Morishita, Y; Murata, M; Nagafuji, K; Naoe, T; Saito, S; Sawa, M; Shimada, K; Suzuki, R; Taniguchi, S; Terakura, S; Yasuda, T, 2012) |
| " This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT." | 2.77 | Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. ( Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M, 2012) |
| "The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥ 55 years of age remains to be determined." | 2.76 | Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. ( Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W, 2011) |
| "BU used to treat patients with acute lymphoblastic leukemia (ALL)." | 2.76 | Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. ( Chen, YB; Hu, J; Shen, ZX; Tang, W; Wang, L; Zhao, WL, 2011) |
| "Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens." | 2.73 | Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. ( Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ, 2007) |
| "Diagnosis was primary myelofibrosis in 18 patients and secondary myelofibrosis in 6 patients; in 4 of them, primary myelofibrosis evolved from polycythemia vera, and in 2 of them from essential thrombocythemia." | 2.73 | Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. ( Bethge, W; Bornhäuser, M; de Witte, T; Kobbe, G; Kröger, N; Kvasnicka, HM; Schubert, J; Schwerdtfeger, R; Thiele, J; Zander, A, 2007) |
| " To decrease acute toxicities, we have prospectively evaluated a reduced intensity conditioning (RIC) regimen using targeted dosing of i." | 2.72 | Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. ( Baxter-Lowe, LA; Cowan, M; Desantes, K; Englert, L; Horn, B; McMillan, A; Quinn, M, 2006) |
| "Busulfan was added at the dose of 4 mg/kg to 200 mg/kg cyclophosphamide in 81 patients (3-53 years, median 24) with aplastic anemia to reduce graft rejection." | 2.71 | Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. ( Aranha, FJ; Bacigalupo, A; Chamone, DA; Da Silva, RL; De Souza, CA; Dulley, FL; Macedo, MC; Mehta, J; Ruiz, MA; Saboya, R; Sturaro, D; Vigorito, AC, 2004) |
| " qd is a safe and effective regimen for allogeneic transplantation and is at least clinically equivalent to every 6 h dosing schemes using either oral or parenteral Bu." | 2.71 | Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. ( Agura, ED; Berryman, RB; Fay, JW; Mamlouk, K; Pineiro, LA; Sandler, I; Saracino, G; Vance, EA; White, M, 2005) |
| " Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML." | 2.71 | Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. ( Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K, 2005) |
| "Complete bioavailability of i." | 2.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| " A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics." | 2.70 | A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ( Aschan, J; Eber, S; Gungor, T; Hassan, M; Hassan, Z; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O; Seger, R; Winiarski, J, 2002) |
| "Cladribine (2-CdA) is a purine analogue that exhibits activity against a variety of hematological malignancies and has a potent immunosuppressive effect." | 2.70 | Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. ( Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H, 2002) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 2.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| "Leukemic recurrence was observed in eight patients." | 2.68 | Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. ( Bernaudin, F; Cornu, G; Demeocq, F; Donadieu, J; Esperou-Bourdeau, H; Mechinaud-Lacroix, F; Michel, G; Sadoun, A; Souillet, G; von Bueltzingsloewen, A, 1995) |
| "Fifty-two BMT institutions were sent a questionnaire asking for details of dosing for busulphan, cyclophosphamide (bu-cy), cyclosporin and methotrexate (CSA-MTX)." | 2.68 | Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. ( Grigg, A; Harun, MH; Szer, J, 1997) |
| "Busulphan (BU) pharmacokinetic (PK) studies in children undergoing bone marrow transplantation suggest that individual BU dosing may be necessary to optimise BU systemic exposure." | 2.68 | An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. ( Calderwood, S; Chattergoon, DS; Doyle, J; Freedman, MH; Klein, J; Koren, G; Saunders, EF, 1997) |
| "One hundred fifteen patients with chronic myelocytic leukemia (CML) were administered busulphan 4 mg/kg for 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from histocompatible sibling donors." | 2.67 | Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. ( Atkinson, K; Avalos, B; Biggs, JC; Concannon, AJ; Crilley, P; Dodds, A; Downs, K; Kapoor, N; Szer, J; Tutschka, P, 1992) |
| "One hundred twenty-seven patients with acute myelocytic leukemia (AML) were given busulfan 4 mg/kg on each of 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or one antigen disparate sibling." | 2.67 | Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. ( Atkinson, K; Avalos, BR; Biggs, JC; Copelan, EA; Crilley, P; Cunningham, I; Kapoor, N; Klein, JP; Szer, J; Thompson, JM, 1991) |
| "Busulfan has a very narrow therapeutic index, and acute toxicity may be related to absorption and disposition of the drug and metabolites." | 2.44 | Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. ( Bentur, Y; Hoffer, E; Krivoy, N; Lurie, Y; Rowe, JM, 2008) |
| "Exacerbation of infection during aplasia was observed in 3 patients; inflammatory flare at the infection site during neutrophil engraftment in 2: all 5 patients belonged to the subgroup of 9 with pre-existing infection." | 2.41 | Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. ( Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F, 2002) |
| "To evaluate the toxic extramedullary morbidity of the conditioning treatment with BuCy for BMT, as well as the usefulness of pentoxyphyllin (PTX) and methylprednisolone (MP) in the prophylaxis of mucositis." | 2.39 | [Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning]. ( Maldonado, J; Pascual, MJ, 1995) |
| "Such opportunistic viral infections, leading to either interstitial pneumonia or hemorrhagic gastroenteritis, are the major threat in the early recovery phase after engraftment has taken place." | 2.37 | Infections and immunodeficiency in bone marrow transplantation. ( Tutschka, PJ, 1988) |
| "For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population." | 1.91 | Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. ( Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z, 2023) |
| " Here, we compared post-transplant outcomes after individualized versus fixed busulfan dosage in intermediate-risk AML who achieved CR prior to allograft focusing on pre-transplant flow-MRD." | 1.91 | Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR. ( Ayuk, F; Bacher, U; Badbaran, A; Dadkhah, A; Freiberger, P; Janson, D; Klyuchnikov, E; Kröger, N; Langebrake, C; Massoud, R; Wolschke, C, 2023) |
| "All patients had high-risk hematologic malignancies, were younger than 20 years, and were in complete cytological remission at the time of allo-HSCT." | 1.91 | Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. ( Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S, 2023) |
| " We evaluated two myeloablative conditioning dosing ranges of intravenous (IV) busulfan (Bu) in combination with fludarabine in 70 patients." | 1.91 | Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation. ( Ahmad, S; Edgar, CM; Guo, M; Mcvey, CP; Mori, S; Patel, RD; Rivera-Robles, N; Varela, JC; Yi, F, 2023) |
| "Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT)." | 1.91 | Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party ( Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R, 2023) |
| "In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children." | 1.91 | Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. ( Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023) |
| " The prediction of transplantation-related mortality (TRM) using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score and an arbitrary upper age limit of 55 years for administering myeloablative conditioning (MAC) are common strategies to ensure a safe procedure." | 1.91 | Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. ( Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H, 2023) |
| "We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity." | 1.72 | Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. ( Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB, 2022) |
| "Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far." | 1.72 | Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022) |
| " In 2019, we changed Bu dosing from 4×/day (Bu-4) to 1×/day (Bu-1) for ease of application." | 1.72 | Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. ( Battegay, R; Halter, J; Heim, D; Medinger, M; Passweg, JR; Rentsch, KM; Seydoux, C, 2022) |
| " PT was graded using Common Terminology Criteria for Adverse Events version 5." | 1.72 | Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. ( Chen, YH; Duncan, CN; Lehmann, LE; Liu, KX; Marcus, KJ; Margossian, S; Moore, N; Poux, N; Shin, KY; Whangbo, JS, 2022) |
| " Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative and safe at the pediatric age but remains underperformed in adults." | 1.72 | Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency. ( Asnafi, V; Catherinot, É; Cheminant, M; Couderc, LJ; Fischer, A; Hermine, O; Jeljeli, M; Lanternier, F; Lortholary, O; Mahlaoui, N; Marçais, A; Moshous, D; Neven, B; Picard, C; Salvator, H; Suarez, F; van Endert, P, 2022) |
| "However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern." | 1.72 | Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. ( Albert, MH; Bader, P; Basu, O; Beier, R; Burkhardt, B; Classen, CF; Claviez, A; Corbacioglu, S; Deubzer, HE; Eichinger, A; Glogova, E; Greil, J; Gruhn, B; Güngör, T; Kafa, K; Kühl, JS; Lang, P; Lange, BS; Meisel, R; Müller, I; Peters, C; Poetschger, U; Sauer, MG; Schlegel, PG; Schulz, A; Stachel, D; Strahm, B; Wawer, A, 2022) |
| "Myalgia was reported in 37 patients; 34 patients in the treosulfan group and 3 patients in the busulfan group (p = 0." | 1.62 | Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool. ( Berghuis, D; Bredius, RGM; Buddingh, EP; Guchelaar, HJ; Lankester, AC; Mohseny, AB; Smiers, FJW; van der Stoep, MYEC; Zwaveling, J, 2021) |
| "We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion." | 1.62 | Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. ( Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I, 2021) |
| "Busulfan was administered IV and according to body weight." | 1.62 | Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. ( Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S, 2021) |
| "Busulfan (Bu) is an alkylating agent routinely used for conditioning regimens before allogeneic stem cell transplantation (allo-SCT)." | 1.62 | Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie ( Bartoli, A; Bramanti, S; Castagna, L; De Gregori, S; De Philippis, C; Giordano, L; Mannina, D; Mariotti, J; Pieri, G; Roperti, M; Sarina, B; Valli, V, 2021) |
| "The most common primary cancer was acute lymphoblastic leukemia (22 patients, 31." | 1.56 | Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. ( Kazukawa, I; Kihara, M; Minagawa, M; Mori, K; Shimazaki, S, 2020) |
| "Among patients with acute lymphoblastic leukemia (ALL) (n = 314), there were no differences in overall survival (OS) by conditioning regimen." | 1.56 | Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. ( Atsuta, Y; Fukuda, T; Imahashi, N; Inamoto, Y; Ishikawa, J; Kako, S; Kanda, J; Kimura, T; Kobayashi, H; Kondo, E; Kozai, Y; Matsuoka, KI; Sakai, H; Tanaka, M; Terakura, S; Uchida, N, 2020) |
| "Patients with primary HLH transplanted 2009-2016 after treosulfan- or melphalan-based conditioning regimens were analyzed in a retrospective multicenter study for survival, engraftment, chimerism, and adverse events." | 1.56 | Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. ( Albert, MH; Bader, P; Beier, R; Burkhardt, B; Chada, M; Ehl, S; Greil, J; Gruhn, B; Janka, G; Kühl, JS; Lang, P; Lehmberg, K; Meisel, R; Müller, I; Ozga, AK; Schlegel, PG; Schulz, A; Seidel, M; Speckmann, C; Sykora, KW; Wawer, A; Wössmann, W; Wustrau, K, 2020) |
| "We analyzed 257 patients with acute myeloid leukemia (AML) who received allogeneic stem cell transplantation (SCT) and fulfilled the following criteria: intermediate- or poor-risk disease by National Comprehensive Cancer Network guidelines (2017, version 3), in first complete remission (CR1) at SCT, received either myeloablative conditioning (MAC; busulfan plus cyclophosphamide or cyclophosphamide plus total body irradiation) or reduced-intensity conditioning (RIC; FluBu2TBI400) peripheral blood SCT from 8/8 matched sibling or unrelated donor, and having bone marrow Wilms tumor gene 1 (WT1) expression results before transplant." | 1.56 | Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH, 2020) |
| "Factors independently associated with delayed puberty were extensive chronic GVHD (P = ." | 1.56 | Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. ( Dalle, JH; Lebon Labich, B; Leheup, B; Pochon, C; Weinhard, S; Wiedemann, A, 2020) |
| " Prophylactic T cell depletion via antithymocyte globulin (ATG) during ASCT conditioning is one of the standards of care for GVHD prophylaxis, although the optimal dosing strategy is still unclear." | 1.56 | Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ( Bene, MC; Blin, N; Chevallier, P; Debord, C; Dubruille, V; Duquesne, A; Eveillard, M; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Bris, Y; Le Gouill, S; Mahe, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Wuilleme, S, 2020) |
| "Busulfan is an alkylating agent used in pre-transplant conditioning for patients undergoing hematopoietic stem cell transplantation." | 1.51 | A novel drug interaction between busulfan and blinatumomab. ( Lee, J; Oh, A; Patel, P; Quigley, JG; Rondelli, D; Sweiss, K; Ye, R, 2019) |
| "Busulfan is a major component of chemotherapy conditioning in hematopoietic cell transplantation (HCT)." | 1.51 | Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient. ( Bezinelli, LM; Carvalho, DLC; Corrêa, L; da Silva, CC; Eduardo, FP; Ferreira, MH; Gobbi, M; Hamerschlak, N; Rosin, FCP, 2019) |
| "Primary refractory acute myeloid leukemia (AML) is associated with a dismal prognosis." | 1.51 | Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. ( Amit, O; Avivi, I; Chemnitz, JM; Hallek, M; Holtick, U; Moshe, Y; Ram, R; Scheid, C; Wolf, D, 2019) |
| "Twenty patients with primary acute myeloid leukemia had been randomized into busulfan/fludarabine and modified busulfan/cyclophosphamide groups." | 1.48 | Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. ( Fang, X; Jiang, Y; Li, Y; Liu, X; Sui, X; Wang, X; Xu, H; Zhang, L, 2018) |
| "Only viral infections were significantly increased in the non-TBI group." | 1.48 | Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. ( Anagnostopoulos, A; Apostolou, C; Athanasiadou, A; Batsis, I; Bousiou, Z; Bouziana, S; Chatziioannou, K; Constantinou, V; Douka, V; Gavriilaki, E; Gianouzakos, V; Iskas, M; Lalayanni, C; Mallouri, D; Papathanasiou, M; Sakellari, I; Sotiropoulos, D; Yannaki, E, 2018) |
| "Alopecia was defined as clinically apparent decreased hair density." | 1.46 | Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood. ( Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM, 2017) |
| "Busulfan was administered in four daily divided doses either orally (n = 72) or intravenously (n = 59) with pharmacokinetics on the first-dose and as necessary on subsequent doses to achieve a target area-under-the-concentration-curve (AUC) of 800-1400 μmol*min/L per dose." | 1.43 | Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. ( Ambinder, RF; Bolaños-Meade, J; Borrello, I; Brodsky, RA; Durakovic, N; Fuchs, EJ; Gladstone, DE; Huff, CA; Jones, RJ; Kanakry, CG; Kasamon, YL; Lombardi, LR; Luznik, L; Matsui, W; Rosner, GL; Swinnen, LJ; Zahurak, M, 2016) |
| "Animal disease models have been criticized for lack of resemblance to human illnesses, hampering transfer of knowledge from preclinical research to clinical medicine." | 1.43 | A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation. ( Elezkurtaj, S; Kalupa, M; Penack, O; Riesner, K; Shi, Y, 2016) |
| " Moreover, it appears to be safe with a low NRM rate among high-risk patients." | 1.43 | The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel ( Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ, 2016) |
| "Thirty-four patients had thalassemia major and 4 had SCA." | 1.43 | Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. ( Ben-Arush, M; Elhasid, R; Khalil, A; Rowe, JM; Zaidman, I, 2016) |
| "A total of 30 patients with hematologic malignancies (8 cases of AML, 17 AML, 2 MDS and 3 Mix-AL) received related haploidentical and unrelated HLA-mismatched allo-HSCT combined with related haploidentical bone marrow infusion." | 1.43 | [Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies]. ( Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ, 2016) |
| "Relapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge." | 1.43 | Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. ( Balsalobre, P; Bento, L; Buño, I; Castilla-Llorente, C; Díez-Martín, JL; Ferrá, C; Figuera, A; Gayoso, J; Heras, I; Herrera, P; Kwon, M; López-Corral, L; Montesinos, P; Pascual, C; Pascual, MJ; Piñana, JL; Serrano, D; Zabalza, A, 2016) |
| "busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)." | 1.43 | Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. ( Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL, 2016) |
| "Cataract was prospectively assessed by serial slip lamp tests in 271 patients included in the Leucémie Enfants Adolescents (LEA) programme, the French cohort of childhood leukaemia survivors." | 1.42 | Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study. ( Auquier, P; Barlogis, V; Berbis, J; Bertrand, Y; Chastagner, P; Contet, A; Galambrun, C; Horwitz, M; Kanold, J; Michel, G; Oudin, C; Plantaz, D; Poiree, M; Sirvent, N; Villes, V, 2015) |
| " Pharmacokinetic treatment with targeted intravenous busulfan combined with fludarabine (BuFlu) was developed as a preparative regimen for acute leukemia and myelodysplasia." | 1.42 | Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ( Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B, 2015) |
| " We aimed this retrospective study for comparison of weight- and age-based dosing in terms of clinical outcomes such as time to engraftment, early complications, EFS, OS, and toxicity profiles in children receiving iv Bu." | 1.42 | Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. ( Avci, Z; Azik, F; Gürlek Gökçebay, D; Isik, P; Kara, A; Ozbek, N; Tavil, B; Tunc, B, 2015) |
| " In conclusion, once-daily administration of ivBu has a stable pharmacokinetic profile, and was safely performed in Japanese patients." | 1.42 | Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. ( Akahoshi, Y; Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Matsumoto, K; Morita, K; Nakano, H; Nakasone, H; Nishida, J; Oshima, K; Sakamoto, K; Sato, M; Tanaka, Y; Tanihara, A; Terasako-Saito, K; Ugai, T; Wada, H; Yamasaki, R; Yamazaki, R, 2015) |
| " This regimen was associated with durable donor engraftment and relatively low rates of regimen related toxicity (RRT); future alemtuzumab pharmacokinetic studies may improve outcomes, by allowing targeted alemtuzumab clearance to reduce graft rejection and promote more rapid immune reconstitution." | 1.42 | Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ( Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q, 2015) |
| "Pediatric patients with acute myeloid leukemia (AML) mainly receive myeloablative conditioning regimens based on busulfan (BU) or total body irradiation (TBI) before allogeneic hematopoietic cell transplantation (allo-HCT); however, the optimal conditioning regimen remains unclear." | 1.42 | Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A ( Adachi, S; Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kato, M; Kawano, Y; Koh, K; Kudo, K; Miyamura, T; Ogawa, A; Sawada, A; Taga, T; Terui, K; Tomizawa, D; Yamashita, T, 2015) |
| "A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation." | 1.42 | Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Choi, B; Han, N; Ji, E; Kim, IW; Kim, MG; Kim, T; Oh, JM; Park, S, 2015) |
| "Intravenous (IV) busulfan (Bu) combined with therapeutic drug monitoring-guided dosing is associated with better event-free survival (EFS), lower transplant-related mortality." | 1.40 | Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. ( Ansari, M; Bittencourt, H; Champagne, MA; Desjean, C; Duval, M; Krajinovic, M; Mezziani, S; Peters, C; Rezgui, MA; Théoret, Y; Vachon, MF, 2014) |
| " Our data indicate that Flu (160 mg/m(2)) with targeted myeloablative Bu (90 mg·h/L) is less toxic than and equally effective as BuCy (Mel) in patients with similar indications for allo-HCT." | 1.40 | Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. ( Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B, 2014) |
| " In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI." | 1.40 | Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. ( Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014) |
| " The FB3-ATG2 regimen is safe and efficient in both lymphoid and myeloid disorders." | 1.40 | Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience. ( Chantepie, SP; Gac, AC; Reman, O, 2014) |
| "For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice." | 1.40 | Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome. ( Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C, 2014) |
| " busulfan dosing (total dose 3." | 1.39 | Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. ( Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR, 2013) |
| "Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study." | 1.38 | Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. ( Chae, YS; Choi, JY; Kang, BW; Kim, JG; Kim, YK; Lee, SJ; Lee, YJ; Moon, JH; Seo, JW; Shin, HC; Sohn, SK; Suh, JS, 2012) |
| "We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT." | 1.37 | Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. ( Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V, 2011) |
| "Acute kidney injury was defined as doubling serum creatinine from baseline at any time during the first 180 days posttransplant." | 1.36 | Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran. ( Attari, F; Bahar, B; Falaknazi, K; Hakemi, MS; Najafi, I; Saddadi, F, 2010) |
| "A prevalence of sleep disorders of 26." | 1.36 | Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation. ( Astigarraga, CC; Faulhaber, GA; Furlanetto, TW; Moser Filho, HL; Paludo, AP; Silla, LM, 2010) |
| " Results of clinical outcome of previous studies performed to optimize busulfan and CsA therapy by controlling their pharmacokinetic variability by means of maximum a posteriori (MAP) Bayesian individualization of both drugs are presented." | 1.35 | The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. ( Bleyzac, N, 2008) |
| " The responses and adverse events of the 2 groups were assessed." | 1.34 | [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia]. ( Li, J; Luo, SK; Peng, AH; Tong, XZ; Xu, DR; Zhang, GC; Zheng, D; Zou, WY, 2007) |
| "The only radical cure for thalassemia major patients today is the replacement of the defective hematopoietic system by allogeneic stem cell transplantation (allo-SCT)." | 1.34 | Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. ( Abdul-Hai, A; Ackerstein, A; Aker, M; Amar, A; Bitan, M; Gesundheit, B; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, P, 2007) |
| "Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the appropriate role and timing of transplantation are unclear." | 1.33 | Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. ( Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K, 2006) |
| "This study reports on overall and recurrence-free survival (OS and RFS) of 37 consecutive patients with low- and intermediate-grade NHL receiving a related donor allogeneic BMT using a nonradiation-containing preparative regimen." | 1.32 | Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. ( Kiss, TL; Lipton, JH; Meharchand, J; Messner, HA; Panzarella, T; Reddy, V; Schimmer, AD, 2003) |
| "Busulfan is a common component of pretransplant conditioning but has an erratic and unpredictable bioavailability when administered orally." | 1.32 | Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. ( Avigdor, A; Ben-Bassat, I; Bielorai, B; Hardan, I; Nagler, A; Shimoni, A; Toren, A; Yeshurun, M, 2003) |
| "Busulfan was given once daily." | 1.32 | Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. ( Chan, KW; Gomez Almaguer, D; Gordon, N; Mullen, CA; Tran, H; Worth, L, 2003) |
| "Three patients with myelofibrosis received allogeneic stem cell transplantation after a dose-reduced conditioning regimen of busulphan (8 mg/kg), fludarabine (180 mg/m2) and antithymocyte globulin (4 x 10 mg/kg)." | 1.31 | Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. ( Ayuk, FA; Erttmann, R; Hansen, A; Hessling, J; Kordes, U; Kröger, N; Panse, J; Renges, H; Werner, M; Zabelina, T; Zander, AR, 2002) |
| "To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg)." | 1.31 | Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. ( Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR, 2000) |
| " Plasma concentrations of BU at steady state (C(SS)BU) during the dosing interval were measured for each patient." | 1.30 | Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. ( Anasetti, C; Appelbaum, FR; Bensinger, WI; Bowden, R; Bryant, E; Buckner, CD; Chauncey, T; Clift, RA; Deeg, HJ; Doney, KC; Flowers, M; Gooley, T; Hansen, JA; Martin, PJ; McDonald, GB; Nash, R; Petersdorf, EW; Radich, J; Sanders, JE; Schoch, G; Slattery, JT; Soll, E; Stewart, P; Storb, R; Storer, B; Sullivan, KM; Thomas, ED; Witherspoon, RP, 1997) |
| "Fifty patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) underwent allogeneic bone marrow transplantation between October 1988 and January 1997." | 1.30 | Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. ( Goto, S; Hirabayashi, N; Ishii, M; Mitsuma, A; Noda, N; Yuge, M, 1998) |
| "Diagnoses included acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 8) and chronic myelogenous leukemia (n = 2)." | 1.30 | Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. ( Kato, K; Kojima, S; Matsuyama, T, 1998) |
| "Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases." | 1.30 | Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. ( Alimoghadam, K; Ghahremani, G; Ghavamzadeh, A; Jahani, M; Khodabandeh, A; Nasseri, P, 1999) |
| "Busulfan dose was 16 mg/kg given over 4 days." | 1.29 | Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide. ( Czyzewski, EA; Ghalie, R; Hartsell, WF; Kaizer, H, 1995) |
| " There were seven acute toxic deaths (8%) and in total 15 patients experienced life-threatening or fatal toxicity." | 1.29 | Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. ( Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D, 1995) |
| "A 25-year-old woman with AIDS was submitted to HLA-identical allogeneic BMT after cytoablation with busulphan and cyclophosphamide and combined anti-HIV-1 therapy with zidovudine, IFN-alpha 2 and anti-HIV-1-specific T cell clones." | 1.29 | Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. ( Arras, M; Boero, R; Carcassi, C; Contu, L; La Nasa, G; Ledda, A; Orrù, S; Pintus, A; Pizzati, A; Vacca, A, 1993) |
| "This high risk of relapse is not observed when the dose of cyclophosphamide is increased to 200 mg/kg." | 1.29 | Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. ( Bernaudin, F; Blaise, D; Bordigoni, P; Esperou-Bourdeau, H; Gluckman, E; Jouet, JP; Michel, G; Pico, JL; Reiffers, J; Thuret, I, 1994) |
| "Twenty-three patients developed a malignancy 1." | 1.29 | Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. ( Deeg, HJ; Devergie, A; Gluckman, E; Henry-Amar, M; Schoch, G; Socié, G; Storb, R; Sullivan, KM; Witherspoon, RP, 1996) |
| "Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia." | 1.29 | Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. ( Avalos, B; Bolwell, B; Copelan, E; Crilley, P; Gajewski, J; Klein, J; Sahebi, F; Territo, M, 1996) |
| " Alterations in bioavailability (absorption or first pass elimination) or in actual volume of distribution may account for these differences in drug disposition." | 1.28 | Busulfan disposition in children. ( Blazar, B; Grochow, LB; Krivit, W; Whitley, CB, 1990) |
| "Twenty-five consecutive patients with acute myelogenous leukemia (AML) underwent 26 allogeneic bone marrow transplants at Hahnemann University Hospital." | 1.28 | Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia. ( Bigler, R; Brodsky, I; Bulova, S; Crilley, P; Topolsky, D, 1990) |
| "Ninety-nine patients with acute nonlymphocytic leukemia (ANLL) received HLA-identical bone marrow transplants (BMTs) from sibling donors after preparation with high doses of busulfan and cyclophosphamide." | 1.28 | Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. ( Ambinder, RF; Beschorner, WB; Braine, HG; Burns, WH; Geller, RB; Piantadosi, S; Saral, R; Vogelsang, GB; Wingard, JR; Zahurak, M, 1989) |
| "Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT)." | 1.27 | Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. ( Burns, WH; Geller, RB; Santos, GW; Saral, R; Vogelsang, GB; Wingard, JR; Yeager, AM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (5.34) | 18.7374 |
| 1990's | 107 (14.64) | 18.2507 |
| 2000's | 180 (24.62) | 29.6817 |
| 2010's | 252 (34.47) | 24.3611 |
| 2020's | 153 (20.93) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, Y | 2 |
| Nakano, N | 2 |
| Fuji, S | 4 |
| Eto, T | 6 |
| Kawakita, T | 6 |
| Suehiro, Y | 1 |
| Miyamoto, T | 1 |
| Sawayama, Y | 1 |
| Uchida, N | 8 |
| Kondo, T | 5 |
| Kanda, J | 9 |
| Atsuta, Y | 19 |
| Fukuda, T | 19 |
| Yoshimitsu, M | 1 |
| Kato, K | 8 |
| Kurosawa, S | 4 |
| Shimomura, Y | 5 |
| Itonaga, H | 2 |
| Najima, Y | 4 |
| Kobayashi, T | 3 |
| Ozawa, Y | 6 |
| Kanda, Y | 14 |
| Kako, S | 5 |
| Matsuoka, KI | 5 |
| Maruyama, Y | 4 |
| Ota, S | 4 |
| Nakazawa, H | 3 |
| Imada, K | 2 |
| Aoki, J | 2 |
| Shimoni, A | 10 |
| Robin, M | 3 |
| Iacobelli, S | 2 |
| Beelen, D | 4 |
| Mufti, GJ | 4 |
| Ciceri, F | 6 |
| Bethge, W | 10 |
| Volin, L | 7 |
| Blaise, D | 28 |
| Ganser, A | 4 |
| Luft, T | 1 |
| Chevallier, P | 7 |
| Schwerdtfeger, R | 9 |
| Koster, L | 1 |
| de Witte, T | 3 |
| Kröger, N | 36 |
| Nagler, A | 37 |
| Yakoub-Agha, I | 14 |
| Kume, T | 1 |
| Shimizu, R | 1 |
| Akiyama, K | 1 |
| Tsuchiya, T | 1 |
| Shino, M | 1 |
| Ikeda, T | 2 |
| Iwai, S | 1 |
| van der Stoep, MYEC | 1 |
| Berghuis, D | 1 |
| Bredius, RGM | 2 |
| Buddingh, EP | 1 |
| Mohseny, AB | 1 |
| Smiers, FJW | 1 |
| Guchelaar, HJ | 1 |
| Lankester, AC | 4 |
| Zwaveling, J | 2 |
| Yamada, Y | 1 |
| Ikegawa, S | 1 |
| Konuma, R | 1 |
| Adachi, H | 1 |
| Wada, A | 1 |
| Kishida, Y | 1 |
| Konishi, T | 1 |
| Nagata, A | 1 |
| Kaito, S | 1 |
| Nagata, R | 1 |
| Noguchi, Y | 1 |
| Marumo, A | 1 |
| Mukae, J | 2 |
| Inamoto, K | 1 |
| Toya, T | 1 |
| Igarashi, A | 1 |
| Sakamaki, H | 3 |
| Ohashi, K | 4 |
| Doki, N | 2 |
| O'Hagan Henderson, S | 1 |
| Frietsch, JJ | 1 |
| Hilgendorf, I | 5 |
| Hochhaus, A | 1 |
| Köhne, CH | 1 |
| Casper, J | 9 |
| Uppugunduri, CRS | 2 |
| Huezo-Diaz Curtis, P | 1 |
| Nava, T | 2 |
| Rezgui, MA | 2 |
| Mlakar, V | 1 |
| Mlakar, SJ | 1 |
| Waespe, N | 1 |
| Théoret, Y | 2 |
| Gumy-Pause, F | 1 |
| Bernard, F | 1 |
| Chalandon, Y | 4 |
| Boelens, JJ | 6 |
| Dalle, JH | 5 |
| Nath, C | 1 |
| Corbacioglu, S | 2 |
| Peters, C | 9 |
| Bader, P | 6 |
| Shaw, P | 3 |
| Bittencourt, H | 2 |
| Krajinovic, M | 3 |
| Ansari, M | 4 |
| Yeh, AC | 1 |
| O'Donnell, PV | 5 |
| Schoch, G | 4 |
| Martin, PJ | 8 |
| McFarland, C | 1 |
| McCune, JS | 5 |
| Cooper, JP | 1 |
| Doney, K | 1 |
| Flowers, MED | 1 |
| Sorror, ML | 3 |
| Appelbaum, FR | 13 |
| Storer, BE | 6 |
| Gooley, T | 3 |
| Deeg, HJ | 18 |
| Fan, S | 1 |
| Chen, J | 14 |
| Liu, Z | 1 |
| Xiao, J | 2 |
| Jiang, F | 1 |
| Liu, X | 6 |
| Sun, Y | 4 |
| Versluijs, AB | 1 |
| de Koning, CCH | 1 |
| Nierkens, S | 1 |
| Kollen, WJ | 1 |
| Bresters, D | 2 |
| Lindemans, CA | 3 |
| Bierings, M | 2 |
| Konuma, T | 3 |
| Ooi, J | 1 |
| Monna-Oiwa, M | 2 |
| Isobe, M | 2 |
| Tomonari, A | 1 |
| Kato, S | 4 |
| Iseki, T | 1 |
| Nannya, Y | 1 |
| Tojo, A | 2 |
| Takahashi, S | 3 |
| Swoboda, R | 5 |
| Labopin, M | 26 |
| Giebel, S | 12 |
| Angelucci, E | 14 |
| Arat, M | 5 |
| Aljurf, M | 5 |
| Sica, S | 3 |
| Pavlu, J | 3 |
| Socié, G | 16 |
| Bernasconi, P | 2 |
| Rigacci, L | 1 |
| Tischer, J | 5 |
| Risitano, A | 1 |
| Rovira, M | 3 |
| Saccardi, R | 1 |
| Pioltelli, P | 3 |
| Van Gorkom, G | 2 |
| Vitek, A | 2 |
| Savani, BN | 11 |
| Spyridonidis, A | 11 |
| Peric, Z | 3 |
| Mohty, M | 36 |
| Onizuka, M | 3 |
| Fujii, N | 1 |
| Nakasone, H | 4 |
| Ogata, M | 1 |
| Suzuki, R | 4 |
| Ikegame, K | 3 |
| Nakamae, H | 6 |
| Inoue, M | 4 |
| Chen, T | 2 |
| Chen, C | 1 |
| He, X | 3 |
| Guo, J | 2 |
| Liu, M | 1 |
| Zheng, B | 1 |
| Albert, MH | 6 |
| Slatter, MA | 3 |
| Gennery, AR | 5 |
| Güngör, T | 6 |
| Bakunina, K | 1 |
| Markovitch, B | 1 |
| Hazelaar, S | 1 |
| Sirait, T | 1 |
| Courteille, V | 1 |
| Aiuti, A | 1 |
| Aleinikova, OV | 1 |
| Balashov, D | 5 |
| Bernardo, ME | 4 |
| Bodova, I | 1 |
| Bruno, B | 8 |
| Cavazzana, M | 1 |
| Chiesa, R | 3 |
| Fischer, A | 6 |
| Hauck, F | 1 |
| Ifversen, M | 2 |
| Kałwak, K | 2 |
| Klein, C | 1 |
| Kulagin, A | 1 |
| Kupesiz, A | 1 |
| Kuskonmaz, B | 1 |
| Locatelli, F | 8 |
| Lum, SH | 1 |
| Maschan, A | 5 |
| Meisel, R | 5 |
| Moshous, D | 3 |
| Porta, F | 2 |
| Sauer, MG | 3 |
| Sedlacek, P | 4 |
| Schulz, A | 6 |
| Suarez, F | 3 |
| Vallée, TC | 1 |
| Winiarski, JH | 1 |
| Zecca, M | 9 |
| Neven, B | 2 |
| Veys, P | 9 |
| Pan, WY | 1 |
| Li, KX | 1 |
| Wu, HY | 1 |
| He, YZ | 1 |
| DU, JW | 1 |
| Zheng, YL | 1 |
| Tu, SF | 1 |
| Song, CY | 1 |
| Li, YH | 1 |
| Huang, YX | 1 |
| Suh, JK | 1 |
| Im, HJ | 1 |
| Kang, SH | 1 |
| Kim, H | 6 |
| Choi, ES | 1 |
| Koh, KN | 1 |
| Drozdov, D | 1 |
| Petermann, K | 1 |
| Dougoud, S | 1 |
| Oberholzer, S | 1 |
| Held, L | 1 |
| Hauri-Hohl, M | 1 |
| Rostami, T | 2 |
| Mousavi, SA | 5 |
| Kiumarsi, A | 1 |
| Kasaeian, A | 1 |
| Rad, S | 1 |
| Yaghmaie, M | 1 |
| Ghavamzadeh, A | 10 |
| Uemura, Y | 1 |
| Hirakawa, T | 1 |
| Matsunawa, M | 1 |
| Kozuki, K | 1 |
| Saiki, Y | 1 |
| Takimoto, M | 1 |
| Sano, F | 1 |
| Watanabe, K | 5 |
| Arai, A | 1 |
| Kimura, T | 3 |
| Ishiyama, K | 1 |
| Gurlek Gokcebay, D | 2 |
| Arman Bilir, O | 1 |
| Şahin, S | 1 |
| Ok Bozkaya, İ | 1 |
| Ozbek, NY | 1 |
| Seydoux, C | 2 |
| Battegay, R | 1 |
| Halter, J | 4 |
| Heim, D | 5 |
| Rentsch, KM | 1 |
| Passweg, JR | 3 |
| Medinger, M | 3 |
| Braitsch, K | 1 |
| Schwarz, A | 1 |
| Koch, K | 1 |
| Hubbuch, M | 1 |
| Menzel, H | 1 |
| Keller, U | 1 |
| Götze, KS | 1 |
| Bassermann, F | 1 |
| Herhaus, P | 1 |
| Verbeek, M | 4 |
| Rodríguez-Arbolí, E | 2 |
| Eder, M | 1 |
| Brecht, A | 3 |
| Blau, IW | 5 |
| Huynh, A | 3 |
| Forcade, E | 5 |
| Bondarenko, S | 1 |
| Bulabois, CE | 3 |
| Einsele, H | 6 |
| Stölzel, F | 3 |
| Savani, B | 10 |
| Bazarbachi, A | 5 |
| Brissot, E | 6 |
| Schmid, C | 4 |
| Bonifazi, F | 3 |
| Pavoni, C | 1 |
| Peccatori, J | 2 |
| Giglio, F | 2 |
| Arpinati, M | 1 |
| Busca, A | 1 |
| Grassi, A | 1 |
| Iori, AP | 6 |
| Patriarca, F | 4 |
| Brunello, L | 1 |
| Di Grazia, C | 3 |
| Carella, AM | 1 |
| Cilloni, D | 1 |
| Picardi, A | 2 |
| Proia, A | 1 |
| Santarone, S | 6 |
| Sorasio, R | 1 |
| Carluccio, P | 1 |
| Chiusolo, P | 4 |
| Cupri, A | 1 |
| Luppi, M | 1 |
| Nozzoli, C | 1 |
| Baronciani, D | 10 |
| Casini, M | 1 |
| Grillo, G | 2 |
| Musso, M | 1 |
| Onida, F | 3 |
| Palazzo, G | 1 |
| Parma, M | 1 |
| Tringali, S | 1 |
| Vacca, A | 5 |
| Vallisa, D | 1 |
| Sacchi, N | 1 |
| Oldani, E | 1 |
| Masciulli, A | 1 |
| Gheorghiu, A | 1 |
| Girmenia, C | 2 |
| Martino, M | 3 |
| Rambaldi, A | 8 |
| Zhang, R | 2 |
| Lu, X | 1 |
| Tang, LV | 1 |
| Wang, HF | 1 |
| Yan, H | 2 |
| You, Y | 3 |
| Zhong, ZD | 1 |
| Shi, W | 1 |
| Xia, LH | 2 |
| Yabe, H | 3 |
| Andersson, BS | 20 |
| Thall, PF | 8 |
| Ma, J | 1 |
| Valdez, BC | 7 |
| Bassett, R | 5 |
| Ahmed, S | 5 |
| Alousi, A | 3 |
| Bashir, Q | 6 |
| Ciurea, S | 3 |
| Gulbis, A | 1 |
| Cool, R | 1 |
| Kawedia, J | 3 |
| Hosing, C | 9 |
| Kebriaei, P | 13 |
| Kornblau, S | 1 |
| Myers, A | 1 |
| Oran, B | 10 |
| Rezvani, K | 2 |
| Shah, N | 3 |
| Shpall, E | 2 |
| Parmar, S | 2 |
| Popat, UR | 4 |
| Nieto, Y | 7 |
| Champlin, RE | 18 |
| Beelen, DW | 5 |
| Stelljes, M | 10 |
| Reményi, P | 1 |
| Wagner-Drouet, EM | 1 |
| Dreger, P | 7 |
| Junghanß, C | 1 |
| Labussiere-Wallet, H | 2 |
| Schaefer-Eckart, K | 1 |
| Grigoleit, GU | 1 |
| Scheid, C | 5 |
| Niederwieser, D | 5 |
| Russo, D | 1 |
| Holler, E | 4 |
| Glass, B | 1 |
| Wulf, G | 1 |
| Basara, N | 1 |
| Bieniaszewska, M | 1 |
| Stuhler, G | 4 |
| La Rocca, U | 1 |
| Finke, J | 7 |
| Benedetti, F | 1 |
| Pichlmeier, U | 4 |
| Klein, A | 1 |
| Baumgart, J | 6 |
| Markiewicz, M | 4 |
| Alatrash, G | 4 |
| Saberian, C | 1 |
| Ledesma, C | 2 |
| Lu, Y | 3 |
| Daher, M | 1 |
| Popat, U | 9 |
| Mehta, R | 1 |
| Olson, A | 3 |
| Anderlini, P | 6 |
| Marin, D | 3 |
| Alousi, AM | 7 |
| Shpall, EJ | 10 |
| Rondon, G | 9 |
| Qazilbash, M | 3 |
| Liu, KX | 1 |
| Poux, N | 1 |
| Shin, KY | 1 |
| Moore, N | 1 |
| Chen, YH | 4 |
| Margossian, S | 1 |
| Whangbo, JS | 1 |
| Duncan, CN | 2 |
| Lehmann, LE | 1 |
| Marcus, KJ | 1 |
| Devillier, R | 6 |
| Galimard, JE | 1 |
| Raiola, AM | 5 |
| Castagna, L | 10 |
| Bug, G | 2 |
| Vrhovac, R | 1 |
| Charbonnier, A | 4 |
| Olivieri, A | 2 |
| Bay, JO | 6 |
| Arroyo, H | 1 |
| Avenoso, D | 2 |
| Neubauer, A | 4 |
| Nguyen, S | 2 |
| Al-Atrash, G | 2 |
| Hosing, CM | 2 |
| Im, JS | 2 |
| Qazilbash, MH | 5 |
| Srour, SA | 4 |
| Mehta, RS | 3 |
| Freyer, CW | 2 |
| Babushok, DV | 1 |
| Frey, NV | 3 |
| Gill, SI | 2 |
| Loren, AW | 3 |
| Luger, SM | 3 |
| Maity, A | 1 |
| Martin, ME | 2 |
| Plastaras, JP | 1 |
| Porter, DL | 4 |
| Hexner, EO | 3 |
| Mehta, P | 1 |
| Kapoor, J | 1 |
| Singh, A | 1 |
| Yadav, N | 1 |
| Singh, R | 1 |
| Halder, R | 1 |
| Verma, M | 1 |
| Agrawal, N | 1 |
| Ahmed, R | 2 |
| Bhurani, D | 1 |
| Marçais, A | 2 |
| Mahlaoui, N | 1 |
| Lanternier, F | 1 |
| Catherinot, É | 1 |
| Salvator, H | 1 |
| Cheminant, M | 1 |
| Jeljeli, M | 1 |
| Asnafi, V | 1 |
| van Endert, P | 1 |
| Couderc, LJ | 1 |
| Lortholary, O | 1 |
| Picard, C | 2 |
| Hermine, O | 1 |
| Olivas-Mazón, R | 1 |
| Bueno, D | 1 |
| Sisinni, L | 1 |
| Mozo, Y | 1 |
| Casado-Abad, G | 1 |
| Martínez, AP | 1 |
| Xu, L | 1 |
| Hu, S | 1 |
| Li, C | 1 |
| Tang, Y | 3 |
| Wang, H | 2 |
| Yan, J | 1 |
| Liu, S | 2 |
| Wu, X | 1 |
| Lin, F | 2 |
| Lu, P | 1 |
| Huang, X | 2 |
| Dalla Via, V | 1 |
| Stelmes, A | 1 |
| Recher, M | 1 |
| Arranto, C | 1 |
| Junker, T | 1 |
| Matteazzi, F | 1 |
| van den Berg, J | 1 |
| Zhang, H | 4 |
| Fan, Z | 3 |
| Huang, F | 4 |
| Han, L | 1 |
| Xu, Y | 4 |
| Xu, N | 2 |
| Deng, L | 1 |
| Wang, S | 1 |
| Lin, D | 1 |
| Luo, X | 1 |
| Zhang, Q | 2 |
| Li, X | 3 |
| Liang, X | 2 |
| Xie, S | 1 |
| Qu, H | 2 |
| Yu, S | 2 |
| Zhou, H | 2 |
| Shi, P | 1 |
| Xuan, L | 2 |
| Lin, R | 2 |
| Liu, H | 7 |
| Jin, H | 2 |
| Sun, J | 4 |
| Liu, Q | 3 |
| Pizzola, CJ | 1 |
| Cioccio, J | 1 |
| Rakszawski, KL | 1 |
| Nickolich, M | 1 |
| Ehmann, WC | 1 |
| Rybka, WB | 2 |
| Wirk, B | 3 |
| Naik, S | 1 |
| Zheng, H | 1 |
| Silar, B | 1 |
| Shike, H | 1 |
| Zhou, S | 1 |
| Mineishi, S | 6 |
| Minagawa, K | 1 |
| Claxton, DF | 1 |
| Eichinger, A | 1 |
| Poetschger, U | 1 |
| Glogova, E | 3 |
| Basu, O | 1 |
| Beier, R | 5 |
| Burkhardt, B | 2 |
| Classen, CF | 1 |
| Claviez, A | 2 |
| Deubzer, HE | 1 |
| Greil, J | 3 |
| Gruhn, B | 5 |
| Kafa, K | 1 |
| Kühl, JS | 2 |
| Lang, P | 3 |
| Lange, BS | 1 |
| Müller, I | 5 |
| Schlegel, PG | 3 |
| Stachel, D | 2 |
| Strahm, B | 4 |
| Wawer, A | 2 |
| Yi, ES | 1 |
| Kim, SK | 1 |
| Ju, HY | 1 |
| Lee, JW | 8 |
| Cho, B | 1 |
| Kim, BK | 2 |
| Kang, HJ | 2 |
| Baek, HJ | 1 |
| Kook, H | 1 |
| Yang, EJ | 1 |
| Lim, YT | 1 |
| Ahn, WK | 1 |
| Hahn, SM | 1 |
| Park, SK | 2 |
| Yoo, ES | 1 |
| Yoo, KH | 1 |
| Kawashiri, A | 1 |
| Nakagawa, SI | 1 |
| Ishiguro, C | 1 |
| Mochizuki, K | 1 |
| Maeda, Y | 2 |
| Kurokawa, T | 1 |
| Zhang, W | 4 |
| Gui, R | 1 |
| Zu, Y | 1 |
| Zhang, B | 2 |
| Li, Z | 2 |
| Zhang, Y | 4 |
| Wang, X | 10 |
| Guo, S | 1 |
| Zhan, X | 1 |
| Fu, Y | 1 |
| Song, Y | 1 |
| Zhou, J | 1 |
| Banet, A | 3 |
| Stocker, N | 1 |
| Duléry, R | 3 |
| Malard, F | 5 |
| Van de Wyngaert, Z | 2 |
| Genthon, A | 1 |
| Memoli, M | 2 |
| Legrand, O | 3 |
| Bonnin, A | 2 |
| Ledraa, T | 3 |
| Belhocine, R | 3 |
| Sestili, S | 3 |
| El-Cheikh, J | 5 |
| Firsova, MV | 1 |
| Mendeleeva, LP | 1 |
| Parovichnikova, EN | 2 |
| Solovev, MV | 1 |
| Kuzmina, LA | 1 |
| Risinskaya, NV | 1 |
| Abramova, TV | 1 |
| Galtseva, IV | 1 |
| Savchenko, VG | 2 |
| Klyuchnikov, E | 2 |
| Langebrake, C | 1 |
| Badbaran, A | 1 |
| Dadkhah, A | 1 |
| Massoud, R | 1 |
| Freiberger, P | 1 |
| Ayuk, F | 7 |
| Janson, D | 1 |
| Wolschke, C | 4 |
| Bacher, U | 3 |
| Connor, MP | 1 |
| Mangan, JK | 1 |
| Perl, AE | 1 |
| McCurdy, SR | 1 |
| Pratz, KW | 1 |
| Timlin, C | 1 |
| Carulli, A | 1 |
| Catania, C | 1 |
| Smith, J | 2 |
| Hollander, L | 1 |
| Zebrowski, AM | 1 |
| Stadtmauer, EA | 2 |
| Luo, C | 2 |
| Wu, G | 1 |
| Ding, Y | 1 |
| Huang, Y | 4 |
| Song, Q | 1 |
| Hou, Y | 1 |
| Xu, S | 2 |
| Choi, Y | 3 |
| Choi, EJ | 2 |
| Park, HS | 3 |
| Lee, JH | 21 |
| Lee, YS | 8 |
| Kang, YA | 6 |
| Jeon, M | 5 |
| Woo, JM | 1 |
| Kang, H | 2 |
| Baek, S | 2 |
| Kim, SM | 1 |
| Bong, CE | 1 |
| Lee, KH | 10 |
| Truscott, L | 3 |
| Pariury, H | 3 |
| Hanmod, S | 3 |
| Davini, M | 3 |
| de la Maza, M | 3 |
| Sapp, LN | 3 |
| Staples, K | 3 |
| Proytcheva, M | 3 |
| Katsanis, E | 3 |
| Halahleh, KA | 3 |
| Ma'koseh, M | 3 |
| Sultan, I | 3 |
| Rimawi, DH | 3 |
| Muradi, I | 3 |
| Gale, RP | 7 |
| Tannumsaeung, S | 3 |
| Anurathapan, U | 4 |
| Pakakasama, S | 4 |
| Pongpitcha, P | 3 |
| Songdej, D | 4 |
| Sirachainan, N | 4 |
| Hongeng, S | 4 |
| Laberko, A | 4 |
| Sultanova, E | 3 |
| Idarmacheva, A | 3 |
| Skvortsova, Y | 4 |
| Shelikhova, L | 4 |
| Nechesnyuk, A | 3 |
| Kobyzeva, D | 3 |
| Shcherbina, A | 3 |
| Maschan, M | 4 |
| Schroeder, T | 5 |
| Hamladji, RM | 7 |
| Potter, V | 7 |
| Berceanu, A | 4 |
| Ozdogu, H | 7 |
| Sanz, J | 6 |
| Mori, S | 8 |
| Guo, M | 3 |
| Rivera-Robles, N | 3 |
| Edgar, CM | 3 |
| Mcvey, CP | 3 |
| Yi, F | 3 |
| Ahmad, S | 3 |
| Patel, RD | 3 |
| Varela, JC | 3 |
| Nakano, Y | 2 |
| Hidaka, M | 4 |
| Sekiguchi, M | 2 |
| Fujimura, J | 2 |
| Kato, M | 4 |
| Maertens, J | 1 |
| Bourhis, JH | 5 |
| Salmenniemi, U | 1 |
| Poiré, X | 3 |
| Cornelissen, JJ | 1 |
| Kamijo, K | 1 |
| Shinohara, A | 1 |
| Mizuno, S | 3 |
| Kanaya, M | 1 |
| Usui, Y | 1 |
| Kim, SW | 11 |
| Ara, T | 1 |
| Mizuno, I | 1 |
| Kuriyama, T | 1 |
| Kusumoto, S | 3 |
| Maseki, N | 1 |
| Yamaguchi, M | 2 |
| Ashida, T | 3 |
| Kondo, E | 2 |
| Rehman, MEU | 1 |
| Chattaraj, A | 1 |
| Mahboob, A | 1 |
| Ijaz, Z | 1 |
| Franco, D | 1 |
| Farhan, M | 1 |
| Dharma, K | 1 |
| Mumtaz, H | 1 |
| Saeed, S | 1 |
| Basit, J | 1 |
| Aslam, MM | 1 |
| Iftikhar, A | 1 |
| Faraz, F | 1 |
| Anwer, F | 1 |
| Murthy, GSG | 1 |
| Kim, S | 5 |
| Estrada-Merly, N | 1 |
| Abid, MB | 1 |
| Assal, A | 1 |
| Badar, T | 1 |
| Badawy, SM | 1 |
| Ballen, K | 2 |
| Beitinjaneh, A | 2 |
| Cerny, J | 3 |
| Chhabra, S | 4 |
| DeFilipp, Z | 1 |
| Dholaria, B | 1 |
| Perez, MAD | 1 |
| Farhan, S | 2 |
| Freytes, CO | 1 |
| Ganguly, S | 2 |
| Gupta, V | 3 |
| Grunwald, MR | 2 |
| Hamad, N | 2 |
| Hildebrandt, GC | 3 |
| Inamoto, Y | 3 |
| Jain, T | 4 |
| Jamy, O | 1 |
| Juckett, M | 2 |
| Kalaycio, M | 8 |
| Krem, MM | 1 |
| Lazarus, HM | 3 |
| Litzow, M | 2 |
| Munker, R | 1 |
| Murthy, HS | 2 |
| Nathan, S | 3 |
| Nishihori, T | 5 |
| Ortí, G | 2 |
| Patel, SS | 2 |
| Van der Poel, M | 3 |
| Rizzieri, DA | 2 |
| Seo, S | 3 |
| Solh, M | 1 |
| Verdonck, LF | 2 |
| Yared, JA | 2 |
| Nakamura, R | 6 |
| Scott, B | 3 |
| Saber, W | 3 |
| Hama, A | 2 |
| Taga, T | 2 |
| Tomizawa, D | 3 |
| Muramatsu, H | 1 |
| Hasegawa, D | 5 |
| Adachi, S | 3 |
| Yoshida, N | 4 |
| Noguchi, M | 2 |
| Sato, M | 4 |
| Okada, K | 1 |
| Koh, K | 4 |
| Mitsui, T | 1 |
| Takahashi, Y | 2 |
| Miyamura, T | 2 |
| Hashii, Y | 3 |
| Okamoto, Y | 3 |
| Zhang, Z | 1 |
| Yao, Y | 1 |
| Pan, T | 1 |
| Qi, J | 1 |
| Liu, Y | 1 |
| Cai, C | 1 |
| Zhou, M | 1 |
| Hu, X | 1 |
| Ma, X | 2 |
| Wu, D | 4 |
| Han, Y | 1 |
| Malkan, ÜY | 1 |
| Göker, H | 2 |
| Demiroğlu, H | 1 |
| Tekin, F | 1 |
| Akdemir, NB | 1 |
| Karakulak, EA | 1 |
| Sayınalp, N | 1 |
| Haznedaroğlu, İC | 1 |
| Özcebe, Oİ | 1 |
| Büyükaşık, Y | 1 |
| Niittyvuopio, R | 1 |
| Reinhardt, HC | 1 |
| Kaare, A | 1 |
| Schäfer-Eckart, K | 3 |
| Mielke, S | 2 |
| Carlson, K | 1 |
| Schanz, U | 2 |
| Nair, G | 1 |
| Cantoni, N | 2 |
| Hirschbühl, K | 1 |
| Polge, E | 4 |
| Bonnet, S | 1 |
| Jacoby, E | 1 |
| Adam, E | 1 |
| Hutt, D | 1 |
| Somech, R | 1 |
| Malkiel, S | 1 |
| Toren, A | 2 |
| Bielorai, B | 2 |
| Jurdi, NE | 1 |
| Hoover, A | 1 |
| O'Leary, D | 1 |
| Cao, Q | 2 |
| Gupta, A | 2 |
| Ebens, C | 1 |
| Maakaron, JE | 1 |
| Betts, BC | 1 |
| Rashidi, A | 1 |
| Juckett, MB | 1 |
| Lund, T | 1 |
| Bachanova, V | 1 |
| MacMillan, ML | 2 |
| Miller, JS | 3 |
| Orchard, PJ | 3 |
| Wagner, JE | 4 |
| Vercellotti, G | 1 |
| Weisdorf, DJ | 4 |
| Dusenbery, K | 1 |
| Terezakis, S | 1 |
| Holtan, SG | 1 |
| Ling, Y | 1 |
| Guo, Z | 1 |
| Xu, X | 4 |
| Wu, M | 1 |
| Liu, C | 1 |
| Ou, R | 1 |
| Zhai, X | 2 |
| Zhao, Y | 2 |
| Boga, C | 3 |
| Sisli, SN | 1 |
| Bahar, AR | 1 |
| Tamer, Y | 1 |
| Kasar, M | 2 |
| Bascil, S | 1 |
| Asma, S | 3 |
| Demiroglu, YZ | 1 |
| Yeral, M | 3 |
| Cao, J | 1 |
| Wang, T | 2 |
| Chen, D | 1 |
| Li, S | 6 |
| Ye, P | 1 |
| Zheng, ZZ | 1 |
| Pei, R | 1 |
| Cassanello, G | 1 |
| Serpenti, F | 2 |
| Bagnoli, F | 1 |
| Saporiti, G | 1 |
| Goldaniga, M | 1 |
| Cavallaro, F | 1 |
| Barbullushi, K | 1 |
| Bellani, V | 1 |
| Galassi, G | 1 |
| Mariano, B | 1 |
| Hamerschlak, N | 3 |
| Vera, M | 1 |
| Belén, C | 1 |
| Andrés, GP | 1 |
| Gonzalo, F | 1 |
| José, RJ | 1 |
| Adriana, V | 1 |
| Alberto, GC | 1 |
| Georgina, B | 1 |
| Sebastián, Y | 1 |
| Juliana, MR | 1 |
| Martin, S | 1 |
| Sol, J | 1 |
| Amalia, C | 1 |
| Cinthya, CDS | 1 |
| Morgani, R | 1 |
| Leandro, R | 1 |
| Jorge, A | 1 |
| Gustavo, K | 1 |
| Lisa, BA | 1 |
| Uemura, S | 1 |
| Kishimoto, K | 1 |
| Fujikawa, T | 1 |
| Nakamura, S | 1 |
| Kozaki, A | 1 |
| Saito, A | 3 |
| Ishida, T | 2 |
| Mori, T | 5 |
| Ozaki, K | 1 |
| Kosaka, Y | 2 |
| Wu, W | 1 |
| Xue, N | 1 |
| Yang, H | 1 |
| Gao, P | 1 |
| Han, D | 1 |
| Ersoy, GZ | 1 |
| Çipe, F | 1 |
| Fışgın, T | 1 |
| Aksoy, BA | 1 |
| Öner, ÖB | 1 |
| Hashemi, N | 1 |
| Aydoğdu, S | 1 |
| Erdem, M | 1 |
| Dikme, G | 1 |
| Murat, K | 1 |
| Bozkurt, C | 1 |
| Mehra, V | 1 |
| Slonim, LB | 1 |
| de Farias, M | 1 |
| Alshehri, H | 1 |
| Bouziana, S | 2 |
| Krishnamurthy, P | 2 |
| Kulasekararaj, A | 1 |
| Dazzi, F | 1 |
| Wood, H | 1 |
| Kenyon, M | 5 |
| Leung, YT | 1 |
| Anteh, S | 1 |
| Shah, MN | 1 |
| Hannah, G | 1 |
| Gameil, A | 1 |
| Bourlon, C | 1 |
| Dragoi, OD | 1 |
| Pagliuca, A | 4 |
| Chen, X | 3 |
| Liu, F | 1 |
| Ren, Y | 1 |
| Zhang, L | 5 |
| Wan, Y | 1 |
| Yang, W | 2 |
| Zou, Y | 1 |
| Chen, Y | 3 |
| Zhu, X | 4 |
| Guo, Y | 1 |
| Joseph, J | 1 |
| Milton, DR | 1 |
| Ramdial, JL | 2 |
| Saini, NY | 1 |
| Olson, AL | 2 |
| Long-Boyle, JR | 3 |
| Kohn, DB | 2 |
| Shah, AJ | 2 |
| Spencer, SM | 1 |
| Sevilla, J | 1 |
| Booth, C | 1 |
| López Lorenzo, JL | 1 |
| Nicoletti, E | 1 |
| Shah, A | 1 |
| Reatz, M | 1 |
| Matos, J | 1 |
| Schwartz, JD | 1 |
| Zheng, X | 2 |
| Gao, H | 1 |
| Lu, N | 2 |
| Wang, M | 2 |
| Zheng, Y | 2 |
| Shen, B | 1 |
| Cao, Y | 1 |
| Zhai, W | 1 |
| Wei, J | 1 |
| Yang, D | 2 |
| Pang, A | 1 |
| Feng, S | 2 |
| Jiang, E | 1 |
| Han, M | 1 |
| Wang, J | 5 |
| Gu, X | 1 |
| Kerbauy, MN | 1 |
| Mariano, L | 1 |
| Seber, A | 1 |
| Rocha, V | 3 |
| Shouval, R | 1 |
| Vega, Y | 1 |
| Fein, JA | 1 |
| Danylesko, I | 2 |
| Shem Tov, N | 1 |
| Yerushalmi, R | 3 |
| Sobas, M | 1 |
| Czyż, A | 1 |
| Yu, ZP | 3 |
| Ding, JH | 3 |
| Sun, AN | 2 |
| Chen, BA | 3 |
| Ge, Z | 2 |
| Wu, DP | 2 |
| Andersen, NS | 2 |
| Bornhäuser, M | 14 |
| Gramatzki, M | 2 |
| Karas, M | 1 |
| Michallet, M | 11 |
| Moreno, C | 1 |
| van Gelder, M | 1 |
| Henseler, A | 1 |
| de Wreede, LC | 2 |
| Schönland, S | 1 |
| Schetelig, J | 7 |
| Dimitrova, D | 1 |
| Gea-Banacloche, J | 2 |
| Steinberg, SM | 1 |
| Sadler, JL | 1 |
| Hicks, SN | 1 |
| Carroll, E | 1 |
| Wilder, JS | 1 |
| Parta, M | 3 |
| Skeffington, L | 1 |
| Hughes, TE | 1 |
| Blau, JE | 1 |
| Broadney, MM | 1 |
| Rose, JJ | 1 |
| Hsu, AP | 1 |
| Fletcher, R | 1 |
| Nunes, NS | 1 |
| Yan, XY | 1 |
| Telford, WG | 1 |
| Kapoor, V | 1 |
| Cohen, JI | 1 |
| Freeman, AF | 2 |
| Garabedian, E | 1 |
| Holland, SM | 3 |
| Lisco, A | 1 |
| Malech, HL | 1 |
| Notarangelo, LD | 1 |
| Sereti, I | 1 |
| Shah, NN | 4 |
| Uzel, G | 1 |
| Zerbe, CS | 2 |
| Fowler, DH | 1 |
| Gress, RE | 1 |
| Kanakry, CG | 3 |
| Kanakry, JA | 1 |
| Cao, YG | 1 |
| He, Y | 3 |
| Zhang, SD | 1 |
| Liu, ZX | 1 |
| Zhai, WH | 2 |
| Ma, QL | 2 |
| Pang, AM | 2 |
| Wei, JL | 2 |
| Yang, DL | 2 |
| Feng, SZ | 2 |
| Jiang, EL | 2 |
| Han, MZ | 2 |
| Jentzsch, M | 1 |
| Döhring, C | 1 |
| Linke, R | 1 |
| Hille, A | 1 |
| Grimm, J | 2 |
| Pönisch, W | 1 |
| Vucinic, V | 1 |
| Franke, GN | 2 |
| Behre, G | 1 |
| Schwind, S | 1 |
| Salhotra, A | 1 |
| Hui, S | 1 |
| Mokhtari, S | 1 |
| Mei, M | 2 |
| Al Malki, MM | 1 |
| Aldoss, I | 1 |
| Ali, H | 1 |
| Sandhu, KS | 1 |
| Aribi, A | 1 |
| Khaled, S | 1 |
| Dandapani, S | 1 |
| Peng, K | 1 |
| Teh, JB | 1 |
| Murata-Collins, J | 1 |
| Budde, E | 1 |
| Dadwal, S | 1 |
| Pullarkat, V | 2 |
| Snyder, D | 2 |
| Spielberger, R | 1 |
| Wong, J | 1 |
| Armenian, S | 1 |
| Marcucci, G | 3 |
| Forman, SJ | 5 |
| Stein, A | 2 |
| Tanaka, M | 3 |
| Sawa, M | 2 |
| Katayama, Y | 2 |
| Morishige, S | 2 |
| Ichinohe, T | 6 |
| Yanada, M | 2 |
| Martuszewski, A | 1 |
| Paluszkiewicz, P | 1 |
| Wawrzyniak-Dzierżek, E | 1 |
| Drożyńska-Duklas, M | 1 |
| Bąbol-Pokora, K | 1 |
| Myśliwiec, M | 1 |
| Szymczak, D | 1 |
| Irga-Jaworska, N | 1 |
| Młynarski, W | 1 |
| Ussowicz, M | 1 |
| Rybicki, L | 5 |
| Pohlman, B | 6 |
| Bolwell, B | 5 |
| Gerds, AT | 2 |
| Hamilton, BK | 2 |
| Hanna, R | 2 |
| Majhail, NS | 3 |
| Sobecks, R | 6 |
| Heinicke, T | 2 |
| Platzbecker, U | 5 |
| Sengelov, H | 2 |
| Choi, G | 1 |
| Cornelissen, J | 2 |
| Kuball, J | 2 |
| Schaap, N | 1 |
| Paul, F | 1 |
| Herr, MM | 1 |
| Curtis, RE | 1 |
| Tucker, MA | 1 |
| Tecca, HR | 1 |
| Engels, EA | 1 |
| Cahoon, EK | 1 |
| Battiwalla, M | 1 |
| Buchbinder, D | 1 |
| Flowers, ME | 6 |
| Brazauskas, R | 1 |
| Shaw, BE | 2 |
| Morton, LM | 1 |
| Shimazaki, S | 1 |
| Kazukawa, I | 1 |
| Mori, K | 1 |
| Kihara, M | 1 |
| Minagawa, M | 1 |
| El-Serafi, I | 1 |
| Remberger, M | 9 |
| Ringdèn, O | 11 |
| Törlén, J | 1 |
| Sundin, M | 3 |
| Björklund, A | 1 |
| Winiarski, J | 3 |
| Mattsson, J | 5 |
| Downey, M | 1 |
| Shanley, R | 1 |
| Jennissen, C | 1 |
| Miller, WP | 2 |
| Lund, TC | 2 |
| Smith, AR | 1 |
| Sakaguchi, H | 1 |
| Yabe, M | 2 |
| Terui, K | 2 |
| Cho, Y | 1 |
| Kakuda, H | 2 |
| Shimada, H | 1 |
| Sato, A | 1 |
| Sora, F | 2 |
| Grazia, CD | 1 |
| Bregante, S | 4 |
| Mordini, N | 2 |
| Grisariu, S | 1 |
| Terruzzi, E | 1 |
| Bacigalupo, A | 7 |
| Behfar, M | 2 |
| Koochakzadeh, L | 1 |
| Yazdanian, N | 1 |
| Salajegheh, P | 1 |
| Khodayari-Namini, N | 1 |
| Hamidieh, AA | 2 |
| Pongphitcha, P | 1 |
| Chuansumrit, A | 1 |
| Charoenkwan, P | 1 |
| Jetsrisuparb, A | 1 |
| Sanpakit, K | 1 |
| Rujkijyanont, P | 1 |
| Meekaewkunchorn, A | 1 |
| Lektrakul, Y | 1 |
| Iamsirirak, P | 1 |
| Surapolchai, P | 1 |
| Sirireung, S | 1 |
| Sruamsiri, R | 1 |
| Wahidiyat, PA | 1 |
| Narra, RK | 1 |
| Wu, R | 1 |
| Szabo, A | 1 |
| George, G | 1 |
| Michaelis, LC | 1 |
| D'Souza, A | 1 |
| Dhakal, B | 1 |
| Drobyski, WR | 1 |
| Fenske, TS | 3 |
| Jerkins, JH | 1 |
| Pasquini, MC | 2 |
| Rizzo, RD | 1 |
| Hamadani, M | 7 |
| Hari, PN | 1 |
| Saglio, F | 1 |
| Pagliara, D | 2 |
| Giorgiani, G | 4 |
| Balduzzi, A | 1 |
| Calore, E | 1 |
| Favre, C | 1 |
| Faraci, M | 2 |
| Prete, A | 1 |
| Tambaro, FP | 1 |
| Quarello, P | 1 |
| Fagioli, F | 2 |
| Wedge, E | 1 |
| Sengeløv, H | 1 |
| Hansen, JW | 1 |
| Schjødt, I | 1 |
| Petersen, SL | 1 |
| Kornblit, B | 1 |
| Grønbæk, K | 1 |
| Friis, LS | 1 |
| Yamashita, T | 5 |
| Takami, A | 3 |
| Shiratori, S | 1 |
| Akasaka, T | 1 |
| Miyakoshi, S | 4 |
| Yano, S | 4 |
| Al-Mofareh, M | 1 |
| Ayas, M | 3 |
| Al-Seraihy, A | 2 |
| Siddiqui, K | 1 |
| Al-Jefri, A | 2 |
| Ghemlas, I | 1 |
| Alsaedi, H | 1 |
| El-Solh, H | 2 |
| Al-Sweedan, S | 1 |
| Al-Saud, B | 2 |
| Al-Mousa, H | 2 |
| Al-Dhekri, H | 2 |
| Arnaout, R | 2 |
| Mohammed, R | 1 |
| Al-Muhsen, S | 2 |
| Al-Ahmari, A | 2 |
| Ghosh, N | 1 |
| Ahn, KW | 3 |
| Khanal, M | 1 |
| Litovich, C | 1 |
| Mussetti, A | 1 |
| Cairo, M | 1 |
| William, B | 2 |
| Bejanyan, N | 1 |
| Olsson, RF | 2 |
| Dahi, PB | 1 |
| Steinberg, A | 1 |
| Kanakry, J | 1 |
| Farooq, U | 1 |
| Kharfan-Dabaja, MA | 8 |
| Sureda, A | 5 |
| Peczynski, C | 1 |
| Carpenter, B | 1 |
| Potter, M | 1 |
| Malladi, R | 2 |
| Byrne, J | 2 |
| Schouten, H | 1 |
| Fegueux, N | 3 |
| Gilleece, M | 2 |
| Imahashi, N | 1 |
| Terakura, S | 3 |
| Kobayashi, H | 2 |
| Sakai, H | 1 |
| Ishikawa, J | 1 |
| Kozai, Y | 1 |
| Khandelwal, P | 1 |
| Yeh, RF | 1 |
| Yu, L | 2 |
| Lane, A | 2 |
| Dandoy, CE | 2 |
| El-Bietar, J | 1 |
| Davies, SM | 3 |
| Grimley, MS | 1 |
| Lee, SS | 1 |
| Jung, SH | 1 |
| Do, YR | 1 |
| Kim, DS | 1 |
| Moon, JH | 3 |
| Yi, JH | 1 |
| Park, Y | 1 |
| Koh, Y | 1 |
| Yhim, HY | 1 |
| Mun, YC | 1 |
| Lee, WS | 3 |
| Lee, S | 7 |
| Yang, DH | 2 |
| Wang, L | 5 |
| Fan, X | 1 |
| Tang, W | 2 |
| Hu, J | 2 |
| Contreras, CF | 1 |
| Shimano, KA | 1 |
| Melton, A | 1 |
| Kharbanda, S | 1 |
| Dara, J | 1 |
| Higham, C | 1 |
| Huang, JN | 1 |
| Cowan, MJ | 2 |
| Dvorak, CC | 4 |
| Abdelaty, MM | 1 |
| Gawaly, A | 1 |
| Fathy, GM | 1 |
| Kabbash, I | 1 |
| Taha, A | 1 |
| Woo Ahn, K | 1 |
| Kolb, AE | 1 |
| Levine, J | 1 |
| Bo-Subait, S | 1 |
| Abdel-Azim, H | 2 |
| Bhatt, N | 1 |
| Chewning, J | 1 |
| Gadalla, S | 1 |
| Gloude, N | 1 |
| Hayashi, R | 1 |
| Lalefar, NR | 1 |
| Law, J | 2 |
| MacMillan, M | 1 |
| O'Brien, T | 1 |
| Prestidge, T | 1 |
| Sharma, A | 1 |
| Winestone, L | 1 |
| Eapen, M | 2 |
| Ousia, S | 1 |
| Kalra, A | 1 |
| Williamson, TS | 1 |
| Prokopishyn, N | 1 |
| Dharmani-Khan, P | 1 |
| Khan, FM | 1 |
| Jimenez-Zepeda, V | 1 |
| Jamani, K | 1 |
| Duggan, PR | 1 |
| Daly, A | 6 |
| Russell, JA | 8 |
| Storek, J | 6 |
| Ramprakash, S | 1 |
| Raghuram, CP | 1 |
| Marwah, P | 1 |
| Soni, R | 1 |
| Trivedi, D | 1 |
| Khalid, S | 1 |
| Yaqub, N | 1 |
| Itrat, F | 1 |
| Gilani, SK | 1 |
| Zahra, T | 1 |
| Dhanya, R | 1 |
| Agarwal, RK | 1 |
| Faulkner, L | 1 |
| Wustrau, K | 1 |
| Sykora, KW | 5 |
| Wössmann, W | 2 |
| Chada, M | 1 |
| Speckmann, C | 1 |
| Seidel, M | 2 |
| Ozga, AK | 1 |
| Janka, G | 2 |
| Ehl, S | 1 |
| Lehmberg, K | 2 |
| Fox, ML | 2 |
| García-Cadenas, I | 2 |
| Pérez, AM | 1 |
| Villacampa, G | 1 |
| Piñana, JL | 7 |
| Montoro, J | 1 |
| Roldán, E | 1 |
| Bosch Vilaseca, A | 1 |
| Martino, R | 10 |
| Salamero, O | 1 |
| Saavedra, S | 1 |
| Hernandez-Boluda, JC | 2 |
| Esquirol, A | 4 |
| Sierra, J | 8 |
| Solano, C | 5 |
| Bosch, F | 1 |
| Barba, P | 4 |
| Valcarcel, D | 5 |
| Park, S | 4 |
| Min, GJ | 2 |
| Park, SS | 2 |
| Yahng, SA | 4 |
| Jeon, YW | 4 |
| Shin, SH | 4 |
| Yoon, JH | 4 |
| Lee, SE | 4 |
| Cho, BS | 4 |
| Eom, KS | 5 |
| Kim, YJ | 6 |
| Min, CK | 6 |
| Cho, SG | 4 |
| Kim, DW | 4 |
| Kim, HJ | 10 |
| D'Angelo, CR | 1 |
| Hall, A | 1 |
| Woo, KM | 1 |
| Kim, K | 1 |
| Longo, W | 1 |
| Hematti, P | 1 |
| Callander, N | 2 |
| Kenkre, VP | 2 |
| Mattison, R | 1 |
| Weinhard, S | 1 |
| Wiedemann, A | 1 |
| Leheup, B | 1 |
| Lebon Labich, B | 1 |
| Pochon, C | 2 |
| Milano, F | 3 |
| Gutman, JA | 1 |
| Nemecek, ER | 3 |
| Thur, L | 1 |
| Dahlberg, A | 1 |
| Salit, RB | 1 |
| Summers, C | 1 |
| Delaney, C | 3 |
| Kalhs, P | 2 |
| Bunjes, D | 3 |
| Sobczyk-Kruszelnicka, M | 1 |
| Byrne, JL | 1 |
| Karadogan, I | 1 |
| Jullien, M | 1 |
| Guillaume, T | 3 |
| Peterlin, P | 2 |
| Garnier, A | 1 |
| Le Bourgeois, A | 4 |
| Debord, C | 1 |
| Mahe, B | 3 |
| Dubruille, V | 3 |
| Wuilleme, S | 1 |
| Blin, N | 3 |
| Touzeau, C | 1 |
| Gastinne, T | 3 |
| Tessoulin, B | 2 |
| Le Bris, Y | 1 |
| Eveillard, M | 1 |
| Duquesne, A | 1 |
| Moreau, P | 3 |
| Le Gouill, S | 4 |
| Bene, MC | 2 |
| Yao, W | 3 |
| Chu, X | 1 |
| Fang, X | 2 |
| Tang, B | 2 |
| Wan, X | 2 |
| Geng, L | 2 |
| Tong, J | 3 |
| Song, K | 2 |
| Zhang, X | 3 |
| Qiang, P | 2 |
| Sun, G | 1 |
| Sun, Z | 2 |
| Paviglianiti, A | 2 |
| Battipaglia, G | 3 |
| Médiavilla, C | 2 |
| Bianchessi, A | 1 |
| Lapusan, S | 2 |
| Hirsch, P | 1 |
| Favale, F | 1 |
| Boussaroque, A | 1 |
| Vekhoff, A | 2 |
| Ceballos, P | 3 |
| El Cheikh, J | 3 |
| Wagner, E | 1 |
| McKiernan, JS | 1 |
| van Maarseveen, E | 1 |
| Huitema, ADR | 1 |
| Randolph, TW | 1 |
| Baker, KS | 6 |
| Rasor, B | 1 |
| Dickerson, T | 1 |
| Zhao, Q | 2 |
| Elder, P | 4 |
| Brammer, JE | 3 |
| Larkin, K | 1 |
| Jaglowski, S | 3 |
| Mims, A | 1 |
| Penza, S | 6 |
| Vasu, S | 2 |
| Wall, SA | 1 |
| Saad, A | 1 |
| Roddy, JVF | 1 |
| Choe, H | 1 |
| Puto, M | 1 |
| Giammarco, S | 1 |
| Gualandi, F | 3 |
| Varaldo, R | 2 |
| Laurenti, L | 2 |
| Metafuni, E | 1 |
| Innocenti, I | 1 |
| Autore, F | 1 |
| Murgia, B | 1 |
| Craddock, C | 1 |
| Jackson, A | 1 |
| Loke, J | 1 |
| Siddique, S | 1 |
| Hodgkinson, A | 1 |
| Mason, J | 1 |
| Andrew, G | 1 |
| Nagra, S | 1 |
| Peniket, A | 2 |
| Salim, R | 1 |
| Tholouli, E | 1 |
| Crawley, C | 1 |
| Wheatley, K | 1 |
| Protheroe, R | 1 |
| Vyas, P | 1 |
| Hunter, A | 2 |
| Parker, A | 2 |
| Wilson, K | 1 |
| Dillon, R | 1 |
| Khan, N | 1 |
| McCarthy, N | 1 |
| Freeman, SD | 1 |
| Lopez, R | 1 |
| Plat, G | 1 |
| Bertrand, Y | 6 |
| Ducassou, S | 1 |
| Saultier, P | 1 |
| Berbis, J | 2 |
| Hamidou, Z | 1 |
| Poiree, M | 2 |
| Tabone, MD | 1 |
| Kanold, J | 2 |
| Gandemer, V | 1 |
| Paillard, C | 1 |
| Sirvent, N | 2 |
| Plantaz, D | 2 |
| Thouvenin, S | 1 |
| Pellier, I | 1 |
| Ansoborlo, S | 1 |
| Leverger, G | 1 |
| Baruchel, A | 1 |
| Auquier, P | 2 |
| Michel, G | 6 |
| Versluys, AB | 1 |
| Pronk, C | 1 |
| Lankester, A | 4 |
| Bordon, V | 1 |
| Buechner, J | 1 |
| Jackmann, N | 1 |
| Vettenranta, K | 1 |
| Abrahamsson, J | 2 |
| Mellgren, K | 2 |
| Mauff, K | 1 |
| Wendel, L | 1 |
| Arcese, W | 6 |
| Rubio, MT | 3 |
| Fanin, R | 1 |
| Marotta, G | 1 |
| Sever, M | 1 |
| Contentin, N | 2 |
| Czerw, T | 1 |
| Hayden, P | 1 |
| McLornan, D | 1 |
| Nishimura, A | 1 |
| Aoki, Y | 1 |
| Ishiwata, Y | 1 |
| Ichimura, T | 1 |
| Ueyama, J | 2 |
| Kawahara, Y | 1 |
| Tomoda, T | 1 |
| Matsumoto, K | 3 |
| Inoue, K | 1 |
| Hiroki, H | 1 |
| Ono, S | 1 |
| Yamashita, M | 1 |
| Okano, T | 1 |
| Tanaka-Kubota, M | 1 |
| Ashiarai, M | 1 |
| Miyamoto, S | 1 |
| Miyawaki, R | 1 |
| Yamagishi, C | 1 |
| Tezuka, M | 1 |
| Okawa, T | 1 |
| Hoshino, A | 1 |
| Endo, A | 1 |
| Yasuhara, M | 1 |
| Kamiya, T | 1 |
| Mitsuiki, N | 1 |
| Ono, T | 1 |
| Isoda, T | 1 |
| Yanagimachi, M | 1 |
| Nagasawa, M | 1 |
| Mizutani, S | 1 |
| Kajiwara, M | 1 |
| Takagi, M | 1 |
| Kanegane, H | 1 |
| Imai, K | 1 |
| Morio, T | 1 |
| Modi, D | 1 |
| Singh, V | 1 |
| Ayash, L | 3 |
| Deol, A | 1 |
| Ratanatharathorn, V | 5 |
| Uberti, JP | 2 |
| Edahiro, T | 1 |
| Kawase, T | 1 |
| Nagoshi, H | 1 |
| Fujino, K | 1 |
| Toishigawa, K | 1 |
| Miyama, T | 1 |
| Mino, T | 1 |
| Yoshida, T | 3 |
| Morioka, T | 1 |
| Hirata, Y | 1 |
| Noma, M | 1 |
| Fujii, T | 1 |
| Nishizawa, M | 1 |
| Fukushima, N | 1 |
| Yalcin, K | 1 |
| Pehlivan, B | 1 |
| Celen, S | 1 |
| Bas, EG | 1 |
| Kabakci, C | 1 |
| Pashayev, D | 1 |
| Daloglu, H | 1 |
| Zhumatayev, S | 1 |
| Uygun, V | 1 |
| Karasu, GT | 1 |
| Hazar, V | 1 |
| Yesilipek, A | 1 |
| Tang, X | 3 |
| Ma, Y | 2 |
| Qu, C | 1 |
| Dai, H | 1 |
| Yin, J | 2 |
| Xu, T | 1 |
| Chen, Z | 1 |
| Hara, M | 3 |
| Yamamoto, H | 1 |
| Takada, S | 1 |
| Wake, A | 2 |
| Takanashi, M | 1 |
| Ishikawa, T | 1 |
| Pascual, MJ | 4 |
| Herruzo, B | 1 |
| Ferrà, C | 4 |
| Pérez, A | 1 |
| Torio, A | 1 |
| Torrent, A | 1 |
| Cuesta, M | 1 |
| Benakli, M | 1 |
| Ahmed Nacer, R | 1 |
| Mehdid, F | 1 |
| Rahmoune, N | 1 |
| Baazizi, M | 1 |
| Ait Ouali, D | 1 |
| Bouarab, H | 1 |
| Zerkout, S | 1 |
| Harieche, F | 1 |
| Saliba, RM | 5 |
| Okabe, M | 1 |
| Hirabayashi, S | 1 |
| Wang, YH | 1 |
| Tien, FM | 1 |
| Tsai, CH | 1 |
| Huang, HH | 1 |
| Liu, JH | 2 |
| Liao, XW | 1 |
| Tang, JL | 1 |
| Yao, M | 1 |
| Ko, BS | 1 |
| Araqi Houssaini, L | 1 |
| Hali, F | 1 |
| Quessar, A | 1 |
| Marnissi, F | 1 |
| Chiheb, S | 1 |
| Marsh, RA | 1 |
| Hebert, K | 1 |
| Aquino, VM | 1 |
| Chellapandian, D | 1 |
| Dávila Saldaña, B | 1 |
| Eckrich, MJ | 1 |
| Georges, GE | 2 |
| Olson, TS | 1 |
| Pulsipher, MA | 1 |
| Shenoy, S | 1 |
| Stenger, E | 1 |
| Lugt, MV | 1 |
| Yu, LC | 1 |
| Bramanti, S | 2 |
| De Philippis, C | 1 |
| Bartoli, A | 2 |
| Giordano, L | 1 |
| Mariotti, J | 1 |
| Sarina, B | 1 |
| Mannina, D | 1 |
| Valli, V | 1 |
| De Gregori, S | 1 |
| Roperti, M | 1 |
| Pieri, G | 1 |
| Fretham, C | 1 |
| Bashey, A | 2 |
| Pawarode, A | 1 |
| Scott, BL | 3 |
| Bredeson, C | 1 |
| Weisdorf, D | 1 |
| Marks, DI | 6 |
| Rizzieri, D | 2 |
| Copelan, E | 5 |
| Hale, GA | 1 |
| Liesveld, JL | 1 |
| Yves-Cahn, J | 1 |
| Szer, J | 7 |
| Diaz, MA | 1 |
| Sabloff, M | 2 |
| Farhadfar, N | 1 |
| Reshef, R | 2 |
| Hashmi, S | 1 |
| Agrawal, V | 1 |
| Wanders, DCM | 1 |
| Louwerens, M | 1 |
| Ball, LM | 1 |
| Fiocco, M | 1 |
| van Doorn, R | 1 |
| Logan, BR | 1 |
| Wu, J | 2 |
| Devine, SM | 5 |
| Maziarz, RT | 3 |
| Warlick, ED | 1 |
| Fernandez, HF | 2 |
| Alyea, EP | 9 |
| Giralt, S | 9 |
| Geller, NL | 1 |
| Leifer, E | 1 |
| Le-Rademacher, J | 1 |
| Mendizabal, AM | 1 |
| Horowitz, MM | 3 |
| Horwitz, ME | 2 |
| Uddin, R | 1 |
| Hübel, K | 1 |
| Weber, T | 1 |
| Afanasyev, B | 3 |
| Deliliers, GL | 2 |
| Pini, M | 1 |
| Guidi, S | 2 |
| Günther, A | 1 |
| Kobbe, G | 5 |
| van Os, M | 1 |
| Brand, R | 3 |
| Kim, DY | 7 |
| Ko, SH | 1 |
| Seol, M | 7 |
| Kang, YL | 1 |
| Kim, SH | 4 |
| Yun, SC | 5 |
| Jo, JC | 1 |
| Joo, YD | 3 |
| Lim, SN | 1 |
| Leon Rodriguez, E | 1 |
| Rivera Franco, MM | 1 |
| Perez Alvarez, SI | 1 |
| Spitzer, B | 1 |
| Jakubowski, AA | 3 |
| Papadopoulos, EB | 2 |
| Fuller, K | 1 |
| Hilden, PD | 1 |
| Young, JW | 2 |
| Barker, JN | 3 |
| Koehne, G | 1 |
| Perales, MA | 2 |
| Hsu, KC | 2 |
| van den Brink, MR | 1 |
| Kernan, NA | 4 |
| Prockop, SE | 2 |
| Scaradavou, A | 2 |
| Castro-Malaspina, H | 1 |
| O'Reilly, RJ | 4 |
| Boulad, F | 3 |
| Dhere, V | 1 |
| Edelman, S | 1 |
| Waller, EK | 2 |
| Langston, A | 1 |
| Graiser, M | 1 |
| Connolly, EC | 1 |
| Switchenko, JM | 1 |
| Esiashvili, N | 1 |
| Khan, MK | 1 |
| Tinelli, C | 1 |
| Lanino, E | 1 |
| Giardino, S | 1 |
| Leoni, M | 1 |
| Ferretti, M | 1 |
| Castagnola, E | 1 |
| Broglia, M | 1 |
| De Silvestri, A | 1 |
| Di Martino, D | 1 |
| Sweiss, K | 2 |
| Quigley, JG | 1 |
| Oh, A | 1 |
| Lee, J | 2 |
| Ye, R | 1 |
| Rondelli, D | 3 |
| Patel, P | 1 |
| Vigouroux, S | 4 |
| Peffault de Latour, R | 4 |
| Chantepie, S | 1 |
| Deconinck, E | 4 |
| Daguindau, E | 1 |
| Cornillon, J | 1 |
| Mercier, M | 1 |
| Turlure, P | 1 |
| Rorhlich, PS | 1 |
| N'Guyen, S | 1 |
| Maillard, N | 2 |
| Marchand, T | 2 |
| Epperla, N | 1 |
| Armand, P | 7 |
| Jagasia, M | 2 |
| Smith, SM | 1 |
| Rangarajan, HG | 1 |
| Abu-Arja, R | 1 |
| Pai, V | 1 |
| Guilcher, GMT | 1 |
| Soni, S | 2 |
| Rao, K | 5 |
| Abd Hamid, IJ | 1 |
| Nademi, Z | 2 |
| Elfeky, R | 1 |
| Pearce, MS | 1 |
| Amrolia, P | 3 |
| Worth, A | 1 |
| Flood, T | 3 |
| Abinun, M | 2 |
| Hambleton, S | 2 |
| Qasim, W | 2 |
| Gaspar, HB | 3 |
| Cant, AJ | 1 |
| Baird, K | 1 |
| Rafei, H | 1 |
| Calvo, KR | 1 |
| Hughes, T | 1 |
| Cole, K | 1 |
| Schuver, BB | 1 |
| Cuellar-Rodriguez, J | 2 |
| Hickstein, DD | 3 |
| Gereklioglu, C | 1 |
| Maytalman, E | 2 |
| Aytan, P | 1 |
| Kozanoglu, I | 2 |
| Sariturk, C | 1 |
| Satwani, P | 5 |
| Stieglitz, E | 1 |
| Cairo, MS | 6 |
| Dang, H | 1 |
| Pei, Q | 1 |
| Gao, Y | 1 |
| Wall, D | 1 |
| Mazor, T | 1 |
| Olshen, AB | 1 |
| Parker, JS | 1 |
| Kahwash, S | 1 |
| Hirsch, B | 1 |
| Raimondi, S | 1 |
| Patel, N | 1 |
| Skeens, M | 1 |
| Cooper, T | 1 |
| Mehta, PA | 2 |
| Grupp, SA | 1 |
| Loh, ML | 1 |
| Gooptu, M | 1 |
| Kim, HT | 6 |
| Ho, VT | 7 |
| Koreth, J | 4 |
| Ritz, J | 6 |
| Nikiforow, S | 2 |
| Glotzbecker, BE | 1 |
| Nageshwar, P | 1 |
| Soiffer, RJ | 11 |
| Antin, JH | 12 |
| Cutler, CS | 2 |
| Hou, H | 1 |
| Yao, YH | 1 |
| Lu, J | 1 |
| Xiao, PF | 1 |
| Bian, XN | 1 |
| Hu, DX | 1 |
| Ling, J | 1 |
| Li, J | 3 |
| Zhai, Z | 1 |
| Kong, LJ | 1 |
| Hu, SY | 1 |
| Yue, Y | 1 |
| Song, Z | 3 |
| Liu, R | 1 |
| Shi, X | 1 |
| Fujiwara, S | 1 |
| Kimura, SI | 1 |
| Maeda, T | 1 |
| Morishita, T | 1 |
| Kurata, M | 1 |
| Zhao, J | 2 |
| Fei, X | 1 |
| Yin, Y | 2 |
| Cheng, H | 1 |
| Gu, J | 1 |
| Yang, F | 1 |
| Yang, Y | 2 |
| Xue, S | 2 |
| Tian, Z | 1 |
| He, J | 2 |
| Zhang, S | 1 |
| Jiang, Y | 1 |
| Sui, X | 1 |
| Li, Y | 3 |
| Xu, H | 1 |
| Kunze, KL | 2 |
| Temkit, M | 1 |
| Partain, DK | 1 |
| Patnaik, MS | 2 |
| Slack, JL | 2 |
| Khera, N | 2 |
| Hogan, WJ | 2 |
| Roy, V | 1 |
| Noel, P | 2 |
| Leis, JF | 3 |
| Sproat, LZ | 2 |
| Fauble, V | 1 |
| Mesa, RA | 1 |
| Palmer, J | 3 |
| Gayoso, J | 3 |
| Balsalobre, P | 2 |
| Kwon, M | 2 |
| Herrera, P | 2 |
| Bermúdez, A | 3 |
| Sampol, A | 2 |
| Jiménez, S | 1 |
| López-Corral, L | 3 |
| Serrano, D | 3 |
| Heras, I | 3 |
| Bento, L | 2 |
| Varela, R | 1 |
| Humala, K | 1 |
| Zabalza, A | 2 |
| Laiglesia, A | 1 |
| Bastos-Oreiro, M | 1 |
| Pérez-Corral, A | 1 |
| Martínez-Laperche, C | 1 |
| Buño, I | 2 |
| Díez-Martín, JL | 3 |
| Sakellari, I | 1 |
| Gavriilaki, E | 1 |
| Chatziioannou, K | 1 |
| Papathanasiou, M | 1 |
| Mallouri, D | 1 |
| Batsis, I | 1 |
| Bousiou, Z | 1 |
| Constantinou, V | 1 |
| Douka, V | 1 |
| Apostolou, C | 1 |
| Iskas, M | 1 |
| Lalayanni, C | 1 |
| Athanasiadou, A | 1 |
| Sotiropoulos, D | 1 |
| Yannaki, E | 1 |
| Gianouzakos, V | 1 |
| Anagnostopoulos, A | 1 |
| Al-Jomaie, M | 1 |
| Al-Ghonaium, A | 1 |
| Elshorbagi, S | 1 |
| Khalil, MMI | 1 |
| Messner, HA | 3 |
| Lipton, JH | 3 |
| Kim, DD | 2 |
| Viswabandya, A | 2 |
| Thyagu, S | 1 |
| Deotare, U | 1 |
| Michelis, FV | 2 |
| Haskoloğlu, Ş | 1 |
| Köstel Bal, S | 1 |
| İslamoğlu, C | 1 |
| Altun, D | 1 |
| Kendirli, T | 1 |
| Doğu, EF | 1 |
| İkincioğulları, A | 1 |
| Saraceni, F | 1 |
| Beohou, E | 2 |
| Stepensky, P | 2 |
| Passweg, J | 3 |
| Lanza, F | 1 |
| Eduardo, FP | 1 |
| Bezinelli, LM | 1 |
| Gobbi, M | 1 |
| Rosin, FCP | 1 |
| Carvalho, DLC | 1 |
| Ferreira, MH | 1 |
| da Silva, CC | 1 |
| Corrêa, L | 1 |
| Speziali, C | 1 |
| Abuhaleeqa, M | 1 |
| Nitta, J | 1 |
| Abou Mourad, Y | 1 |
| Seftel, MD | 1 |
| Paulson, K | 1 |
| Yang, J | 1 |
| Cai, Y | 1 |
| Jiang, JL | 1 |
| Wan, LP | 1 |
| Bai, HT | 1 |
| Zhu, J | 1 |
| Song, XM | 1 |
| Wang, C | 1 |
| Andreani, M | 5 |
| Gregori, S | 1 |
| Arnold, DE | 1 |
| Seif, AE | 1 |
| Jyonouchi, S | 1 |
| Sullivan, KE | 1 |
| Bunin, NJ | 1 |
| Heimall, JR | 1 |
| Calip, GS | 1 |
| Oh, AL | 1 |
| Patel, PR | 1 |
| Khetarpal, BK | 1 |
| McCallen, MR | 1 |
| Betcher, JA | 1 |
| Ofori, HT | 1 |
| Ram, R | 1 |
| Amit, O | 1 |
| Chemnitz, JM | 1 |
| Moshe, Y | 1 |
| Hallek, M | 2 |
| Wolf, D | 1 |
| Avivi, I | 1 |
| Holtick, U | 1 |
| Bastos, J | 1 |
| Giannotti, F | 1 |
| de Wyngaert, ZV | 1 |
| Adaeva, R | 1 |
| Isnard, F | 1 |
| Ruggeri, A | 1 |
| Ciurea, SO | 1 |
| Khouri, I | 5 |
| Molldrem, JJ | 1 |
| Sun, L | 1 |
| Wang, N | 1 |
| Tang, L | 1 |
| Xing, C | 1 |
| Shi, Y | 2 |
| Yu, K | 1 |
| Feng, J | 1 |
| Pagliardini, T | 1 |
| Harbi, S | 4 |
| Porta, MD | 1 |
| Rey, J | 2 |
| Fürst, S | 8 |
| Saillard, C | 2 |
| Legrand, F | 1 |
| Maisano, V | 1 |
| Faucher, C | 9 |
| Granata, A | 5 |
| Hospital, MA | 1 |
| Lining, W | 1 |
| Weiller, PJ | 2 |
| Calmels, B | 5 |
| Lemarie, C | 6 |
| Chabannon, C | 10 |
| Vey, N | 8 |
| Mokart, D | 1 |
| Saco, A | 1 |
| Alòs, S | 1 |
| Esteve, R | 1 |
| Suárez-Lledó, M | 1 |
| Martínez, C | 1 |
| Perez, FM | 1 |
| Vega, N | 1 |
| Martí, C | 1 |
| Torne, A | 1 |
| Ordi, J | 1 |
| Del Pino, M | 1 |
| Zhao, XL | 1 |
| Eroglu, C | 1 |
| Pala, C | 1 |
| Kaynar, L | 1 |
| Yaray, K | 1 |
| Aksozen, MT | 1 |
| Bankir, M | 1 |
| Zararsız, G | 1 |
| Orhan, O | 1 |
| Gündog, M | 1 |
| Yıldız, OG | 1 |
| Eser, B | 1 |
| Cetin, M | 1 |
| Unal, A | 2 |
| Bayraktar, UD | 1 |
| de Lima, M | 10 |
| Maloy, M | 1 |
| Castro-Malaspina, HR | 1 |
| Chiattone, A | 3 |
| Mårtensson, T | 1 |
| Priftakis, P | 1 |
| Casswall, T | 1 |
| Hassan, M | 11 |
| Gustafsson, B | 1 |
| Mohr, C | 1 |
| Delaunay, J | 2 |
| Loirat, M | 1 |
| Planche, L | 2 |
| Lode, L | 1 |
| Ago, H | 1 |
| Kakihana, K | 1 |
| Adachi, T | 1 |
| Yujiri, T | 1 |
| Taniguchi, S | 9 |
| Taguchi, J | 1 |
| Morishima, Y | 2 |
| Nagamura, T | 1 |
| Murata, M | 3 |
| Chen, YB | 5 |
| Coughlin, E | 1 |
| Kennedy, KF | 1 |
| Attar, EC | 1 |
| Ballen, KK | 2 |
| Cutler, C | 7 |
| Dey, BR | 2 |
| McAfee, SL | 2 |
| Spitzer, TR | 4 |
| Anasetti, C | 11 |
| Perkins, J | 4 |
| Ochoa-Bayona, JL | 2 |
| Pidala, J | 4 |
| Perez, LE | 1 |
| Ayala, E | 5 |
| Field, T | 4 |
| Alsina, M | 2 |
| Locke, F | 3 |
| Pinilla-Ibarz, J | 1 |
| Tomblyn, M | 2 |
| Kumar, AJ | 1 |
| Boyer, J | 1 |
| Levine, BL | 1 |
| June, CH | 1 |
| Goldstein, SC | 1 |
| Mathews, V | 1 |
| George, B | 2 |
| Abraham, A | 1 |
| Ganapule, A | 1 |
| Sindhuvi, E | 1 |
| Lakshmi, KM | 1 |
| Srivastava, A | 1 |
| Crocchiolo, R | 6 |
| Signori, A | 1 |
| Oudin, C | 3 |
| Ben Othman, T | 2 |
| Campos, A | 2 |
| Masszi, T | 1 |
| Veelken, H | 2 |
| Kunter, G | 1 |
| Perkins, JB | 1 |
| Fernandez, H | 3 |
| Perez, L | 3 |
| Betts, B | 1 |
| Nieder, M | 1 |
| Li, YF | 1 |
| Ding, BH | 1 |
| Qian, J | 1 |
| Gao, L | 2 |
| Gong, Y | 1 |
| Zhang, C | 1 |
| Chen, XH | 1 |
| Storci, G | 1 |
| Bandini, G | 3 |
| Marasco, E | 1 |
| Dan, E | 1 |
| Zani, E | 1 |
| Albani, F | 1 |
| Bertoni, S | 1 |
| Bontadini, A | 1 |
| De Carolis, S | 1 |
| Sapienza, MR | 1 |
| Rizzi, S | 3 |
| Motta, MR | 3 |
| Ferioli, M | 1 |
| Garagnani, P | 1 |
| Cavo, M | 2 |
| Mantovani, V | 1 |
| Bonafè, M | 1 |
| Mezziani, S | 1 |
| Desjean, C | 1 |
| Vachon, MF | 1 |
| Champagne, MA | 1 |
| Duval, M | 1 |
| Hussein, AA | 1 |
| Hamadah, T | 1 |
| Domm, J | 2 |
| Al-Zaben, A | 1 |
| Frangoul, H | 2 |
| D'Incan, E | 1 |
| Coso, D | 3 |
| Etienne, A | 2 |
| Schiano, JM | 1 |
| Stoppa, AM | 6 |
| Bouabdallah, R | 5 |
| Teira, P | 1 |
| Slatter, M | 4 |
| Stussi, G | 1 |
| Vermont, C | 1 |
| Ahmad, I | 1 |
| Shaw, PJ | 1 |
| Telles da Cunha, JM | 1 |
| Hough, R | 2 |
| Fasth, A | 2 |
| Kentouche, K | 1 |
| Fernandes, JF | 1 |
| Lachance, S | 1 |
| Bredius, R | 1 |
| Resnick, IB | 5 |
| Belohradsky, BH | 2 |
| Gennery, A | 1 |
| Seger, R | 2 |
| Rentsch, K | 1 |
| Haddad, E | 1 |
| Beutel, K | 1 |
| Woessmann, W | 1 |
| Liu, DH | 5 |
| Xu, LP | 4 |
| Zhang, XH | 3 |
| Wang, Y | 2 |
| Yan, CH | 1 |
| Wang, JZ | 2 |
| Wang, FR | 1 |
| Sun, YQ | 1 |
| Ji, Y | 1 |
| Zhang, YY | 1 |
| Liu, KY | 4 |
| Huang, XJ | 4 |
| Taimur, S | 1 |
| Askar, M | 1 |
| Warshawsky, I | 1 |
| Mossad, S | 1 |
| Bartelink, IH | 2 |
| van Reij, EM | 1 |
| Gerhardt, CE | 1 |
| van Maarseveen, EM | 1 |
| de Wildt, A | 1 |
| Versluys, B | 2 |
| Bierings, MB | 2 |
| Mohty, B | 1 |
| Broussais-Guillaumot, F | 1 |
| Yoshimi, A | 1 |
| Baumann, I | 1 |
| Furlan, I | 1 |
| Schwarz, S | 1 |
| Teigler-Schlegel, A | 1 |
| Walther, JU | 1 |
| Schlegelberger, B | 1 |
| Göhring, G | 1 |
| Nöllke, P | 1 |
| Führer, M | 1 |
| Niemeyer, CM | 2 |
| de Berranger, E | 1 |
| Cousien, A | 1 |
| Petit, A | 1 |
| Galambrun, C | 3 |
| Salmon, A | 1 |
| Rialland, F | 1 |
| Rohrlich, PS | 1 |
| Vannier, JP | 2 |
| Lutz, P | 3 |
| Yakouben, K | 1 |
| Duhamel, A | 1 |
| Rauenzahn, S | 1 |
| Truong, Q | 1 |
| Cumpston, A | 2 |
| Goff, L | 1 |
| Leadmon, S | 2 |
| Evans, K | 1 |
| Zhang, J | 1 |
| Wen, S | 1 |
| Craig, M | 2 |
| Kanate, AS | 1 |
| Gazourian, L | 1 |
| Rogers, AJ | 1 |
| Ibanga, R | 1 |
| Weinhouse, GL | 1 |
| Pinto-Plata, V | 1 |
| Washko, GR | 1 |
| Baron, RM | 1 |
| Matsuyama, T | 2 |
| Gyurkocza, B | 1 |
| Gutman, J | 1 |
| Bar, M | 1 |
| Ramakrishnan, A | 1 |
| Fang, M | 1 |
| Wood, B | 1 |
| Pagel, JM | 1 |
| Sandmaier, BM | 4 |
| Estey, EH | 1 |
| Nagatoshi, Y | 2 |
| Kikuchi, A | 1 |
| Kigasawa, H | 1 |
| Horikoshi, Y | 1 |
| Oda, M | 1 |
| Kaneda, M | 1 |
| Mugishima, H | 1 |
| Tsuchida, M | 1 |
| Kawano, Y | 5 |
| Huezo-Diaz, P | 1 |
| Uppugunduri, CR | 1 |
| Tyagi, AK | 1 |
| Choi, I | 1 |
| Yoon, SR | 1 |
| Park, SY | 1 |
| Jung, SJ | 1 |
| Jang, YJ | 1 |
| Kang, M | 1 |
| Yeom, YI | 1 |
| Lee, JL | 2 |
| Berger, R | 1 |
| Bouazzaoui, A | 1 |
| Dickhöfer, S | 1 |
| Kreuz, M | 1 |
| Huber, E | 1 |
| Wolff, D | 3 |
| Chantepie, SP | 1 |
| Gac, AC | 1 |
| Reman, O | 2 |
| Kim, JH | 3 |
| Tsai, N | 1 |
| Schultheiss, TE | 1 |
| Liu, A | 1 |
| Rosenthal, J | 2 |
| Wong, JY | 1 |
| Gross, TG | 1 |
| Rangarajan, H | 1 |
| Sturm, M | 1 |
| Rhodes, M | 1 |
| Schwab, L | 1 |
| Goroncy, L | 1 |
| Palaniyandi, S | 1 |
| Gautam, S | 1 |
| Triantafyllopoulou, A | 1 |
| Mocsai, A | 1 |
| Reichardt, W | 1 |
| Karlsson, FJ | 1 |
| Radhakrishnan, SV | 1 |
| Hanke, K | 1 |
| Schmitt-Graeff, A | 1 |
| Freudenberg, M | 1 |
| von Loewenich, FD | 1 |
| Wolf, P | 1 |
| Leonhardt, F | 1 |
| Baxan, N | 1 |
| Pfeifer, D | 1 |
| Schmah, O | 1 |
| Schönle, A | 1 |
| Martin, SF | 1 |
| Mertelsmann, R | 2 |
| Duyster, J | 1 |
| Prinz, M | 1 |
| Henneke, P | 1 |
| Häcker, H | 1 |
| Häcker, G | 1 |
| Zeiser, R | 1 |
| Forcina, A | 1 |
| Clerici, D | 1 |
| Vago, L | 1 |
| Stanghellini, MT | 1 |
| Noviello, M | 1 |
| Messina, C | 1 |
| Crotta, A | 1 |
| Assanelli, A | 1 |
| Marktel, S | 2 |
| Olek, S | 1 |
| Mastaglio, S | 1 |
| Crucitti, L | 1 |
| Lorusso, A | 1 |
| Guggiari, E | 1 |
| Lunghi, F | 1 |
| Carrabba, M | 1 |
| Tassara, M | 1 |
| Battaglia, M | 1 |
| Ferraro, A | 1 |
| Carbone, MR | 1 |
| Oliveira, G | 1 |
| Roncarolo, MG | 2 |
| Rossini, S | 1 |
| Bernardi, M | 1 |
| Corti, C | 1 |
| Marcatti, M | 1 |
| Bordignon, C | 1 |
| Fleischhauer, K | 1 |
| Bondanza, A | 1 |
| Bonini, C | 1 |
| Zhao, XF | 1 |
| Mao, XF | 1 |
| Wan, DM | 1 |
| Liu, W | 2 |
| Fedele, R | 1 |
| Messina, G | 1 |
| Martinello, T | 1 |
| Gallo, GA | 1 |
| Pontari, A | 1 |
| Moscato, T | 1 |
| Console, G | 1 |
| Dattola, A | 1 |
| Princi, D | 1 |
| Cuzzola, M | 1 |
| Alati, C | 1 |
| Ronco, F | 1 |
| Molica, S | 1 |
| Irrera, G | 2 |
| Abedin, S | 1 |
| Peres, E | 1 |
| Levine, JE | 2 |
| Choi, S | 1 |
| Yanik, G | 2 |
| Couriel, DR | 1 |
| Uhm, J | 1 |
| Shanavas, M | 1 |
| Kuruvilla, J | 1 |
| Seftel, M | 1 |
| Schwinger, W | 1 |
| Sovinz, P | 1 |
| Benesch, M | 1 |
| Lackner, H | 1 |
| Strenger, V | 1 |
| Sperl, D | 1 |
| Raicht, A | 1 |
| Brunner-Krainz, M | 1 |
| Paschke, E | 1 |
| Plecko, B | 1 |
| Urban, C | 2 |
| Wang, Z | 1 |
| Li, D | 2 |
| Tao, Y | 1 |
| Wu, B | 2 |
| Du, Q | 1 |
| Sun, C | 2 |
| Lin, X | 1 |
| Tu, S | 2 |
| Song, C | 1 |
| Lu, Z | 1 |
| Salem, G | 1 |
| Ruppert, AS | 1 |
| Hofmeister, CC | 1 |
| Benson, DM | 3 |
| Andritsos, L | 3 |
| Klisovic, R | 2 |
| Blum, W | 5 |
| Efebera, YA | 1 |
| Oshrine, B | 1 |
| Morsheimer, M | 1 |
| Heimall, J | 1 |
| Bunin, N | 2 |
| Burroughs, LM | 1 |
| Torgerson, TR | 1 |
| Talano, JA | 2 |
| Giller, RH | 1 |
| Shimamura, A | 1 |
| Skoda-Smith, S | 1 |
| Thakar, MS | 1 |
| Rawlings, DJ | 1 |
| Englund, JA | 1 |
| Storb, R | 14 |
| Woolfrey, AE | 1 |
| Boztug, H | 2 |
| Skinner, R | 2 |
| Wachowiak, J | 4 |
| Pötschger, U | 2 |
| Hunter, MR | 1 |
| Sabo, RT | 1 |
| McCarty, JM | 1 |
| Newland, AM | 1 |
| Furlong, T | 3 |
| de Lima, MJ | 1 |
| Wei, W | 2 |
| Medeot, M | 1 |
| Mielcarek, M | 3 |
| Jones, RJ | 4 |
| Luznik, L | 2 |
| Horwitz, M | 1 |
| Barlogis, V | 1 |
| Contet, A | 1 |
| Villes, V | 1 |
| Chastagner, P | 1 |
| Li, JJ | 1 |
| Chen, XC | 1 |
| Liu, ZG | 1 |
| Lu, ZP | 1 |
| Huang, XO | 1 |
| Liu, T | 1 |
| Min, WS | 5 |
| Park, CW | 1 |
| Bouabdallah, K | 2 |
| Asselineau, J | 1 |
| Chevalier, P | 2 |
| Tournilhac, O | 2 |
| Tabrizi, R | 4 |
| Doussau, A | 1 |
| Milpied, N | 6 |
| Baron, F | 1 |
| Jindra, P | 1 |
| Sanz, MA | 3 |
| Stentz, A | 1 |
| Gajewski, J | 5 |
| Curtin, P | 1 |
| Hayes-Lattin, B | 1 |
| Kovacsovics, T | 1 |
| Meyers, G | 1 |
| Nemecek, E | 1 |
| Subbiah, N | 1 |
| Frires, R | 1 |
| Palmbach, G | 1 |
| Avraham, GP | 1 |
| Slater, S | 1 |
| Choi, YS | 1 |
| Ohtsuka, Y | 1 |
| Inagaki, J | 3 |
| Sakashita, K | 1 |
| Kurosawa, H | 1 |
| Kudo, K | 3 |
| Manabe, A | 1 |
| Ishida, H | 2 |
| Goto, H | 3 |
| Kawa, K | 1 |
| Depau, C | 2 |
| Targhetta, C | 1 |
| Derudas, D | 1 |
| Culurgioni, F | 1 |
| Tandurella, I | 1 |
| Latte, G | 1 |
| Palmas, A | 1 |
| Grossman, J | 1 |
| Su, H | 1 |
| Murdock, H | 1 |
| Bollard, C | 1 |
| Kong, HH | 1 |
| Moutsopoulos, N | 1 |
| Stone, K | 1 |
| Figueroa, J | 1 |
| Kim, J | 2 |
| Yue, B | 1 |
| Riches, M | 1 |
| Azik, F | 1 |
| Ozbek, N | 1 |
| Isik, P | 1 |
| Avci, Z | 1 |
| Tavil, B | 1 |
| Kara, A | 1 |
| Tunc, B | 1 |
| Andersson, B | 4 |
| Jones, R | 2 |
| Al Atrash, G | 1 |
| Oshima, K | 1 |
| Akahoshi, Y | 1 |
| Nakano, H | 1 |
| Ugai, T | 1 |
| Yamasaki, R | 1 |
| Wada, H | 1 |
| Ishihara, Y | 1 |
| Sakamoto, K | 1 |
| Kawamura, K | 1 |
| Ashizawa, M | 1 |
| Terasako-Saito, K | 1 |
| Kimura, S | 2 |
| Kikuchi, M | 1 |
| Tanihara, A | 1 |
| Yamazaki, R | 1 |
| Tanaka, Y | 1 |
| Nishida, J | 1 |
| Morita, K | 1 |
| Aldenhoven, M | 1 |
| Jones, SA | 1 |
| Bonney, D | 1 |
| Borrill, RE | 1 |
| Coussons, M | 1 |
| Mercer, J | 1 |
| van Hasselt, PM | 1 |
| Wijburg, FA | 1 |
| van der Ploeg, AT | 1 |
| Wynn, RF | 1 |
| Strocchio, L | 1 |
| Comoli, P | 2 |
| Mina, T | 1 |
| Giraldi, E | 1 |
| Vinti, L | 1 |
| Merli, P | 2 |
| Regazzi, M | 1 |
| Parody, R | 1 |
| Montesinos, P | 2 |
| Terol, MJ | 2 |
| Moscardó, F | 1 |
| Sanz, G | 2 |
| Li, N | 2 |
| Hu, W | 1 |
| Chen, P | 1 |
| Dehghani, SS | 1 |
| Hosseini, AS | 1 |
| Jalali, A | 2 |
| Schneider, S | 1 |
| Strumpf, A | 1 |
| Wunderlich, G | 1 |
| Ehninger, G | 11 |
| Kotzerke, J | 1 |
| Kroeger, N | 2 |
| Or, R | 12 |
| Lioure, B | 3 |
| Fisher, DC | 2 |
| Driscoll, J | 2 |
| Del Rio, C | 1 |
| Abramson, J | 1 |
| Barnes, J | 1 |
| Brown, J | 1 |
| El-Jawahri, A | 2 |
| Hochberg, E | 1 |
| McAfee, S | 1 |
| Takvorian, R | 1 |
| Soiffer, R | 1 |
| Jacobsen, E | 1 |
| Lange, PB | 1 |
| Bindra, B | 1 |
| Reynolds, CG | 1 |
| Chammas, MJ | 1 |
| Glotzbecker, B | 1 |
| Blazar, BR | 4 |
| Yuan, J | 1 |
| Ren, H | 1 |
| Qiu, Z | 1 |
| Xu, W | 1 |
| Liang, Z | 1 |
| Dong, Y | 1 |
| Ou, J | 1 |
| Wang, W | 1 |
| Cen, X | 1 |
| Wang, Q | 1 |
| Lee, HC | 1 |
| Charafeddine, Y | 1 |
| Medeiros, LJ | 1 |
| Champlin, R | 4 |
| Masuda, A | 1 |
| Totani, H | 1 |
| Narita, T | 1 |
| Masaki, A | 1 |
| Ito, A | 1 |
| Ri, M | 1 |
| Komatsu, H | 1 |
| Iida, S | 1 |
| Shea, TC | 2 |
| Walko, C | 1 |
| Chung, Y | 1 |
| Ivanova, A | 1 |
| Sheets, J | 1 |
| Gabriel, D | 1 |
| Comeau, T | 1 |
| Wood, W | 1 |
| Coghill, J | 1 |
| Armistead, P | 1 |
| Sarantopoulos, S | 1 |
| Serody, J | 1 |
| Mahadeo, KM | 1 |
| Khazal, S | 1 |
| Crooks, GM | 1 |
| Kapoor, N | 7 |
| Hunnewell, C | 1 |
| Poliquin, C | 1 |
| Saylor, M | 1 |
| Alyea, E | 1 |
| Ogawa, A | 1 |
| Sawada, A | 1 |
| Koh, H | 2 |
| Katayama, T | 1 |
| Nishimoto, M | 2 |
| Hayashi, Y | 2 |
| Nakashima, Y | 1 |
| Nakane, T | 2 |
| Nakamae, M | 4 |
| Hirose, A | 1 |
| Hino, M | 5 |
| Lombardi, LR | 1 |
| Zahurak, M | 2 |
| Durakovic, N | 1 |
| Bolaños-Meade, J | 1 |
| Kasamon, YL | 1 |
| Gladstone, DE | 1 |
| Matsui, W | 1 |
| Borrello, I | 1 |
| Huff, CA | 1 |
| Swinnen, LJ | 1 |
| Brodsky, RA | 1 |
| Ambinder, RF | 2 |
| Fuchs, EJ | 1 |
| Rosner, GL | 1 |
| Trenschel, R | 3 |
| Arnold, R | 2 |
| Martin, H | 2 |
| Heinzelmann, M | 1 |
| Meyer, RG | 1 |
| Gökbuget, N | 1 |
| Hölzer, D | 1 |
| Zander, A | 7 |
| Cant, A | 3 |
| Chaudhry, HM | 1 |
| Bruce, AJ | 1 |
| Wolf, RC | 1 |
| Litzow, MR | 1 |
| Kremers, WK | 1 |
| Phillips, GL | 3 |
| Hashmi, SK | 1 |
| Choi, B | 1 |
| Kim, MG | 1 |
| Han, N | 1 |
| Kim, T | 1 |
| Ji, E | 1 |
| Kim, IW | 1 |
| Oh, JM | 1 |
| Owzar, K | 1 |
| Mulkey, F | 1 |
| Stone, RM | 1 |
| Hsu, JW | 1 |
| Vij, R | 1 |
| Slack, J | 1 |
| Larson, RA | 2 |
| Hars, V | 1 |
| Sibley, AB | 1 |
| Carter, S | 1 |
| Linker, C | 1 |
| Ravinet, A | 1 |
| Cabrespine, A | 1 |
| Yakoub Agha, I | 1 |
| Menard, AL | 1 |
| Deteix, C | 1 |
| Cassuto, JP | 2 |
| Maury, S | 1 |
| Hagiwara, S | 1 |
| Ito, T | 1 |
| Hatanaka, K | 2 |
| Yamaguchi, T | 1 |
| Riesner, K | 1 |
| Kalupa, M | 1 |
| Elezkurtaj, S | 1 |
| Penack, O | 1 |
| Jaiswal, SR | 1 |
| Chakrabarti, A | 1 |
| Chatterjee, S | 1 |
| Bhargava, S | 1 |
| Ray, K | 1 |
| O'Donnell, P | 1 |
| Chakrabarti, S | 2 |
| Li, ZH | 1 |
| Fan, SF | 1 |
| Shen, Y | 1 |
| Yi, W | 1 |
| Ye, Y | 1 |
| Guo, K | 2 |
| Luan, Z | 1 |
| Wu, N | 1 |
| Jing, Y | 2 |
| Du, H | 1 |
| Lu, W | 1 |
| Chen, F | 1 |
| Miao, M | 1 |
| Fu, C | 1 |
| Qiu, H | 1 |
| Jin, Z | 2 |
| Sun, A | 1 |
| Chang, W | 1 |
| Ruan, C | 1 |
| Carpenter, PA | 1 |
| Shaffer, BC | 1 |
| Le Luduec, JB | 1 |
| Forlenza, C | 1 |
| Zahler, S | 1 |
| Bhatia, M | 5 |
| Ricci, A | 1 |
| Roy, S | 1 |
| Morris, E | 4 |
| Harrison, L | 4 |
| van de Ven, C | 5 |
| Fabricatore, S | 1 |
| Wolownik, K | 2 |
| Cooney-Qualter, E | 1 |
| Baxter-Lowe, LA | 7 |
| Luisi, P | 1 |
| Militano, O | 2 |
| Kletzel, M | 1 |
| Ilushina, M | 1 |
| Kurnikova, E | 1 |
| Boyakova, E | 1 |
| Persiantseva, M | 1 |
| Muzalevskii, Y | 1 |
| Kazachenok, A | 1 |
| Glushkova, S | 1 |
| Bobrynina, V | 1 |
| Kalinina, V | 1 |
| Olshanskaya, Y | 1 |
| Baidildina, D | 1 |
| Novichkova, G | 1 |
| Wanquet, A | 1 |
| Zheng, C | 1 |
| Ding, K | 1 |
| De La Serna, J | 1 |
| Cabrero, M | 2 |
| Vallejo, C | 1 |
| Gómez, V | 1 |
| Moraleda, JM | 3 |
| Perez, SG | 1 |
| Caballero, MD | 2 |
| Conde, E | 1 |
| Lahuerta, JJ | 1 |
| Porcher, R | 2 |
| Sicre de Fontbrune, F | 1 |
| Alchalby, H | 1 |
| Christopeit, M | 1 |
| Cassinat, B | 1 |
| Zabelina, T | 11 |
| Zaidman, I | 2 |
| Rowe, JM | 3 |
| Khalil, A | 1 |
| Ben-Arush, M | 1 |
| Elhasid, R | 2 |
| Ji, YS | 1 |
| Lee, MS | 2 |
| Min, CW | 1 |
| Yun, J | 1 |
| Kim, KH | 1 |
| Kim, CK | 1 |
| Lee, KT | 1 |
| Won, JH | 1 |
| Hong, DS | 1 |
| Li, WD | 1 |
| Gao, ZY | 2 |
| Yu, XJ | 1 |
| Lu, DY | 1 |
| Lu, DP | 3 |
| Castilla-Llorente, C | 1 |
| Pascual, C | 1 |
| Figuera, A | 1 |
| Morillo-Gutierrez, B | 1 |
| Burroughs, L | 1 |
| Ewins, AM | 1 |
| Gibson, B | 2 |
| Krol, L | 1 |
| Kalwak, K | 1 |
| Woolfrey, A | 2 |
| Fraser, C | 1 |
| Meyts, I | 1 |
| Huang, WR | 1 |
| Li, HH | 1 |
| Gao, CJ | 1 |
| Bo, J | 1 |
| Li, F | 1 |
| Dou, LP | 1 |
| Wang, LL | 1 |
| Fox, PS | 1 |
| Ning, J | 1 |
| Garber, HR | 1 |
| Janbey, S | 1 |
| Worth, LL | 2 |
| Jones, RB | 3 |
| Kennedy, VE | 1 |
| Greer, JP | 1 |
| Kassim, AA | 1 |
| Engelhardt, BG | 1 |
| Goodman, SA | 1 |
| Sengsayadeth, S | 1 |
| Chinratanalab, W | 1 |
| Kekre, N | 1 |
| Marquez-Malaver, FJ | 1 |
| Piñana, J | 1 |
| Caballero, D | 3 |
| Pérez-Simon, JA | 4 |
| Sun, ZM | 1 |
| Liu, HL | 1 |
| Wu, Y | 1 |
| Geng, LQ | 1 |
| Zheng, CC | 1 |
| Tang, BL | 1 |
| Zhu, XY | 1 |
| Wang, XB | 1 |
| Ding, KY | 1 |
| Han, YS | 1 |
| Yang, HZ | 1 |
| Zhu, WW | 1 |
| Wu, JS | 1 |
| Wang, ZY | 1 |
| Bittenbring, J | 1 |
| Yokoyama, H | 2 |
| Ohno, H | 1 |
| Ueda, Y | 2 |
| Iwato, K | 1 |
| Lucchini, G | 1 |
| Dalissier, A | 1 |
| Cornish, J | 1 |
| Samarasinghe, S | 1 |
| Abdel-Rahman, F | 1 |
| Heilmann, C | 1 |
| Mallhi, K | 1 |
| Tolar, J | 1 |
| Mustafa Ali, M | 1 |
| Abounader, DM | 1 |
| Rybicki, LA | 1 |
| Yurch, MA | 1 |
| Starn, J | 1 |
| Ferraro, C | 1 |
| Winslow, V | 1 |
| Dean, R | 2 |
| Hill, BT | 1 |
| Andresen, S | 4 |
| Bolwell, BJ | 3 |
| Sobecks, RM | 1 |
| D'Aveni-Piney, M | 1 |
| Daguindeau, E | 1 |
| Richard, C | 1 |
| Yeshurun, M | 2 |
| Maher, OM | 1 |
| Silva, JG | 1 |
| Liu, D | 1 |
| Cooper, LJ | 1 |
| Tarek, N | 1 |
| Worth, L | 3 |
| Lee, DA | 1 |
| Petropoulos, D | 2 |
| Franklin, AR | 1 |
| Zweidler-Mckay, P | 1 |
| Wells, RJ | 1 |
| Tewari, P | 1 |
| Leemhuis, T | 1 |
| Myers, K | 1 |
| Williams, DA | 1 |
| Lehmann, L | 1 |
| Guinan, E | 1 |
| Margolis, D | 1 |
| Lam, W | 1 |
| Li, H | 1 |
| Geddes, M | 5 |
| Bonanomi, S | 1 |
| Bonnanomi, S | 1 |
| Connor, P | 1 |
| Webb, D | 1 |
| Ancliff, P | 1 |
| McCloskey, D | 1 |
| Hemmatpour, S | 1 |
| Goulden, N | 2 |
| Di Bartolomeo, P | 4 |
| Pilo, F | 1 |
| Pettinau, M | 1 |
| Mico, C | 1 |
| Duan, Q | 1 |
| Chaudhry, MA | 5 |
| Savoie, ML | 4 |
| Balogh, A | 3 |
| Turner, AR | 5 |
| Larratt, L | 5 |
| Bahlis, NJ | 5 |
| Brown, CB | 4 |
| Quinlan, D | 6 |
| Zacarias, N | 3 |
| Duggan, P | 3 |
| Stewart, DA | 5 |
| Ho, V | 3 |
| Krivoy, N | 2 |
| Hoffer, E | 1 |
| Lurie, Y | 1 |
| Bentur, Y | 1 |
| Bredeson, CN | 1 |
| Zhang, MJ | 2 |
| Agovi, MA | 1 |
| Brown, C | 2 |
| Kurian, S | 1 |
| Muehlenbien, CE | 1 |
| Savoie, L | 1 |
| Rizzo, JD | 1 |
| Tokimasa, S | 1 |
| Ohta, H | 1 |
| Takizawa, S | 1 |
| Kusuki, S | 1 |
| Sakai, N | 1 |
| Taniike, M | 1 |
| Ozono, K | 1 |
| Hara, J | 1 |
| Saito, B | 1 |
| Takahashi, T | 1 |
| Takahashi, N | 1 |
| Tajima, K | 2 |
| Mori, SI | 2 |
| Tanosaki, R | 11 |
| Takaue, Y | 14 |
| Heike, Y | 6 |
| Sadeghi, B | 3 |
| Aghdami, N | 1 |
| Hassan, Z | 4 |
| Forouzanfar, M | 1 |
| Rozell, B | 3 |
| Abedi-Valugerdi, M | 2 |
| Piras, E | 2 |
| Cugno, C | 1 |
| Caocci, G | 2 |
| Mastronuzzi, A | 2 |
| La Nasa, G | 5 |
| Kami, M | 9 |
| Kodera, Y | 1 |
| Usui, N | 1 |
| Harada, M | 1 |
| Okamoto, S | 2 |
| Saito, AM | 2 |
| Ohashi, Y | 2 |
| Ueda, R | 1 |
| Bleyzac, N | 2 |
| Kerbauy, FR | 1 |
| Tirapelli, B | 1 |
| Akabane, H | 1 |
| Oliveira, JS | 1 |
| Moreno, E | 1 |
| Vega, M | 1 |
| Delgado, J | 2 |
| Briones, J | 2 |
| Brunet, S | 3 |
| Shin, HJ | 3 |
| Ryu, SG | 2 |
| Bredius, RG | 1 |
| Belitser, SV | 1 |
| Suttorp, MM | 1 |
| Knibbe, CA | 1 |
| Egeler, M | 1 |
| Egberts, AC | 1 |
| Peranteau, WH | 1 |
| Heaton, TE | 1 |
| Gu, YC | 1 |
| Volk, SW | 1 |
| Bauer, TR | 1 |
| Alcorn, K | 1 |
| Tuschong, LM | 1 |
| Johnson, MP | 1 |
| Flake, AW | 1 |
| Wiedemann, B | 1 |
| Zander, AR | 13 |
| Cappelli, B | 1 |
| Evangelio, C | 1 |
| Biffi, A | 1 |
| Roccia, T | 1 |
| Frugnoli, I | 1 |
| Biral, E | 1 |
| Noè, A | 1 |
| Fossati, M | 1 |
| Finizio, V | 1 |
| Miniero, R | 2 |
| Napolitano, S | 1 |
| Ferrua, F | 1 |
| Soliman, C | 1 |
| Li, QB | 1 |
| Li, L | 2 |
| Chen, ZC | 1 |
| Zou, P | 2 |
| Baurmann, H | 1 |
| Uharek, L | 3 |
| Wandt, H | 5 |
| Burchert, A | 1 |
| Corradini, P | 2 |
| Schubert, J | 3 |
| Kaufmann, M | 1 |
| Wulf, GG | 1 |
| Kvasnicka, HM | 3 |
| Thiele, J | 3 |
| de Witte, TM | 1 |
| Phillips, G | 1 |
| Hofmeister, C | 2 |
| O'Donnell, L | 1 |
| Garzon, R | 2 |
| Krugh, D | 1 |
| Lin, T | 2 |
| Bechtel, T | 1 |
| Byrd, JC | 2 |
| Irish, W | 1 |
| Rodriguez, R | 2 |
| Palmer, JM | 2 |
| Parker, P | 1 |
| Shayani, S | 1 |
| Nademanee, A | 3 |
| Kogut, N | 3 |
| Smith, E | 2 |
| Karanes, C | 3 |
| O'Donnell, M | 2 |
| Krishnan, AY | 1 |
| Senitzer, D | 2 |
| Aldridge, J | 1 |
| Saddadi, F | 1 |
| Najafi, I | 1 |
| Hakemi, MS | 1 |
| Falaknazi, K | 1 |
| Attari, F | 1 |
| Bahar, B | 2 |
| Derigs, G | 2 |
| Krüll, A | 3 |
| Iravani, M | 5 |
| Tavakoli, E | 1 |
| Babaie, MH | 1 |
| Ashouri, A | 3 |
| Khatami, F | 1 |
| Mickelson, DM | 1 |
| Sproat, L | 1 |
| Sweetenham, J | 1 |
| Copelan, EA | 9 |
| Pérez, WS | 1 |
| Khoury, HJ | 1 |
| Klumpp, TR | 1 |
| Lewis, VA | 1 |
| McCarthy, P | 1 |
| Tallman, MS | 1 |
| Gerull, S | 1 |
| Bucher, C | 1 |
| Buser, A | 1 |
| Tsakiris, DA | 1 |
| Tichelli, A | 1 |
| Stern, M | 1 |
| Gratwohl, A | 2 |
| Atallah, E | 1 |
| Abrams, J | 1 |
| Bentley, G | 1 |
| Abidi, M | 1 |
| Uberti, J | 3 |
| Sprecher, E | 1 |
| Adler, L | 1 |
| Elkin, H | 1 |
| Efrati, E | 1 |
| Chen, H | 3 |
| Liu, YR | 1 |
| Han, W | 3 |
| Au, MA | 2 |
| Boeckh, MJ | 1 |
| Chien, JW | 2 |
| Styczynski, J | 1 |
| Tallamy, B | 1 |
| Waxman, I | 1 |
| Milone, MC | 1 |
| Shaw, LM | 1 |
| George, D | 4 |
| Bradley, MB | 2 |
| Garvin, JH | 3 |
| Schwartz, J | 3 |
| Waki, F | 1 |
| Masuoka, K | 1 |
| Yakushijin, K | 1 |
| Togami, K | 1 |
| Nishiwaki, K | 1 |
| Kawano, F | 1 |
| Kasai, M | 1 |
| Nagafuji, K | 2 |
| Hagihara, M | 1 |
| Taniwaki, M | 1 |
| Shirafuji, N | 1 |
| Utsunomiya, A | 1 |
| Nakagawa, H | 1 |
| Uchida, T | 1 |
| Iida, H | 1 |
| Yakushiji, K | 1 |
| Farnault, L | 1 |
| Marchetti, N | 1 |
| Ladaique, P | 1 |
| Prebet, T | 3 |
| Esterni, B | 2 |
| Faulhaber, GA | 1 |
| Furlanetto, TW | 1 |
| Astigarraga, CC | 1 |
| Moser Filho, HL | 1 |
| Paludo, AP | 1 |
| Silla, LM | 1 |
| Madden, T | 4 |
| El Kourashy, S | 1 |
| Williamson, T | 1 |
| Yang, M | 1 |
| Fernandez-Vina, M | 1 |
| de Padua Silva, L | 2 |
| Sharma, M | 1 |
| Rodrigues, M | 1 |
| Ding, J | 1 |
| Bao, W | 1 |
| Zhao, G | 1 |
| Song, H | 1 |
| Au, BK | 1 |
| Al-Hashmi, S | 2 |
| Concha, H | 1 |
| Lundmark, C | 1 |
| Grönvik, KO | 1 |
| Farag, SS | 2 |
| Wood, LL | 1 |
| Schwartz, JE | 1 |
| Srivastava, S | 1 |
| Nelson, RP | 2 |
| Robertson, MJ | 1 |
| Abonour, R | 1 |
| Secrest, A | 1 |
| Cox, E | 1 |
| Baute, J | 1 |
| Sullivan, C | 1 |
| Kane, K | 1 |
| Jones, DR | 1 |
| Gaziev, J | 2 |
| Isgrò, A | 1 |
| Marziali, M | 1 |
| Daniele, N | 1 |
| Gallucci, C | 1 |
| Sodani, P | 2 |
| Simone, MD | 1 |
| Adorno, G | 1 |
| Paciaroni, K | 1 |
| Lanti, A | 1 |
| Del Proposto, G | 1 |
| Testi, M | 1 |
| De Angelis, G | 1 |
| Roveda, A | 1 |
| Alfieri, C | 1 |
| Saltarelli, F | 1 |
| Lucarelli, G | 13 |
| Davies, G | 1 |
| Pelosini, M | 1 |
| Xiao, L | 2 |
| Kerbauy, F | 1 |
| Giralt, SA | 1 |
| Luo, Y | 1 |
| Tan, Y | 2 |
| Shi, J | 1 |
| Han, X | 1 |
| Xie, W | 1 |
| Ye, X | 1 |
| Cai, Z | 1 |
| Lin, M | 1 |
| Huang, H | 1 |
| Phillips, GS | 1 |
| Abraham, J | 1 |
| Tse, W | 1 |
| Gibson, L | 1 |
| Remick, SC | 1 |
| Bunner, P | 1 |
| Efebera, Y | 1 |
| Goździk, J | 1 |
| Pituch-Noworolska, A | 1 |
| Skoczeń, S | 1 |
| Czogała, W | 1 |
| Wędrychowicz, A | 1 |
| Baran, J | 1 |
| Krasowska-Kwiecień, A | 1 |
| Wiecha, O | 1 |
| Zembala, M | 1 |
| Di Nicola, M | 1 |
| Janssen, W | 1 |
| Ochoa, L | 1 |
| Raychaudhuri, J | 1 |
| Yoshimura, T | 1 |
| Inoue, E | 1 |
| Inoue, A | 1 |
| Aimoto, R | 1 |
| Aimoto, M | 1 |
| Terada, Y | 2 |
| Koh, KR | 1 |
| Yamane, T | 3 |
| Hong, M | 1 |
| Wu, Q | 1 |
| Hu, C | 1 |
| Fang, J | 1 |
| Zhong, Z | 1 |
| Hu, Y | 1 |
| Xia, L | 1 |
| Gupta, T | 1 |
| Kannan, S | 1 |
| Dantkale, V | 1 |
| Laskar, S | 1 |
| Choi, SJ | 3 |
| Kang, MJ | 1 |
| Park, JH | 2 |
| Bae, SH | 2 |
| Ryoo, HM | 2 |
| Kim, MK | 2 |
| Hyun, MS | 2 |
| Zhao, WL | 1 |
| Shen, ZX | 1 |
| Ruutu, T | 5 |
| Schnitzler, M | 1 |
| Holowiecki, J | 3 |
| Kienast, J | 4 |
| Larsson, K | 1 |
| Repp, R | 1 |
| Mylius, HA | 1 |
| Freund, M | 5 |
| Ruiz-Delgado, GJ | 1 |
| Mancias-Guerra, C | 1 |
| Macias-Gallardo, J | 1 |
| Gonzalez-Llano, O | 3 |
| Hernandez-Arizpe, A | 1 |
| Rodriguez-Romo, LN | 1 |
| Martinez-Cabriales, SA | 1 |
| Gómez-Almaguer, D | 4 |
| Ruiz-Argüelles, GJ | 4 |
| Zain, J | 2 |
| Delioukina, M | 1 |
| Thomas, S | 1 |
| Tsai, NC | 1 |
| Popplewell, L | 2 |
| Gaal, K | 1 |
| Nagi, W | 1 |
| Lim, ZY | 2 |
| Tindell, V | 1 |
| Reiff-Zall, L | 1 |
| Abdullah, A | 1 |
| Lea, N | 1 |
| Marsh, J | 2 |
| Ho, AY | 3 |
| Hwang, HJ | 1 |
| Jung, AR | 1 |
| Garming-Legert, K | 1 |
| Dahllöf, G | 1 |
| Krejci, M | 2 |
| Brychtova, Y | 2 |
| Doubek, M | 2 |
| Tomiska, M | 1 |
| Navratil, M | 1 |
| Racil, Z | 2 |
| Dvorakova, D | 2 |
| Horky, O | 2 |
| Lengerova, M | 2 |
| Pospisilova, S | 1 |
| Mayer, J | 2 |
| Melot, C | 1 |
| Coiffard, J | 1 |
| Lafarge, X | 1 |
| Marit, G | 1 |
| Pigneux, A | 1 |
| Leguay, T | 1 |
| Dilhuydy, MS | 1 |
| Schmitt, A | 1 |
| Boiron, JM | 4 |
| Geyer, MB | 1 |
| Jacobson, JS | 1 |
| Freedman, J | 1 |
| Moore, V | 1 |
| Della-Latta, P | 1 |
| Woodahl, EL | 1 |
| Storer, B | 5 |
| Heimfeld, S | 2 |
| Saure, C | 1 |
| Zohren, F | 1 |
| Groten, A | 1 |
| Bruns, I | 1 |
| Czibere, A | 1 |
| Galonska, L | 1 |
| Kondakci, M | 1 |
| Weigelt, C | 1 |
| Fenk, R | 1 |
| Germing, U | 1 |
| Haas, R | 1 |
| Facchini, L | 1 |
| Ferrari, A | 1 |
| Granell, M | 1 |
| Dela Cruz, F | 1 |
| Le Gall, J | 1 |
| Duffy, D | 1 |
| Foley, S | 2 |
| Hawks, R | 2 |
| Lee, SH | 2 |
| Yu, KS | 1 |
| Kim, NH | 1 |
| Yuk, YJ | 1 |
| Jang, MK | 1 |
| Han, EJ | 1 |
| Song, SH | 1 |
| Park, KD | 1 |
| Shin, HY | 1 |
| Jang, IJ | 1 |
| Ahn, HS | 1 |
| Guthrie, KA | 1 |
| Sale, GE | 1 |
| Argenyi, ZB | 1 |
| Myerson, D | 2 |
| Raida, L | 1 |
| Tucek, P | 1 |
| Faber, E | 1 |
| Vondrakova, J | 1 |
| Rusinakova, Z | 1 |
| Skoumalova, I | 1 |
| Hubacek, J | 1 |
| Jarosova, M | 1 |
| Katrincsakova, B | 1 |
| Pikalova, Z | 1 |
| Kurfurst, P | 1 |
| Indrak, K | 1 |
| Hamidieh, A | 1 |
| Kargar, M | 1 |
| Jahani, M | 3 |
| Alimoghaddam, K | 3 |
| Jalili, M | 1 |
| Shin, HC | 1 |
| Lee, YJ | 1 |
| Lee, SJ | 2 |
| Kang, BW | 1 |
| Chae, YS | 2 |
| Kim, JG | 2 |
| Choi, JY | 1 |
| Seo, JW | 1 |
| Kim, YK | 2 |
| Suh, JS | 1 |
| Sohn, SK | 2 |
| Musick, L | 1 |
| Horn, B | 2 |
| Kuwatsuka, Y | 1 |
| Kohno, A | 1 |
| Saito, S | 1 |
| Shimada, K | 1 |
| Yasuda, T | 1 |
| Miyamura, K | 1 |
| Karasuno, T | 1 |
| Fukumoto, M | 1 |
| Naoe, T | 1 |
| Morishita, Y | 1 |
| Bertaina, A | 1 |
| Contoli, B | 1 |
| Pinto, RM | 1 |
| Corker, E | 1 |
| Astwood, E | 1 |
| Williams, J | 1 |
| Vora, A | 1 |
| Dominietto, A | 1 |
| Ghiso, A | 1 |
| Lamparelli, T | 2 |
| Van Lint, MT | 2 |
| Geroldi, S | 1 |
| Luchetti, S | 1 |
| Ballerini, F | 1 |
| Miglino, M | 1 |
| Borkhardt, A | 1 |
| Creutzig, U | 1 |
| Eyrich, M | 1 |
| Ehlert, K | 1 |
| Handgretinger, R | 1 |
| Holter, W | 2 |
| Klingebiel, T | 3 |
| Kremens, B | 1 |
| Mauz-Körholz, C | 1 |
| Reinhardt, D | 1 |
| Schuster, FR | 1 |
| Schrauder, A | 1 |
| Zimmermann, M | 1 |
| Lee, GW | 1 |
| Kim, SD | 1 |
| Min, YJ | 1 |
| Choudhary, D | 1 |
| Sharma, SK | 1 |
| Gupta, N | 1 |
| Kharya, G | 1 |
| Pavecha, P | 1 |
| Handoo, A | 1 |
| Setia, R | 1 |
| Katewa, S | 1 |
| Thall, P | 2 |
| Ganesan, P | 1 |
| Liu, QF | 1 |
| Fan, ZP | 1 |
| Wu, MQ | 1 |
| Wu, XL | 1 |
| Xu, D | 1 |
| Jiang, QL | 1 |
| Wei, YQ | 1 |
| Yu, GP | 1 |
| Meng, FY | 1 |
| Lestang, E | 1 |
| Ayari, S | 1 |
| Clavert, A | 1 |
| Roland, V | 1 |
| Xiao, Y | 1 |
| Nie, D | 1 |
| Guo, X | 1 |
| Yu, G | 1 |
| Yan, D | 1 |
| Slattery, JT | 2 |
| Doney, KC | 6 |
| Hansen, JA | 5 |
| Kiem, HP | 2 |
| Petersdorf, E | 1 |
| Radich, JP | 2 |
| Sanders, JE | 5 |
| Shulman, HM | 1 |
| Warren, EH | 2 |
| Witherspoon, RP | 7 |
| Bryant, EM | 1 |
| Chauncey, TR | 1 |
| Getzendaner, L | 1 |
| Simón, JA | 1 |
| Canals, C | 1 |
| Urbano-Ispízua, A | 1 |
| Bargay, J | 1 |
| Léon, A | 1 |
| Sarrá, J | 1 |
| Sanz, GF | 1 |
| San Miguel, J | 1 |
| Murotani, Y | 1 |
| Kuroda, J | 1 |
| Terao, K | 1 |
| Fukiya, E | 1 |
| Ozawa, M | 1 |
| Kobayashi, Y | 1 |
| Yoshikawa, T | 1 |
| Couriel, D | 3 |
| Tran, HT | 1 |
| Lush, R | 1 |
| Cavenagh, J | 1 |
| Milligan, DW | 1 |
| Schey, S | 1 |
| Clark, FJ | 1 |
| Hunt, L | 1 |
| Fuller, S | 1 |
| Vandenberghe, E | 1 |
| Littlewood, T | 1 |
| Smith, GM | 1 |
| Culligan, D | 1 |
| Chopra, R | 1 |
| Davies, A | 1 |
| Towlson, K | 1 |
| Williams, CD | 1 |
| Seger, RA | 1 |
| Blanche, S | 2 |
| Bordigoni, P | 6 |
| Landais, P | 1 |
| Müller, S | 1 |
| Ozsahin, H | 1 |
| Passwell, JH | 1 |
| Slavin, S | 11 |
| Wulffraat, N | 1 |
| Zintl, F | 1 |
| Shapira, MY | 5 |
| Resnick, I | 1 |
| Amar, A | 2 |
| Ackerstein, A | 5 |
| Samuel, S | 6 |
| Aker, M | 4 |
| Naparstek, E | 5 |
| Zhu, K | 2 |
| Zhong, J | 2 |
| Chen, S | 1 |
| Zeng, H | 1 |
| Hessling, J | 1 |
| Werner, M | 1 |
| Hansen, A | 1 |
| Kordes, U | 1 |
| Ayuk, FA | 1 |
| Renges, H | 7 |
| Panse, J | 3 |
| Erttmann, R | 3 |
| Nilsson, C | 3 |
| Aschan, J | 4 |
| Hentschke, P | 3 |
| Eber, S | 1 |
| Ljungman, P | 5 |
| Ravandi, F | 1 |
| Shahjahan, M | 2 |
| Donato, M | 1 |
| van Besien, K | 2 |
| Kantarjian, H | 1 |
| Thiede, C | 5 |
| Kiehl, M | 5 |
| Beyer, J | 4 |
| Hensel, M | 2 |
| Scheffold, C | 2 |
| Ho, AD | 2 |
| Fauser, AA | 4 |
| Siegert, W | 5 |
| Kiss, TL | 1 |
| Panzarella, T | 1 |
| Meharchand, J | 1 |
| Reddy, V | 1 |
| Schimmer, AD | 1 |
| Biasin, E | 1 |
| Berger, M | 1 |
| Nesi, F | 1 |
| Saroglia, EH | 1 |
| Martino, S | 1 |
| Tovo, PA | 1 |
| Choufi, B | 2 |
| Bilger, K | 3 |
| Viens, P | 2 |
| Maraninchi, D | 6 |
| Reynolds, C | 1 |
| Ferrara, JL | 1 |
| Silver, SM | 1 |
| Braun, T | 1 |
| Hutchinson, R | 1 |
| Leisenring, W | 1 |
| Maloney, DG | 2 |
| Maris, MB | 2 |
| Saito, T | 4 |
| Nakai, K | 4 |
| Makimoto, A | 5 |
| Wakasugi, H | 3 |
| Tobinai, K | 7 |
| Biersack, H | 1 |
| Sayer, HG | 4 |
| Schäfer-Eckardt, K | 1 |
| DeFor, TE | 1 |
| Hansz, J | 1 |
| Milligan, D | 1 |
| Russell, N | 1 |
| Van Biezen, A | 1 |
| Hardan, I | 3 |
| Avigdor, A | 1 |
| Ben-Bassat, I | 1 |
| Wittkowsky, G | 1 |
| Schmitz, N | 3 |
| Krüger, W | 5 |
| Held, TK | 2 |
| Hoffken, K | 1 |
| Chi, HS | 1 |
| Park, CJ | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Uzunel, M | 2 |
| Cahn, JY | 2 |
| Gratecos, N | 1 |
| Sotto, JJ | 2 |
| François, S | 1 |
| Fleury, J | 1 |
| Gravis, G | 1 |
| Viret, F | 1 |
| Braud, AC | 1 |
| Bardou, VJ | 1 |
| Bitan, M | 4 |
| Elad, S | 3 |
| Zilberman, I | 2 |
| Miron, S | 2 |
| Arima, F | 1 |
| Tamaki, H | 1 |
| Kawakami, M | 2 |
| Fujioka, T | 3 |
| Tsuboi, A | 1 |
| Oji, Y | 1 |
| Oka, Y | 1 |
| Sugiyama, H | 1 |
| Kawase, I | 2 |
| Ogawa, H | 3 |
| Kusumi, E | 3 |
| Gordon, N | 1 |
| Mullen, CA | 1 |
| Tran, H | 2 |
| Gomez Almaguer, D | 1 |
| Chan, KW | 1 |
| Dulley, FL | 1 |
| Vigorito, AC | 1 |
| Aranha, FJ | 1 |
| Sturaro, D | 1 |
| Ruiz, MA | 1 |
| Saboya, R | 1 |
| Macedo, MC | 1 |
| Da Silva, RL | 1 |
| Chamone, DA | 1 |
| Mehta, J | 2 |
| De Souza, CA | 1 |
| Yamamoto, R | 1 |
| Yuji, K | 1 |
| Hamaki, T | 3 |
| Murasgihe, N | 1 |
| Hori, A | 4 |
| Morinaga, S | 1 |
| Masuo, S | 2 |
| Mutou, Y | 1 |
| Nürnberger, W | 1 |
| Suttorp, M | 1 |
| Dörffel, W | 1 |
| Zakrzewski, JL | 1 |
| Asano, Y | 1 |
| Ogawa, N | 1 |
| Sakata-Yanagimoto, M | 1 |
| Nakagawa, M | 2 |
| Kawazu, M | 1 |
| Goyama, S | 1 |
| Kandabashi, K | 1 |
| Izutsu, K | 1 |
| Imai, Y | 1 |
| Hangaishi, A | 1 |
| Kurokawa, M | 1 |
| Tsujino, S | 1 |
| Ogawa, S | 1 |
| Aoki, K | 1 |
| Chiba, S | 1 |
| Motokura, T | 1 |
| Hirai, H | 1 |
| Runde, V | 2 |
| Neudorf, S | 1 |
| Sanders, J | 1 |
| Kobrinsky, N | 1 |
| Alonzo, TA | 1 |
| Buxton, AB | 1 |
| Gold, S | 1 |
| Barnard, DR | 1 |
| Wallace, JD | 1 |
| Kalousek, D | 1 |
| Lange, BJ | 1 |
| Woods, WG | 2 |
| Onishi, Y | 3 |
| Kishi, Y | 2 |
| Murashige, N | 2 |
| Kojima, R | 1 |
| Sakiyama, M | 1 |
| Imataki, O | 1 |
| Robien, K | 1 |
| Schubert, MM | 1 |
| Bruemmer, B | 1 |
| Lloid, ME | 1 |
| Potter, JD | 1 |
| Ulrich, CM | 1 |
| Parker, JE | 1 |
| Mijovic, A | 1 |
| Devereux, S | 2 |
| Pierre, B | 1 |
| Korbling, M | 2 |
| Ploemacher, RE | 1 |
| Johnson, KW | 1 |
| Rombouts, EJ | 1 |
| Etienne, K | 1 |
| Westerhof, GR | 1 |
| White-Scharf, ME | 1 |
| Down, JD | 1 |
| Omori, S | 1 |
| Ono, Y | 1 |
| Numaoka, H | 1 |
| Ishida, Y | 1 |
| Damaj, G | 1 |
| Michallet, AS | 1 |
| Perreau, V | 1 |
| Gastaut, JA | 2 |
| Lähteenmäki, PM | 1 |
| Cornish, JM | 1 |
| Oakhill, AH | 1 |
| Souillet, G | 5 |
| Werck-Gallois, MC | 1 |
| So Satta, A | 1 |
| Bellon, G | 1 |
| Lee, MY | 1 |
| Chiou, TJ | 2 |
| Bai, LY | 1 |
| Hsiao, LT | 2 |
| Hung, GY | 1 |
| Chang, CY | 1 |
| Chen, PM | 2 |
| Kuczkowski, E | 2 |
| Aoyama, Y | 1 |
| Yamamura, R | 1 |
| Ohta, K | 2 |
| Dai, QY | 1 |
| Manel, AM | 1 |
| Souillet, AL | 1 |
| Homole, E | 1 |
| Pages, MP | 1 |
| Berlier, P | 1 |
| David, M | 1 |
| Berthier, JC | 1 |
| Massenavette, B | 1 |
| Contamin, B | 1 |
| Philippe, N | 1 |
| Massenkeil, G | 1 |
| Nagy, M | 1 |
| Le Coutre, P | 1 |
| Heine, F | 1 |
| Rosen, O | 1 |
| Dörken, B | 1 |
| Ball, E | 1 |
| Cook, D | 1 |
| Chauncey, T | 4 |
| Petersdorf, S | 1 |
| Slattery, J | 1 |
| Appelbaum, F | 2 |
| Elder, PJ | 3 |
| Avalos, BR | 6 |
| Schieder, H | 3 |
| Stute, N | 4 |
| Fehse, N | 2 |
| Waschke, O | 2 |
| Fehse, B | 2 |
| Mamlouk, K | 1 |
| Saracino, G | 1 |
| Berryman, RB | 1 |
| Fay, JW | 1 |
| Pineiro, LA | 1 |
| Vance, EA | 1 |
| White, M | 1 |
| Sandler, I | 1 |
| Agura, ED | 1 |
| Parikh, CR | 1 |
| Schrier, RW | 1 |
| Diaconescu, R | 1 |
| McSweeney, P | 1 |
| Rao, PS | 1 |
| Sundberg, B | 1 |
| Wall, DA | 1 |
| Carter, SL | 1 |
| Kamani, NR | 1 |
| Brochstein, JA | 1 |
| Goyal, RK | 1 |
| Horan, JT | 1 |
| Pietryga, D | 2 |
| Kurtzberg, J | 1 |
| Reddy, P | 1 |
| Garban, F | 2 |
| Drillat, P | 1 |
| Makowski, C | 1 |
| Jacob, MC | 1 |
| Richard, MJ | 1 |
| Favrot, M | 1 |
| Bensa, JC | 1 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Kim, CC | 3 |
| Wilhelm, S | 1 |
| Steiner, B | 1 |
| Grobe, N | 1 |
| Hähling, D | 1 |
| Hartung, G | 1 |
| Lück, A | 1 |
| Junghanss, C | 1 |
| Kahl, C | 1 |
| Roman, E | 1 |
| Cooney, E | 1 |
| Unal, E | 1 |
| Bradley, B | 1 |
| Del Toro, G | 1 |
| Garvin, J | 1 |
| Oyekunle, AA | 1 |
| Kabisch, H | 5 |
| Englert, L | 1 |
| McMillan, A | 1 |
| Quinn, M | 1 |
| Desantes, K | 1 |
| Cowan, M | 1 |
| Torjemane, L | 1 |
| Ladeb, S | 1 |
| Abdelkefi, A | 1 |
| Lakhal, A | 1 |
| Ben Abdeladhim, A | 1 |
| Polchi, P | 11 |
| Mundhenk, P | 1 |
| Fruehauf, S | 1 |
| Kiehl, MG | 1 |
| Theuser, C | 2 |
| Stachel, DK | 1 |
| Leipold, A | 1 |
| Kuhlen, M | 1 |
| Gravou-Apostolatou, C | 1 |
| Hirv, K | 1 |
| Beck, JD | 1 |
| Dong, L | 1 |
| Wu, T | 1 |
| Zhang, YC | 1 |
| Ren, HY | 1 |
| Dahlke, J | 1 |
| Atanackovic, D | 1 |
| Al-Seraihi, A | 1 |
| Al-Mahr, M | 1 |
| Belgaumi, A | 1 |
| Elhassan, I | 1 |
| Shaiegan, M | 1 |
| Babaee, GR | 1 |
| Vela-Ojeda, J | 1 |
| Jaime-Pérez, JC | 3 |
| Gutiérrez-Aguirre, CH | 2 |
| Cantú-Rodríguez, OG | 2 |
| Sobrevilla-Calvo, P | 1 |
| Rivas-Vera, S | 1 |
| Gómez-Rangel, JD | 1 |
| Boeckh, M | 1 |
| Nash, RA | 2 |
| McSweeney, PA | 1 |
| Nelson, JL | 1 |
| Wener, M | 1 |
| Langston, AA | 1 |
| Shulman, H | 2 |
| Sullivan, KM | 6 |
| Henstorf, G | 1 |
| Furst, DE | 1 |
| Hasegawa, T | 1 |
| Hagihara, K | 1 |
| Goebel, WS | 1 |
| Brahmi, Z | 1 |
| Gowan, DJ | 1 |
| Towell, PJ | 1 |
| Robertson, KA | 1 |
| Haut, PR | 1 |
| Ingram, W | 1 |
| Pearce, L | 1 |
| Czepulkowski, B | 1 |
| Duarte, RF | 1 |
| Merup, M | 1 |
| Lazarevic, V | 1 |
| Nahi, H | 1 |
| Andreasson, B | 1 |
| Malm, C | 1 |
| Nilsson, L | 1 |
| Brune, M | 3 |
| LeBlanc, K | 1 |
| Kutti, J | 1 |
| Birgegård, G | 1 |
| Pospisil, Z | 1 |
| Koristek, Z | 1 |
| Dolezal, T | 1 |
| Vorlicek, J | 1 |
| DeAngelo, DJ | 1 |
| Stone, R | 1 |
| Brown, JR | 1 |
| Stephans, K | 1 |
| Milford, EL | 1 |
| Gribben, JG | 1 |
| Yoshihara, S | 1 |
| Masuda, T | 1 |
| Taniguchi, Y | 1 |
| Hasei, H | 1 |
| Kaida, K | 1 |
| Inoue, T | 1 |
| Kim, EH | 1 |
| Li, JM | 1 |
| Gorechlad, J | 1 |
| Larsen, CP | 1 |
| Ruel, N | 1 |
| Krishnan, A | 1 |
| Patane, K | 1 |
| Sarkodee-Adoo, C | 1 |
| Markova, M | 1 |
| Arora, M | 1 |
| Burns, LJ | 1 |
| Douek, D | 1 |
| DeFor, T | 2 |
| Repka, T | 1 |
| Schmidt-Hieber, M | 2 |
| Andreesen, R | 1 |
| Kanz, L | 1 |
| Keilholz, U | 1 |
| Marinets, O | 1 |
| Fietz, T | 1 |
| Knauf, W | 2 |
| Hopfenmüller, W | 2 |
| Thiel, E | 2 |
| Chaudhry, A | 1 |
| Morris, D | 1 |
| Stewart, D | 1 |
| Mayama, T | 1 |
| Higashishiba, M | 1 |
| Kawanishi, K | 1 |
| Miyatake, J | 1 |
| Tatsumi, Y | 1 |
| Kanamaru, A | 1 |
| Habib, S | 1 |
| Nalesnik, MA | 1 |
| Ahmad, J | 1 |
| BuchBarker, D | 1 |
| Shakil, AO | 1 |
| Zhu, KE | 1 |
| Li, JP | 1 |
| Zhang, T | 1 |
| Evazi, MR | 1 |
| Shamshiri, AR | 1 |
| Tavakoli, M | 1 |
| Samiee, S | 1 |
| Chahardovali, B | 1 |
| Ghaffari, SH | 1 |
| Leschinger, N | 1 |
| Göldner, H | 1 |
| Blau, O | 1 |
| Sugimoto, K | 1 |
| Akahane, D | 1 |
| Morita-Hoshi, Y | 1 |
| Attal, M | 3 |
| Ades, L | 1 |
| Bernard, M | 1 |
| Facon, T | 1 |
| Ifrah, N | 2 |
| Renaud, M | 2 |
| Tilly, H | 1 |
| Vernant, JP | 1 |
| Kuentz, M | 2 |
| Wojnar, J | 2 |
| Krawczyk-Kulis, M | 2 |
| Wylezoł, I | 1 |
| Seweryn, M | 1 |
| Holowiecka-Goral, A | 2 |
| Salazar-Riojas, R | 1 |
| Martinez-González, O | 1 |
| Morales-Toquero, A | 1 |
| Tarín-Arzaga, LC | 1 |
| Kim, SY | 1 |
| Takemoto, Y | 1 |
| Hoogendoorn, M | 1 |
| Jedema, I | 1 |
| Barge, RM | 1 |
| van Luxemburg-Heijs, SA | 1 |
| Beaumont, F | 1 |
| Marijt, EW | 1 |
| Willemze, R | 1 |
| Falkenburg, JH | 1 |
| Cho, YY | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Lee, JJ | 1 |
| Shem-Tov, N | 2 |
| Rand, A | 2 |
| Herscovici, C | 1 |
| Tong, XZ | 1 |
| Xu, DR | 1 |
| Zou, WY | 1 |
| Luo, SK | 1 |
| Peng, AH | 1 |
| Zhang, GC | 1 |
| Zheng, D | 1 |
| Hur, EH | 1 |
| Bae, KS | 1 |
| Noh, GJ | 1 |
| Han, SB | 1 |
| Muñoz, A | 1 |
| Olivé, T | 1 |
| Martinez, A | 1 |
| Bureo, E | 1 |
| Maldonado, MS | 1 |
| Diaz de Heredia, C | 1 |
| Sastre, A | 1 |
| Gonzalez-Vicent, M | 1 |
| Demidova, IA | 1 |
| Kut'ina, RM | 1 |
| Poreshina, LP | 1 |
| Shpakova, AP | 1 |
| Ol'shanskaia, IuV | 1 |
| Misiurin, AV | 1 |
| Tsirigotis, P | 1 |
| Abdul-Hai, A | 1 |
| Gesundheit, B | 1 |
| Chen, MH | 1 |
| Lin, PC | 1 |
| Gau, JP | 1 |
| Hsu, HC | 1 |
| Martin, J | 1 |
| Nieto, JB | 1 |
| Bernal, MT | 1 |
| Vazquez, L | 1 |
| Ribera, JM | 1 |
| Besalduch, J | 1 |
| Carrera, D | 1 |
| Brunet, MS | 1 |
| Miura, Y | 1 |
| Azuma, T | 1 |
| Matsumura, T | 1 |
| Komatsu, T | 1 |
| Yamasaki, S | 1 |
| Maruyama, D | 1 |
| Kato, R | 1 |
| Usui, E | 1 |
| Koido, K | 1 |
| Teshima, T | 1 |
| Mahdavi, N | 1 |
| Shamshiri, A | 1 |
| Hadjibabaie, M | 1 |
| Namdar, R | 1 |
| Nedaeifard, L | 1 |
| Ghaffari, H | 1 |
| Qureshi, A | 1 |
| Marshall, L | 1 |
| Lancaster, D | 1 |
| Le, QH | 1 |
| Nicolini, F | 1 |
| Esperou, H | 1 |
| Rio, B | 1 |
| Chir, Z | 1 |
| Morris, A | 1 |
| Gasparetto, C | 1 |
| Sullivan, K | 1 |
| Long, G | 1 |
| Chute, J | 1 |
| McPherson, J | 1 |
| Chao, N | 1 |
| Kobayashi, K | 1 |
| Rebollo, N | 1 |
| de la Cámara, R | 1 |
| de Oteiza, JP | 1 |
| Calvo, MV | 1 |
| San Miguel, JF | 1 |
| Novitzky, N | 1 |
| Thomas, V | 1 |
| du Toit, C | 1 |
| Mcdonald, A | 1 |
| Santos, GW | 4 |
| Tutschka, PJ | 7 |
| Brookmeyer, R | 1 |
| Saral, R | 3 |
| Beschorner, WE | 4 |
| Bias, WB | 1 |
| Braine, HG | 2 |
| Burns, WH | 3 |
| Elfenbein, GJ | 1 |
| Kaizer, H | 2 |
| Zwaan, FE | 1 |
| Jansen, J | 1 |
| van Bekkum, DW | 1 |
| Clift, RA | 8 |
| Buckner, CD | 10 |
| Thomas, ED | 3 |
| Bryant, E | 5 |
| Bensinger, WI | 8 |
| Bowden, R | 3 |
| Fisher, LD | 2 |
| Hartsell, WF | 1 |
| Czyzewski, EA | 1 |
| Ghalie, R | 1 |
| Link, H | 2 |
| Arseniev, L | 1 |
| Bähre, O | 1 |
| Berenson, RJ | 1 |
| Battmer, K | 1 |
| Kadar, JG | 1 |
| Jacobs, R | 1 |
| Kühl, J | 1 |
| Diedrich, H | 1 |
| Poliwoda, H | 1 |
| Maldonado, J | 1 |
| Békássy, AN | 1 |
| Oberg, G | 1 |
| Castenskiold, EC | 1 |
| Kelsey, SM | 1 |
| Collins, PW | 1 |
| Coldwell, RD | 1 |
| Allen, PD | 1 |
| Side, LE | 1 |
| Makin, HL | 1 |
| Goldstone, AH | 1 |
| Newland, AC | 1 |
| Crilley, P | 9 |
| Topolsky, D | 4 |
| Styler, MJ | 3 |
| Bernstein, E | 1 |
| Resnick, K | 1 |
| Mullaney, R | 1 |
| Bulova, S | 4 |
| Brodsky, I | 6 |
| Gomez, L | 1 |
| Le Deist, F | 1 |
| Cavazzana-Calvo, M | 1 |
| Griscelli, C | 1 |
| Camitta, B | 1 |
| Truitt, R | 1 |
| Lawton, C | 1 |
| Murray, K | 1 |
| Hunter, J | 1 |
| Garbrecht, F | 1 |
| Lynch, MH | 1 |
| Petersen, FB | 3 |
| Quigley, PM | 1 |
| Yeager, AM | 3 |
| Loughlin, GM | 1 |
| Ashihara, E | 1 |
| Shimazaki, C | 1 |
| Yamagata, N | 1 |
| Hirata, T | 1 |
| Okawa, K | 1 |
| Oku, N | 1 |
| Inaba, T | 1 |
| Fujita, N | 1 |
| Baybordi, E | 1 |
| Dini, G | 1 |
| Boni, L | 1 |
| Abla, O | 1 |
| Uderzo, C | 1 |
| Rossetti, F | 1 |
| Kalaycioglu, ME | 1 |
| Przepiorka, D | 3 |
| Ippoliti, C | 1 |
| van Beisen, K | 1 |
| Mehra, R | 2 |
| Deisseroth, AB | 1 |
| Luna, M | 1 |
| Cork, A | 1 |
| Lee, M | 1 |
| Contu, L | 2 |
| Arras, M | 2 |
| Pizzati, A | 2 |
| Carcassi, C | 2 |
| Ledda, A | 2 |
| Boero, R | 2 |
| Orrù, S | 2 |
| Pintus, A | 1 |
| Xun, CQ | 1 |
| Thompson, JS | 1 |
| Jennings, CD | 1 |
| Brown, SA | 1 |
| Widmer, MB | 1 |
| Nikoskelainen, J | 2 |
| Vindeløv, L | 2 |
| Parkkali, T | 2 |
| Lenhoff, S | 2 |
| Sallerfors, B | 2 |
| Gluckman, E | 3 |
| Esperou-Bourdeau, H | 2 |
| Reiffers, J | 2 |
| Pico, JL | 2 |
| Thuret, I | 1 |
| Bernaudin, F | 3 |
| Jouet, JP | 2 |
| van der Jagt, RH | 1 |
| Pari, G | 1 |
| McDiarmid, SA | 1 |
| Boisvert, DM | 1 |
| Huebsch, LB | 1 |
| Galimberti, M | 8 |
| Giardini, C | 6 |
| Gaziev, D | 2 |
| Erer, B | 2 |
| Ripalti, M | 1 |
| Rapa, S | 1 |
| Le Heup, B | 1 |
| von Bueltzingloewen, A | 1 |
| Sommelet, D | 1 |
| Pierson, M | 1 |
| Vowels, M | 3 |
| Chan, LL | 1 |
| Giri, N | 1 |
| Russell, S | 2 |
| Lam-Po-Tang, R | 1 |
| Paz, HL | 1 |
| Topolsky, DL | 1 |
| Coll, WX | 1 |
| Patchefsky, A | 1 |
| Plouvier, E | 1 |
| Lemerle, S | 1 |
| Mulargia, M | 1 |
| von Bueltzingsloewen, A | 2 |
| Belanger, R | 1 |
| Perreault, C | 1 |
| Bonny, Y | 1 |
| Roy, DC | 1 |
| Lalonde, Y | 1 |
| Boileau, J | 1 |
| Kassis, J | 1 |
| Lavallee, R | 1 |
| Lacombe, M | 1 |
| Mrsić, M | 1 |
| Nemet, D | 1 |
| Labar, B | 1 |
| Bogdanić, V | 1 |
| Radman, I | 1 |
| Zupancić-Salek, S | 1 |
| Kovacević-Metelko, J | 1 |
| Aurer, I | 1 |
| Maravić, N | 1 |
| Rassam, SM | 1 |
| Katz, F | 1 |
| Chessells, JM | 1 |
| Morgan, G | 1 |
| Lum, LG | 2 |
| de Planque, MM | 2 |
| Schultz, KR | 2 |
| Cronin, S | 2 |
| Dan, ME | 2 |
| Mohamed, A | 2 |
| Hussein, M | 1 |
| Demeocq, F | 2 |
| Mechinaud-Lacroix, F | 1 |
| Sadoun, A | 1 |
| Cornu, G | 2 |
| Donadieu, J | 1 |
| Henry-Amar, M | 1 |
| Devergie, A | 3 |
| van Tol, MJ | 1 |
| Gerritsen, EJ | 1 |
| de Lange, GG | 1 |
| van Leeuwen, AM | 1 |
| Jol-van der Zijde, CM | 1 |
| Oudeman-Gruber, NJ | 1 |
| de Vries, E | 1 |
| Radl, J | 1 |
| Vossen, JM | 1 |
| Anderson, JE | 1 |
| Bettoni, C | 1 |
| Lange, A | 2 |
| Malicki, J | 1 |
| Kaczmarek-Kanold, M | 1 |
| Głuszak, B | 1 |
| Suchnicki, K | 1 |
| Daszkiewicz, P | 1 |
| Ebell, W | 1 |
| Greinix, HT | 1 |
| Keil, F | 1 |
| Brugger, SA | 1 |
| Reiter, E | 1 |
| Linkesch, W | 1 |
| Lechner, K | 1 |
| Schneider, B | 1 |
| Dieckmann, KU | 1 |
| Fischer, G | 1 |
| Schwarzinger, I | 1 |
| Haas, O | 1 |
| Hinterberger, W | 1 |
| Mannhalter, C | 1 |
| Geissler, K | 1 |
| Hocker, P | 2 |
| Jager, U | 1 |
| Tang-naitrisorana, Y | 1 |
| Issaragrisil, S | 1 |
| Visuthisakchai, S | 1 |
| Suvatte, V | 1 |
| Piankijakum, A | 1 |
| deMagalhaes-Silverman, M | 1 |
| Bloom, EJ | 1 |
| Donnenberg, A | 1 |
| Lister, J | 1 |
| Pincus, S | 1 |
| Ball, ED | 1 |
| Majolino, I | 2 |
| Laporte, JP | 1 |
| Brinch, L | 1 |
| Cook, G | 1 |
| Lambertenghi-Deliliers, G | 1 |
| Rozman, C | 1 |
| Garcia-Conde, J | 1 |
| Domingo-Albos, A | 1 |
| Klein, JL | 2 |
| Belt, P | 1 |
| Taylor, CA | 1 |
| Ezzone, SA | 3 |
| Scholl, MD | 3 |
| Fisher, J | 1 |
| Young, D | 1 |
| Saglio, G | 1 |
| Scimè, R | 1 |
| Serra, A | 1 |
| Cavallaro, AM | 1 |
| Fiandaca, T | 1 |
| Vasta, S | 1 |
| Pampinella, M | 1 |
| Catania, P | 1 |
| Indovina, A | 1 |
| Marcenò, R | 1 |
| Santoro, A | 1 |
| Sahebi, F | 1 |
| Avalos, B | 3 |
| Klein, J | 3 |
| Territo, M | 1 |
| Maiello, A | 1 |
| Biggs, J | 1 |
| Moul, J | 1 |
| Sabol, P | 1 |
| Downs, K | 3 |
| Arslan, O | 1 |
| Akan, H | 1 |
| Koç, H | 1 |
| Beksaç, M | 1 |
| Ilhan, O | 1 |
| Ozcan, M | 1 |
| Yalçín, S | 1 |
| Gürman, G | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Clift, R | 2 |
| Barnett, T | 1 |
| De Prijck, B | 1 |
| Sainty, D | 1 |
| Lafage, M | 1 |
| Camerlo, J | 1 |
| Penza, SL | 2 |
| Belt, PS | 2 |
| Hehmeyer, DM | 1 |
| Bechtel, TP | 2 |
| Gallardo, D | 1 |
| Berlanga, JJ | 1 |
| Banda, ED | 1 |
| Ponce, C | 1 |
| Salar, A | 1 |
| Alonso, E | 1 |
| Espanñol, I | 1 |
| Riu, C | 1 |
| Grañena, A | 1 |
| Hernández-Bronchud, M | 1 |
| Radich, J | 1 |
| Soll, E | 1 |
| Flowers, M | 1 |
| McDonald, GB | 1 |
| Nash, R | 1 |
| Petersdorf, EW | 1 |
| Stewart, P | 1 |
| Bertz, H | 1 |
| Potthoff, K | 1 |
| Lassau, N | 1 |
| Leclère, J | 1 |
| Auperin, A | 1 |
| Hartmann, O | 1 |
| Valteau-Couanet, D | 1 |
| Benhamou, E | 1 |
| Bosq, J | 1 |
| Ibrahim, A | 1 |
| Girinski, T | 1 |
| Roche, A | 1 |
| Grigg, A | 1 |
| Harun, MH | 1 |
| Pugh, WC | 1 |
| Amin, K | 1 |
| Mirza, N | 1 |
| Seong, D | 1 |
| Hester, J | 1 |
| Cabanillas, F | 1 |
| Chattergoon, DS | 1 |
| Saunders, EF | 1 |
| Calderwood, S | 1 |
| Doyle, J | 1 |
| Freedman, MH | 1 |
| Koren, G | 1 |
| Matsuoka, S | 1 |
| Ishida, A | 1 |
| Wakui, M | 1 |
| Watanabe, R | 1 |
| Moriki, T | 1 |
| Ikeda, Y | 1 |
| Hirabayashi, N | 2 |
| Essell, JH | 2 |
| Schroeder, MT | 1 |
| Harman, GS | 2 |
| Halvorson, R | 1 |
| Lew, V | 1 |
| Snyder, M | 1 |
| Lewis, SK | 1 |
| Allerton, JP | 1 |
| Thompson, JM | 3 |
| Goto, S | 1 |
| Ishii, M | 1 |
| Yuge, M | 1 |
| Mitsuma, A | 1 |
| Noda, N | 1 |
| Bonini, A | 2 |
| Rosti, G | 2 |
| Testoni, N | 1 |
| Remiddi, C | 1 |
| Mangianti, S | 1 |
| Campanini, E | 1 |
| Zuffa, E | 1 |
| Tura, S | 2 |
| Kojima, S | 1 |
| Benni, M | 1 |
| Gozzetti, A | 1 |
| Ronconi, S | 1 |
| Zamagni, E | 1 |
| Lemoli, RM | 1 |
| Belardinelli, A | 1 |
| Minowa, R | 1 |
| Miyagawa, S | 1 |
| Fukumoto, T | 1 |
| Majima, T | 1 |
| Shimoyama, T | 1 |
| Fujimura, Y | 1 |
| Shirai, T | 1 |
| Simpson, DR | 1 |
| Nevill, TJ | 3 |
| Shepherd, JD | 3 |
| Fung, HC | 1 |
| Horsman, DE | 1 |
| Nantel, SH | 2 |
| Vickars, LM | 1 |
| Sutherland, HJ | 1 |
| Toze, CL | 1 |
| Hogge, DE | 1 |
| Klingemann, HG | 3 |
| Naiman, SC | 1 |
| Barnett, MJ | 3 |
| Mistrík, M | 1 |
| Bojtárová, E | 1 |
| Demecková, E | 1 |
| Hrubisko, M | 1 |
| Holománová, D | 1 |
| Buc, M | 1 |
| Fehérvízyová, E | 1 |
| Bátorová, A | 1 |
| Kusiková, M | 1 |
| Sakalová, A | 1 |
| Berger, C | 1 |
| Stockshläder, M | 1 |
| Horstmann, M | 1 |
| Zeller, W | 1 |
| Schönrock, P | 1 |
| Kuse, R | 2 |
| Braumann, D | 2 |
| Illiger, HJ | 1 |
| Fiedler, W | 2 |
| de Witt, M | 1 |
| Hossfeld, KD | 1 |
| Weh, HJ | 1 |
| Alimoghadam, K | 1 |
| Nasseri, P | 1 |
| Khodabandeh, A | 1 |
| Ghahremani, G | 1 |
| Mellander, L | 1 |
| Jacobsen, N | 1 |
| Kulkarni, S | 1 |
| Powles, RL | 1 |
| Treleaven, JG | 1 |
| Singhal, S | 1 |
| Saso, R | 1 |
| Horton, C | 1 |
| Killick, S | 1 |
| Tait, D | 1 |
| Ramiah, V | 1 |
| Rosales, F | 2 |
| Peylan-Ramu, N | 1 |
| Cividalli, G | 3 |
| Varadi, G | 4 |
| de Medeiros, CR | 1 |
| Dantas da Cunha, A | 1 |
| Pasquini, R | 1 |
| Arns da Cunha, C | 1 |
| Culbert, S | 1 |
| Mullen, C | 1 |
| Roberts, W | 1 |
| Chan, K | 1 |
| Carlens, S | 1 |
| Hägglund, H | 1 |
| Klaesson, S | 1 |
| Benvenuto, F | 1 |
| Figari, O | 1 |
| Berisso, G | 1 |
| Frassoni, F | 1 |
| Watanabe, T | 1 |
| Kajiume, T | 1 |
| Abe, T | 1 |
| Iwai, A | 1 |
| Iwai, T | 1 |
| Kuroda, Y | 1 |
| Khojasteh, HN | 1 |
| Zakerinia, M | 1 |
| Ramzi, M | 1 |
| Haghshenas, M | 1 |
| Schuler, U | 1 |
| Freiberg-Richter, J | 2 |
| Helwig, A | 2 |
| Plettig, R | 2 |
| Röllig, C | 2 |
| Naumann, R | 1 |
| Kroschinsky, F | 1 |
| Bostrom, B | 1 |
| Ramsay, NK | 1 |
| Sonnenberg, S | 1 |
| Finkenstein, F | 1 |
| Mayer, U | 1 |
| Holstein, K | 1 |
| Colberg, H | 1 |
| Sonnen, R | 1 |
| Metzner, B | 1 |
| del Valle, F | 1 |
| Theil, KS | 1 |
| Tighe, MB | 1 |
| Young, DC | 1 |
| Mengarelli, A | 2 |
| Guglielmi, C | 2 |
| Perrone, MP | 1 |
| Gozzer, M | 1 |
| Cimino, G | 1 |
| Testi, AM | 1 |
| Ricci, R | 1 |
| De Felice, L | 2 |
| Girelli, G | 1 |
| Mandelli, F | 1 |
| Brunstein, CG | 1 |
| Mcglave, PB | 1 |
| Ruiz-Argüelles, A | 1 |
| Cantú, OG | 1 |
| Jaburg, N | 1 |
| Löliger, C | 1 |
| Suenaga, K | 1 |
| Niiya, H | 1 |
| Ohnishi, M | 1 |
| Takeuchi, T | 1 |
| Miyawaki, S | 1 |
| Ohnishi, T | 2 |
| Kanai, S | 2 |
| Kim, I | 1 |
| Chang, HM | 1 |
| Bang, SM | 1 |
| Byun, JH | 1 |
| Kim, DJ | 1 |
| Jenke, A | 1 |
| Geissler, G | 1 |
| Lutterbeck, K | 1 |
| Oelschlagel, U | 1 |
| Schrum, J | 1 |
| Hertenstein, B | 1 |
| Chevret, S | 1 |
| Johansson, JE | 1 |
| Ekman, T | 1 |
| Iori, A | 1 |
| Romano, A | 1 |
| Cerretti, R | 1 |
| Torromeo, C | 1 |
| Micozzi, A | 1 |
| Fenu, S | 1 |
| Donato, V | 1 |
| Barkholt, L | 1 |
| Stierner, U | 1 |
| Huang, L | 1 |
| Shoji, N | 1 |
| Ogasawara, T | 1 |
| Matsubara, H | 1 |
| Reece, DE | 2 |
| Glejzer, O | 1 |
| Sedzimirska, M | 1 |
| Tomaszewska-Toporska, B | 1 |
| Tomeczko, J | 1 |
| Kołodziej, J | 1 |
| Pacuszko, T | 1 |
| Was, A | 1 |
| Bocheńska, J | 1 |
| Jaźwiec, B | 1 |
| Klimczak, A | 1 |
| Biggs, JC | 3 |
| Atkinson, K | 3 |
| Dodds, A | 1 |
| Concannon, AJ | 1 |
| Tutschka, P | 1 |
| Bianco, JA | 1 |
| Singer, JW | 1 |
| Dalton, W | 1 |
| Beatty, P | 1 |
| Fefer, A | 1 |
| Cullis, JO | 1 |
| Schwarer, AP | 1 |
| Hughes, TP | 1 |
| Hows, JM | 1 |
| Franklin, I | 1 |
| Morgenstern, G | 1 |
| Goldman, JM | 1 |
| Stevens, M | 1 |
| Tiedemann, K | 1 |
| Brown, R | 1 |
| Geller, RB | 3 |
| Myers, S | 1 |
| Devine, S | 1 |
| Williams, SF | 1 |
| Park, CL | 1 |
| O'Toole, K | 1 |
| Chandler, C | 1 |
| Topper, RL | 1 |
| Leisz, MC | 1 |
| Kawahara, K | 1 |
| Bianco, J | 1 |
| Petersen, F | 1 |
| Archimbaud, E | 1 |
| Halvorson, RD | 1 |
| Snyder, MJ | 1 |
| Johnson, RA | 1 |
| Rubinsak, JR | 1 |
| Vogelsang, GB | 3 |
| Farmer, ER | 1 |
| Altomonte, V | 1 |
| Hess, AD | 3 |
| Emminger, W | 2 |
| Emminger-Schmidmeier, W | 2 |
| Haas, OA | 1 |
| Ambros, P | 1 |
| Mann, G | 1 |
| Fink, FM | 1 |
| Ferstl, G | 1 |
| Cunningham, I | 2 |
| Klein, JP | 3 |
| Vaughan, WP | 1 |
| Dennison, JD | 1 |
| Reed, EC | 1 |
| Klassen, L | 1 |
| McGuire, TR | 1 |
| Sanger, WG | 1 |
| Kumar, PP | 1 |
| Warkentin, PI | 1 |
| Gordon, BG | 1 |
| Bierman, PJ | 1 |
| Gadner, H | 1 |
| Durazzi, SM | 3 |
| Nicolini, G | 1 |
| Politi, P | 3 |
| Albertini, F | 2 |
| Vellodi, A | 2 |
| Jurges, E | 1 |
| el-Tumi, M | 1 |
| Abdul-Ahad, A | 2 |
| Hobbs, JR | 3 |
| Vermylen, C | 1 |
| Philippe, M | 1 |
| Ninane, J | 1 |
| Borja, A | 1 |
| Latinne, D | 1 |
| Ferrant, A | 1 |
| Michaux, JL | 1 |
| Sokal, G | 1 |
| Baker, BW | 1 |
| Wilson, CL | 1 |
| Davis, AL | 1 |
| Spearing, RL | 1 |
| Hart, DN | 1 |
| Heaton, DC | 1 |
| Beard, ME | 1 |
| Grochow, LB | 1 |
| Krivit, W | 1 |
| Whitley, CB | 1 |
| Blazar, B | 1 |
| Bigler, R | 1 |
| Filocamo, M | 2 |
| Bartolucci, M | 1 |
| Kolb, HJ | 1 |
| Bender-Götze, C | 1 |
| Walther, U | 1 |
| Mittermüller, J | 1 |
| Clemm, C | 1 |
| Bauchinger, M | 1 |
| Gerhartz, HH | 1 |
| Brehm, G | 1 |
| Ledderose, G | 1 |
| Fischer, AC | 2 |
| Piantadosi, S | 1 |
| Wingard, JR | 2 |
| Beschorner, WB | 1 |
| Manenti, F | 2 |
| Barrett, AJ | 1 |
| Sobocinski, A | 1 |
| Horowitz, M | 1 |
| Bortin, MM | 1 |
| Di Girolamo, G | 1 |
| Angrilli, F | 1 |
| Catinella, V | 1 |
| Ciancarelli, M | 1 |
| Dragani, A | 1 |
| D'Antonio, D | 1 |
| Palka, G | 1 |
| Guanciali-Franchi, P | 1 |
| Iacone, A | 1 |
| Hugh-Jones, K | 2 |
| Jones, ST | 1 |
| Rogers, JR | 1 |
| Frappaz, D | 1 |
| Bergerat, JP | 1 |
| Hervé, P | 1 |
| Freycon, F | 1 |
| Engelhard, D | 1 |
| Brautbar, C | 2 |
| Weshler, Z | 1 |
| Weiss, L | 1 |
| Mumcuoglu, M | 1 |
| Rachmilewitz, EA | 1 |
| Centis, F | 2 |
| Agostinelli, F | 2 |
| Giorgi, C | 2 |
| Filippetti, A | 1 |
| Capriotti, L | 1 |
| Salvadori, P | 1 |
| Dardanelli, C | 1 |
| Barbanti, I | 1 |
| Cottler-Fox, M | 1 |
| Torrisi, J | 1 |
| Cahill, R | 1 |
| Greenspan, A | 1 |
| Lynch, M | 1 |
| Bearman, SI | 1 |
| Rossi, MC | 1 |
| De Biagi, M | 1 |
| Izzi, T | 1 |
| Delfini, C | 1 |
| Manna, M | 1 |
| Ostendorf, P | 1 |
| Schmidt, H | 1 |
| Haen, M | 1 |
| Schüch, K | 1 |
| Müller, C | 1 |
| Wernet, P | 1 |
| Dopfer, H | 1 |
| Hale, G | 1 |
| Waldmann, H | 1 |
| Rachmilewitz, E | 1 |
| Vowels, MR | 1 |
| Berdoukas, V | 1 |
| Lam-Po-Tang, PR | 1 |
| Ford, D | 1 |
| Linch, DC | 1 |
| Burnett, AK | 1 |
| Inoue, S | 1 |
| Ginsburg, D | 1 |
| Smith, BR | 1 |
| Nathan, DG | 1 |
| Orkin, SH | 1 |
| Rappeport, JM | 1 |
| Williamson, S | 1 |
| Chambers, JD | 1 |
| James, DC | 1 |
| Joshi, R | 1 |
| Lemmel, EM | 2 |
| Nouza, K | 2 |
| Motycka, K | 1 |
| Soucek, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation[NCT02670252] | Phase 3 | 550 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms[NCT01707004] | Phase 2 | 20 participants (Actual) | Interventional | 2013-05-16 | Completed | ||
| Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen[NCT00796068] | Phase 2 | 130 participants (Actual) | Interventional | 2009-02-24 | Completed | ||
| Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT[NCT06125483] | 38 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | |||
| Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)[NCT01410344] | Phase 2 | 20 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)[NCT01339910] | Phase 3 | 272 participants (Actual) | Interventional | 2011-06-30 | Terminated (stopped due to Accrual terminated as recommended by the data and safety monitoring board.) | ||
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568] | 110 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| Modified Post-Transplant Cyclophosphamide Combined With DCAG as a Bridge Followed by Busulfan, Fludarabine and Melphalan Based Conditioning Regimen for Children With Juvenile Myelomonocytic Leukemia[NCT03687463] | 6 participants (Actual) | Observational [Patient Registry] | 2015-04-10 | Enrolling by invitation | |||
| The Therapeutic Window of Busulfan in Children With Haemopoietic Stem Cell Transplantation：A Multicenter Study in China[NCT04786002] | 500 participants (Anticipated) | Observational | 2020-11-01 | Recruiting | |||
| Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation[NCT01257854] | 200 participants (Anticipated) | Observational | 2008-02-29 | Recruiting | |||
| A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD[NCT03055247] | Phase 2 | 3 participants (Anticipated) | Interventional | 2015-11-06 | Recruiting | ||
| Investigation of Novel Targetable Kinases in Steroid-refractory Acute Graft-versus-host Disease[NCT04342442] | 24 participants (Actual) | Observational | 2017-01-01 | Completed | |||
| Trial Of Double Umbilical Cord Blood Transplantation[NCT00763490] | Phase 2 | 20 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells[NCT03538899] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2018-05-31 | Recruiting | ||
| Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide[NCT00809276] | Phase 1/Phase 2 | 92 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| The Use of Granulocyte Transfusions After Umbilical Cord Blood Transplant for Leukaemia: A Prospective, Non-randomised, Single-centre Study to Evaluate Safety and Immune Reconstitution[NCT05425043] | 20 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | |||
| Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharido[NCT03488394] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2018-05-11 | Active, not recruiting | ||
| Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas[NCT01181271] | Phase 2 | 42 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study[NCT01323920] | Phase 2 | 35 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen[NCT00448357] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Allogeneic Stem Cell Transplantation With Treosulfan, VP-16 and Cyclophosphamide for Patients With Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-containing Conditioning Regimen: A Phase II-study[NCT00682305] | Phase 2 | 50 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637] | Phase 3 | 84 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen[NCT00070135] | Phase 2 | 121 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)[NCT03992352] | 1,229 participants (Actual) | Observational | 2019-07-19 | Active, not recruiting | |||
| A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation[NCT01427881] | Phase 2 | 43 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Pro[NCT01985061] | Phase 2 | 177 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine[NCT00987480] | Phase 2 | 45 participants (Actual) | Interventional | 2009-09-25 | Completed | ||
| PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612] | Phase 3 | 53 participants (Actual) | Interventional | 2010-06-16 | Terminated (stopped due to Lack of Accrual) | ||
| A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies[NCT01810926] | Phase 2 | 130 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia in Remission Using HLA-matched Sibling Donors, HLA-matched Unrelated Donors, or HLA-mismatched Familial Donors-A Phase 2 Study[NCT01037764] | Phase 2 | 100 participants (Anticipated) | Interventional | 2010-01-31 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | ||
| Allogeneic Stem Cell Transplantation After Dose-reduced Intensity Conditioning Regimen for Patients With Myelofibrosis With Myeloid Metaplasia (MMM): A Phase II-study[NCT00599547] | Phase 2 | 106 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT[NCT02677181] | Phase 4 | 100 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity[NCT01779882] | 72 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study.[NCT00469014] | Phase 2 | 72 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Evaluation of Treosulfan Pharmacokinetics (PK) in Children Undergoing Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)[NCT02048800] | 61 participants (Actual) | Observational | 2014-03-31 | Completed | |||
| Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies[NCT00627666] | Phase 2 | 52 participants (Anticipated) | Interventional | 2003-01-31 | Completed | ||
| Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)[NCT01062490] | Phase 2 | 45 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING[NCT00521430] | 30 participants (Anticipated) | Interventional | 2004-04-30 | Completed | |||
| HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY[NCT00732316] | Phase 2 | 54 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY[NCT01795378] | Phase 1/Phase 2 | 56 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome[NCT02221310] | Phase 2 | 25 participants (Anticipated) | Interventional | 2011-12-07 | Completed | ||
| Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731] | Phase 2 | 18 participants (Anticipated) | Interventional | 2017-08-10 | Active, not recruiting | ||
| Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome[NCT00774280] | Phase 3 | 130 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation[NCT03821519] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-13 | Recruiting | ||
| Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression[NCT03480360] | Phase 3 | 20 participants (Anticipated) | Interventional | 2018-03-28 | Active, not recruiting | ||
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| Transplantation of Ex-vivo Expanded Human Cord Blood Hematopoietic Stem Cells Expanded: Evaluation of Hematopoietic and Immunologic Reconstitution After a Reduced-intensity Conditioning Regimen[NCT01034449] | Phase 2 | 16 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522] | Phase 2 | 23 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases[NCT01828619] | 60 participants (Anticipated) | Observational | 2013-02-28 | Enrolling by invitation | |||
| [NCT00000603] | Phase 2 | 0 participants | Interventional | 1996-09-30 | Completed | ||
| Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation[NCT01277484] | Phase 1 | 19 participants (Actual) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy[NCT02487069] | 876 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.[NCT00491634] | Phase 2 | 24 participants (Anticipated) | Interventional | 2007-06-30 | Completed | ||
| Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma[NCT01208896] | Phase 2 | 32 participants (Actual) | Interventional | 2011-02-03 | Completed | ||
| PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia[NCT00494897] | Phase 4 | 374 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients[NCT03963999] | Phase 4 | 0 participants (Actual) | Interventional | 2020-04-01 | Withdrawn (stopped due to We did not receive grant funding. We will reapply in June of 2020) | ||
| Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study[NCT03426358] | 1,101 participants (Actual) | Interventional | 2015-04-28 | Completed | |||
| Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML[NCT00001144] | Phase 2 | 50 participants | Interventional | 1999-10-31 | Completed | ||
| A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia[NCT03709576] | Phase 2 | 3 participants (Actual) | Interventional | 2018-07-18 | Terminated (stopped due to Funding pulled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Will be summarized with a proportion and a 95% confidence interval. (NCT01707004)
Timeframe: Up to 1 year
| Intervention | percentage (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 40.7 |
Determined by the standard bone marrow transplant (BMT) Clinical Trials Network criteria (BMTCTN). Will be analyzed using KM method, a Graft versus Host Disease (GVHD) grade III-IV will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 27.8 |
(NCT01707004)
Timeframe: Up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Decitabine + Bone Marrow Transplant | 14 |
Defined as less than 5% donor chimerism in the cluster of differentiation (CD)3 and CD33 selected cell populations at any time after transplantation. Will be analyzed using KM method. (NCT01707004)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Decitabine + Bone Marrow Transplant | 0 |
Will be analyzed using Kaplan-Meier (KM) method, and OS will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 64.7 |
Platelet recovery is defined as the first day of a platelet count greater than 20,000/mm^3 with no platelet transfusions. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to day 30
| Intervention | percentage with plt engraftment, day 30 (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 58 |
(NCT01707004)
Timeframe: Up to 1 year
| Intervention | days (Median) |
|---|---|
| Decitabine + Bone Marrow Transplant | 141 |
Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/ul for three consecutive measurements on different days. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to 1 year
| Intervention | days (Mean) |
|---|---|
| Decitabine + Bone Marrow Transplant | 16 |
Summarized using a range and median of measure in days until participants reached platelet engraftment. Platelet engraftment was defined as the first of 7 consecutive days when the platelet count exceeded 20 x 109/L (untransfused). (NCT00796068)
Timeframe: At 6 months
| Intervention | days (Median) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 31 |
| Arm II (High Risk for Graft Failure) | 31 |
Overall GVHD is determined based on the organ stage, response to treatment and whether GVHD was a major cause of death. Chronic GVHD will be defined according to the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Described as mild, moderate, or severe as graded according to the attached Organ Scoring Sheet. Symptoms consistent with both chronic and acute GVHD occurring after day 100 will be considered overlap chronic GVHD syndrome. (NCT00796068)
Timeframe: At 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 7 |
| Arm II (High Risk for Graft Failure) | 6 |
Collected and graded according to the modified National Cancer Institute Common Toxicity Criteria. (NCT00796068)
Timeframe: At 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 53 |
| Arm II (High Risk for Graft Failure) | 61 |
Cumulative incidence estimates using non-relapse mortality as competitive event. (NCT00796068)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 17 |
| Arm II (High Risk for Graft Failure) | 11 |
Death of any cause other than relapse or disease progression was considered. (NCT00796068)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 8 |
| Arm II (High Risk for Graft Failure) | 10 |
Overall survival was measured from the first day of CBT infusion until death from any cause. (NCT00796068)
Timeframe: At 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 51 |
| Arm II (High Risk for Graft Failure) | 47 |
Progression-free survival is the time interval from start of treatment to documented evidence of disease progression. Disease progression was defined by European LeukemiaNet 2017 criteria and International Working Group (IWG) within 3 years of transplant. (NCT00796068)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 37 |
| Arm II (High Risk for Graft Failure) | 41 |
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening. Diagnosing and grading acute GVHD is based on clinical findings (the organ stage, response to treatment and whether GVHD was a major cause of death) and frequently varies between transplant centers and independent reviewers. (NCT00796068)
Timeframe: Day 100
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 36 |
| Arm II (High Risk for Graft Failure) | 37 |
"Patients will be considered primary graft failure provided they meet any criteria listed below, in the absence of documented disease persistence/recurrence or active bone marrow infection (ex. Cytomegalovirus (CMV)):~i. Absence of 3 consecutive days with neutrophils >500/u1 combined with host CD3+ peripheral blood chimerism ≥50% at day 42 ii. Absence of 3 consecutive days with neutrophils >500/u1 under any circumstances at day 55 iii. Death after day 28 with neutrophil count <100/u1 without any evidence of engraftment (< 5% donor CD3+) iv. Primary autologous count recovery with < 5% donor CD3+ peripheral blood chimerism at count recovery and without relapse" (NCT00796068)
Timeframe: Up to 100 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 2 |
| Arm II (High Risk for Graft Failure) | 5 |
Secondary graft failure is defined as decline of neutrophil count to <500/ul with loss of donor chimerism after day 55 (NCT00796068)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 0 |
| Arm II (High Risk for Graft Failure) | 0 |
Defined as death from any cause without sign of disease progression or relapse. Loss to follow up are censored, whereas disease relapse or progression are considered competing risks. (NCT00796068)
Timeframe: At day -200
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 7 |
| Arm II (High Risk for Graft Failure) | 6 |
Overall survival of participants after two-years of follow up. (NCT00796068)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Low Risk for Graft Failure) | 50 |
| Arm II (High Risk for Graft Failure) | 44 |
Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. (NCT01410344)
Timeframe: 1 Year Post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Allogeneic Transplant | 17.6 |
Relapse/Progression is defined as relapse or progression of the primary malignancy. (NCT01410344)
Timeframe: 1 Year Post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Allogeneic Transplant | 29.4 |
Recovery of hematologic function is described by the time to neutrophil and platelet recovery. Time to neutrophil recovery will be the first of three consecutive days of > 500 neutrophils/μL following the expected nadir. Time to platelet engraftment will be described by the date when platelet count is > 20,000/μL for the first of three consecutive labs with no platelet transfusions 7 days prior. (NCT01410344)
Timeframe: Days 28 and 100 Post-transplant
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 28 Neutrophil Recovery | Day 100 Platelet Recovery | |
| Allogeneic Transplant | 100.0 | 94.1 |
"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL 1.2-3 mg/dL 2.3.01-6 mg/dL 3.6.01-15.0 mg/dL 4.>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01410344)
Timeframe: Day 100 Post-transplant
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Grade II-IV Acute GVHD | Grade III-IV Acute GVHD | |
| Allogeneic Transplant | 41.2 | 11.8 |
The events for non-relapse mortality are death due to any cause other than relapse of the underlying malignancy. (NCT01410344)
Timeframe: Day 100, 1 Year, and 2 Years Post-transplant
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 100 | 1 Year | 2 Years | |
| Allogeneic Transplant | 0.0 | 11.8 | 18.3 |
Overall survival is defined as the time from transplant to death from any cause. (NCT01410344)
Timeframe: Six months, 1 Year, and 2 Years Post-transplant
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 6 Months | 1 Year | 2 Years | |
| Allogeneic Transplant | 82.4 | 58.8 | 50.2 |
Donor T-cell and myeloid chimerism will be described separately by conditioning regimen intensity (myeloablative or reduced intensity) according to proportions with mixed chimerism (5-95% donor cells out of all), full chimerism (>95% donor cells), or graft rejection (<5% donor cells). (NCT01410344)
Timeframe: Week 4, Day 100, and 6 months Post-transplant
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 472365409 | Week 472365410 | Day 10072365410 | Day 10072365409 | 6 Months72365409 | 6 Months72365410 | |||||||||||||||||||||||||
| Graft Rejection | No Assay Reported | Full Chimerism | Mixed Chimerism | Dead at Assessment | ||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 4 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 1 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 3 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 4 | |||||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 5 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 2 | |||||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 2 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 0 | |||||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 0 | |||||||||||||||||||||||||||||
Primary graft failure is defined by lack of neutrophil engraftment. (NCT01339910)
Timeframe: 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 1 |
| Reduced Intensity Conditioning (RIC) | 3 |
Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy. (NCT01339910)
Timeframe: 18 months post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 1 |
| Reduced Intensity Conditioning (RIC) | 4 |
Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. (NCT01339910)
Timeframe: 18 months post-transplant
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 64.0 |
| Reduced Intensity Conditioning (RIC) | 47.6 |
Disease Relapse is defined as relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 13.5 |
| Reduced Intensity Conditioning (RIC) | 48.3 |
Overall survival is defined as survival of death from any cause. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 77.5 |
| Reduced Intensity Conditioning (RIC) | 67.7 |
Relapse-free survival is defined as survival without relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 67.8 |
| Reduced Intensity Conditioning (RIC) | 47.3 |
Treatment-related mortality is defined as death without a previous relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 15.8 |
| Reduced Intensity Conditioning (RIC) | 4.4 |
"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL~2-3 mg/dL~3.01-6 mg/dL~6.01-15.0 mg/dL~>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01339910)
Timeframe: Day 100 post-transplant
| Intervention | percentage (Number) | |
|---|---|---|
| Grade II-IV Acute GVHD | Grade III-IV Acute GVHD | |
| Myeloablative Conditioning Regimen (MAC) | 44.7 | 13.6 |
| Reduced Intensity Conditioning (RIC) | 31.6 | 6.8 |
Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days. (NCT01339910)
Timeframe: Days 28 and 60 post-transplant
| Intervention | percentage (Number) | |
|---|---|---|
| Neutrophil Engraftment at Day 28 | Platelet Engraftment at Day 60 | |
| Myeloablative Conditioning Regimen (MAC) | 98.5 | 95.5 |
| Reduced Intensity Conditioning (RIC) | 97.8 | 96.2 |
Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment. (NCT01339910)
Timeframe: Days 28 and 100 and 18 months post-transplant
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2872548419 | Day 2872548420 | Day 10072548420 | Day 10072548419 | 18 Months72548420 | 18 Months72548419 | |||||||||||||||||||||||||
| Mixed Chimerism | Full Donor Chimerism | Graft Rejection | Death Prior to Assessment | Unknown (relapsed or missing assay) | ||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 86 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 80 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 9 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 30 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 1 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 0 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 0 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 36 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 22 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 106 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 86 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 12 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 2 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 6 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 8 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 71 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 66 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 4 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 5 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 1 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 31 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 42 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 25 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 19 | |||||||||||||||||||||||||||||
One-year survival rate after transplant (NCT00763490)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Double Cord Blood Tranplant | 40 |
Event Free Survival (EFS) was determined. Patients were followed up to 5 years (median time of 2.35 years). (NCT00763490)
Timeframe: 5 Years
| Intervention | percentage of patients (Number) |
|---|---|
| Double Cord Blood Tranplant | 35 |
The failure to achieve a neutrophil count > 500/uL or a platelet count >30.0 x 10e9 /L within 35 days of the stem cell infusion will be defined as primary engraftment failure. (NCT00763490)
Timeframe: Day 35
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Cumulative incidence of platlet engraftment | Cumulative incidence of neutrophil engraftment | |
| Double Cord Blood Tranplant | 73 | 89 |
"The percentage of patients with acute GVHD (Grade II-IV) was determined at 100 days. Patients were followed up to 5 years and the percentage of patients that developed chronic GVHD at the end of the study was tabulated.~Acute GVHD is staged and graded (grade 0-IV, where grade 0 is no involvement and involvement increases by grade) by the number and extent of organ involvement. Patients can have involvement of three organs: skin (rash/dermatitis), liver (hepatitis/jaundice), and gastrointestinal tract (abdominal pain/diarrhea)." (NCT00763490)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Acute GVHD (Grades II-IV) | Chronic GVHD | |
| Double Cord Blood Tranplant | 40 | 35 |
Percentage of participants with grade III-IV acute graft versus host disease (GVHD). GVHD is graded on a combination of skin symptoms (rash), gut symptoms (diarrhea), and liver symptoms (using a lab test called bilirubin). Grades range from I to IV, where I is the least severe and IV is the most severe. (NCT00809276)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| BuFlu Transplant | 15 |
(NCT01181271)
Timeframe: 2-years after allogeneic transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 17.2 |
Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression. (NCT01181271)
Timeframe: 1-year after allogeneic transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 37.9 |
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening. (NCT01181271)
Timeframe: within 200 days after allogeneic transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 13.8 |
Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease (NCT01181271)
Timeframe: 2-years after allogeneic transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 11.1 |
(NCT01181271)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 83 |
(NCT01181271)
Timeframe: Two-years after Allogeneic Transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 89 |
(NCT01181271)
Timeframe: two years
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 69 |
(NCT01181271)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 64 |
(NCT01181271)
Timeframe: 2 years after allogeneic transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 72 |
(NCT01181271)
Timeframe: Two Years
| Intervention | percentage of participants (Number) |
|---|---|
| Autologous Then Allogeneic Transplant | 46 |
(NCT01181271)
Timeframe: within 28 days after allogeneic transplant
| Intervention | days (Median) |
|---|---|
| Autologous Then Allogeneic Transplant | 12 |
Successful donor stem cell engraftment is defined as when ≥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation. (NCT01181271)
Timeframe: 100 days post allogeneic transplant
| Intervention | percentage of donor-derived elements (Median) |
|---|---|
| Autologous Then Allogeneic Transplant | 95 |
(NCT01323920)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade/Tac/MTX | 53 |
The primary outcome of this study is the cumulative incidence of grade II-IV acute GVHD up to Day 100 after stem cell infusion. Acute GHVD is graded according to the modified Glucksberg criteria (adapted from Thomas et al., NEJM ,1975, pp. 895-90), which is based on criteria by which the provider classifies acute GVHD per its objective organ staging. Acute GVHD is assessed in weekly standard of care visits post stem cell infusion and is captured in the protocol EDC upon evaluation of clinical notes up to Day 100. Data for acute GVHD organ staging and etiologies are collected in an acute GVHD separate case report form and do not include system organ class, expectedness or attribution. (NCT01323920)
Timeframe: Day 100
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade/Tac/MTX | 32 |
To assess the percentage donor engraftment up to day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) >/= 500 cells/u/L (NCT01323920)
Timeframe: Day 30
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade/Tac/MTX | 94 |
Progression free and overall survival by 1 year after stem cell infusion will be assessed using the method of Kaplan and Meier. Progression-free survival will be defined as the time from stem cell infusion to the time of disease progression or death from any cause. Overall survival will be defined as the time from stem cell infusion to the time to death from any cause. Patients will be censored at the time last documented alive. Cumulative incidence and Kaplan-Meier curves will be constructed as appropriate. Progression is defined per clinical presentation, not protocol specified, and vary per disease, e.g. blasts in bone marrow or peripheral blood for AML/MDS; lymphoma + on PET/CT re-staging etc. (NCT01323920)
Timeframe: 1 year
| Intervention | Percent of participants (Number) | ||
|---|---|---|---|
| non-relapse mortality | progression-free survival | overall survival | |
| Velcade/Tac/MTX | 8.8 | 85 | 84 |
Test doses of busulfan were administered and plasma levels were measured to determine a targeted AUC dosing estimate. The capacity is reported as the precision with which these test dose goals predicted the actual 90-hour mean AUC levels.Dose targeting precision was estimated by root mean squared error. (NCT00448357)
Timeframe: Day -15 to Day -11
| Intervention | percentage of error (Number) |
|---|---|
| Dose Level 1 | 11.7 |
| Dose Level 2 | 4.9 |
| Dose Level 3 | 10.2 |
| Dose Level 4 | 11.1 |
| Dose Level 5 | 15.9 |
Dose limiting toxicity will be defined as any irreversible grade 3 or any grade 4 non-hematologic toxicity that is related to busulfan infusion and not graft vs host disease or late infection after recovery from the initial period of myelosuppression. The maximum tolerated dose (MTD) is defined as the dose with probability of dose limiting toxicity (DLT) of 0.25. The dose of continuous infusion IV busulfan based on blood levels derived from a test dose in conjunction with fludarabine and alemtuzumab plus tacrolimus for GVHD prophylaxis. (NCT00448357)
Timeframe: first 6 weeks or 42 days following stem cell infusion
| Intervention | DLTs (Number) |
|---|---|
| Dose Level 1 | 1 |
| Dose Level 2 | 1 |
| Dose Level 3 | 1 |
| Dose Level 4 | 2 |
| Dose Level 5 | 2 |
Percentage of participants alive at 3 years post transplant (NCT00448357)
Timeframe: Three years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Low Busulfan AUC Tertile (5078) | 28 |
| Intermediate Busulfan AUC Tertile (6372) | 39 |
| High Busulfan AUC Tertile (7605) | 55 |
Relapse is defined as new or increased sites of disease or positive one marrow after a complete response (CR). The RFS was calculated as the percentage of patients who were alive and without relapse at 3 years (NCT00448357)
Timeframe: Three years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Low Busulfan AUC Tertile | 22 |
| Intermediate Busulfan AUC Tertile | 39 |
| High Busulfan AUC Tertile | 43 |
Deoxyribonucleic acid (DNA) chimerism is a measure identifying the genetic profiles of the transplant recipient and of the donor and then evaluating the extent of mixture in the recipient's blood, bone marrow, or other tissue. (NCT00448357)
Timeframe: 30 days post transplant
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Whole blood chimerism-Any | Whole blood chimerism->=95% donor | T Cell chimerism-Any | T Cell chimerism>=95% donor | |
| Experimental: GVHD Prophylaxis | 49 | 47 | 46 | 30 |
"GVHD can be mild, moderate or severe depending on the differences in tissue type between patient and donor. GVHD can be acute or chronic. Its symptoms can include:~Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body~Blistering, causing the exposed skin surface to flake off in severe cases~Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected~Jaundice, or a yellowing of the skin, which can indicate liver damage~Excessive dryness of the mouth and throat, leading to ulcers~Dryness of the lungs, vagina and other surfaces" (NCT00448357)
Timeframe: 100 days post transplant
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Acute GVHD grade >=II | Acute GVHD grades III and IV | Chronic GVHD; intermediate/severe | |
| High Busulfan AUC Tertile | 11 | 3 | 2 |
| Intermediate Busulfan AUC Tertile | 10 | 4 | 6 |
| Low Busulfan AUC Tertile | 7 | 2 | 4 |
Percentage of participants who were alive and relapse free at 2 years for all patients. The 2 year disease free survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00070135)
Timeframe: Up to 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Fludarabine, Busulfan, Allogeneic PBSC) | 42 |
"Percentage of participants who were alive and relapse free at 2 years for patients who were matched with an unrelated donor for transplant. The 2 year disease free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.~A relapse is defined as any of the following:~Reappearance of leukemia blasts cells in peripheral blood~>5% blasts in the marrow, not attributable to another cause (e.g., bone marrow regeneration)~If there are no circulating blasts, but the marrow contains 5-20% blasts, a repeat bone marrow ≥ 1 week later with >5% blasts is necessary to meet the criteria for relapse~The development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid" (NCT00070135)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Fludarabine, Busulfan, Allogeneic PBSC) | 40 |
Percentage of patients who died due to causes other than relapse (NCT00070135)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Fludarabine, Busulfan, Allogeneic PBSC) | 16 |
Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error. (NCT01427881)
Timeframe: At 1 year after transplantation
| Intervention | percent of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 16 |
Disease-free survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 73.8 |
Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood. (NCT01427881)
Timeframe: At day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 6 |
Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of >= 500/uL by >= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to < 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors. (NCT01427881)
Timeframe: By greater than or equal to 28 days post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 2 |
Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence. (NCT01427881)
Timeframe: At 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 14 |
Overall survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 75.6 |
Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation. (NCT01427881)
Timeframe: At 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 17 |
Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots. (NCT01427881)
Timeframe: Through day +100 post-transplant
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Grades II-IV GVHD | Grades III-IV GVHD | |
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 77 | 0 |
Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is > 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is >= 20,000/uL without platelet transfusion support in the seven days prior. (NCT01427881)
Timeframe: Up to day +100
| Intervention | days (Median) | |
|---|---|---|
| Neutrophil Engraftment | Platelet Engraftment | |
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 19 | 14 |
"Defined as time from date of transplant to relapse, graft rejection or graft failure, or death.~Primary non-engraftment is diagnosed when the participants fails to achieve an ANC >/= 500/ul at any time in the first 28 days post-transplant.~For participants with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells. These will be defined by an increasing number of blasts in the marrow over 5% by the presence of circulating peripheral blasts, or by the presence of blasts in any extramedullary site. Cytogenetic analysis of the marrow and/or peripheral blood will also be obtained for the diagnosis of relapse." (NCT00987480)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 77.8 |
Overall Survival is defined as time from date of transplant to event (death from any cause) or last follow-up. (NCT00987480)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 80 |
(NCT00987480)
Timeframe: 100 days
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 6.7 |
(NCT00987480)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 0 |
(NCT01366612)
Timeframe: 1 year
| Intervention | Percent (Number) |
|---|---|
| Group 1 | 38.9 |
| Group 2 | 18.8 |
Number of participants with treatment related mortality (death) within the first 30 days following transplantation. (NCT00469014)
Timeframe: First 30 Days
| Intervention | participants (Number) |
|---|---|
| Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine | 0 |
| Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine | 0 |
| Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine | 0 |
| Arm 4: Busulfan + Clofarabine | 0 |
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
34 reviews available for busulfan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Fixed-dose administration and pharmacokinetically guided adjustment of busulfan dose for patients undergoing hematopoietic stem cell transplantation: a meta-analysis and cost-effectiveness analysis.
Topics: Busulfan; Cost-Benefit Analysis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hum | 2022 |
Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders.
Topics: Activities of Daily Living; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2022 |
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
Topics: Adult; Bayes Theorem; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2023 |
Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell | 2023 |
Association between conditioning intensity and height growth after allogeneic hematopoietic stem cell transplantation in children.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell T | 2023 |
Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospecti | 2023 |
Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children.
Topics: Alkylating Agents; Busulfan; Child; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Genetic Varia | 2014 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
[Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures].
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Cyclosporine; Dise | 2015 |
Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children.
Topics: Animals; Area Under Curve; Busulfan; Drug Interactions; Graft vs Host Disease; Hematopoietic Stem Ce | 2008 |
Safety of conditioning agents for allogeneic haematopoietic transplantation.
Topics: Animals; Busulfan; Graft vs Host Disease; Humans; Immunosuppressive Agents; Transplantation Conditio | 2009 |
Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; D | 2011 |
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoi | 2012 |
Do different conditioning regimens really make a difference?
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hu | 2012 |
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2002 |
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free | 2003 |
[Mini-transplantation from HLA-mismatched donors].
Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematol | 2003 |
[Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases].
Topics: Busulfan; Cause of Death; Clinical Trials as Topic; Disease-Free Survival; Graft vs Host Disease; He | 2003 |
[Mini-transplantation for solid tumors].
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Clinical Trials as Topic | 2003 |
Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Adolescent; Adult; Aged; Anemia, Aplastic; BK Virus; B | 2003 |
Allogenic bone marrow transplantation: current status and future directions.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Cell Separation; Cyclophosphamide; Erythroc | 1983 |
Bone marrow transplantation in acute nonlymphoblastic leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; C | 1984 |
Conditioning regimens for marrow grafting.
Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporins | 1984 |
Destruction of the intestinal mucosa after bone marrow transplantation and graft-versus-host disease.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Chronic Disease; Combined Modality Therapy; Cy | 1984 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning].
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Arrhythmias, Cardiac; Bone Marrow Tran | 1995 |
[Endocrinal sequela in bone marrow transplantations during childhood and adolescence].
Topics: Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cr | 1993 |
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1993 |
The management of chronic myeloid leukaemia--a case history.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Transplantation; Busulfan; | 1997 |
The biology and treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cy | 2001 |
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transpl | 1992 |
Infections and immunodeficiency in bone marrow transplantation.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bone Marrow Transplantation; Busulfan; Graft vs Host Di | 1988 |
Clinical studies of ABMT in acute myeloid leukaemia.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide | 1986 |
[Bone marrow transplantation in pediatric patients: review of progress].
Topics: Anemia, Aplastic; Blast Crisis; Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Graft vs | 1987 |
181 trials available for busulfan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospect | 2022 |
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2022 |
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2022 |
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoieti | 2022 |
A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2022 |
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell | 2023 |
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A
Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematopoietic S | 2023 |
Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
Topics: Acetylcysteine; Behavior Therapy; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Ce | 2023 |
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Topics: Adult; Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplanta | 2023 |
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Diseas | 2023 |
Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2020 |
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Di | 2020 |
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study.
Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2021 |
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; De | 2020 |
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study.
Topics: Busulfan; Fetal Blood; Graft vs Host Disease; Humans; Middle Aged; Prospective Studies | 2020 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressi | 2021 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; | 2017 |
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival | 2018 |
Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
Topics: Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Dise | 2018 |
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Topics: Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease | 2018 |
Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis.
Topics: Adolescent; Adult; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neopl | 2018 |
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; | 2019 |
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality.
Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Allografts; Antineoplastic Combined Chemo | 2019 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Diseas | 2019 |
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Fe | 2019 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Pr | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; | 2019 |
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Busulfan; CD4 Lymphocyte Count; CD4-Positive T-Ly | 2013 |
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; C | 2014 |
Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Child; | 2013 |
Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; | 2014 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic S | 2014 |
Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children.
Topics: Adolescent; Area Under Curve; Asian People; Busulfan; Child; Child, Preschool; Female; Gas Chromatog | 2014 |
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft v | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Ch | 2014 |
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyt | 2015 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blo | 2014 |
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulf | 2014 |
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
Topics: Adult; Aged; Bayes Theorem; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic | 2014 |
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; H | 2015 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Fema | 2016 |
Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.
Topics: Adolescent; Adult; Busulfan; Child; Female; Graft Survival; Graft vs Host Disease; Guanine Nucleotid | 2015 |
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Fr | 2015 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transpla | 2016 |
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, | 2015 |
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disea | 2015 |
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms | 2015 |
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hema | 2015 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female | 2016 |
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
Topics: Adolescent; Adult; Allografts; Busulfan; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ | 2015 |
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Diseas | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cy | 2016 |
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Fr | 2016 |
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Gene Expression; Graft vs Host D | 2016 |
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Chil | 2016 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno- | 2016 |
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Topics: Acute Disease; Adolescent; Adult; Allografts; Blood Platelets; Busulfan; Child; Child, Preschool; Di | 2016 |
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosph | 2017 |
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy | 2008 |
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Graft | 2008 |
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft | 2008 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; F | 2008 |
Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Diseas | 2009 |
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Topics: Adolescent; Adult; Anemia, Aplastic; Busulfan; Cohort Studies; Cyclophosphamide; Follow-Up Studies; | 2009 |
Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Family; Female; Graft vs Host Disease; Hema | 2009 |
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Ag | 2009 |
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; | 2009 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hema | 2010 |
Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease Progression; Disease-Free Survival; | 2010 |
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neop | 2011 |
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busul | 2011 |
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucle | 2011 |
Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antigens, CD34; Bone Marrow Transplantation; Bu | 2012 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival | 2011 |
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Foll | 2011 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfa | 2011 |
Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disea | 2011 |
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem | 2011 |
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2012 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; | 2012 |
Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
Topics: Adult; Bacterial Infections; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transp | 2012 |
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regim
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiat | 2012 |
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplant | 2012 |
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Busulfan; Child; Child, P | 2012 |
Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hemato | 2012 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graf | 2012 |
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Busulfan; Drug Therapy, Combination; Female; | 2013 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan | 2013 |
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteri | 2013 |
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.
Topics: Administration, Oral; Aged; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; H | 2013 |
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modalit | 2013 |
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Bone Marrow Cells; Busulfan; Child; Cyclophosphamide; Cytogenetic Analysis; Disea | 2002 |
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Gr | 2002 |
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2002 |
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Topics: Adult; Age Factors; Busulfan; Child; Cyclophosphamide; Drug Administration Schedule; Drug Carriers; | 2002 |
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Cyclophosp | 2003 |
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host | 2003 |
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality | 2003 |
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs H | 2003 |
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs H | 2003 |
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs H | 2003 |
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs H | 2003 |
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Fre | 2003 |
Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Drug Therapy, Combination; Female; Graft Survival | 2003 |
Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Busulfan; Cell Lineage; Child; Child, Preschool; Dose Fractionation, Radiation; F | 2003 |
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cel | 2003 |
Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2003 |
Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; C | 2004 |
Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; C | 2004 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfa | 2004 |
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2004 |
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft | 2004 |
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cyclosporine; Drug | 2004 |
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytarabine; Female; Graf | 2004 |
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmus | 2005 |
Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Rejectio | 2004 |
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of | 2005 |
Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2005 |
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Topics: Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphami | 2005 |
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD | 2005 |
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Su | 2006 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bu | 2006 |
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cause of Death; Child; Chron | 2006 |
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2006 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; | 2006 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladri | 2007 |
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; G | 2007 |
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2007 |
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graf | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Hos | 2007 |
Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
Topics: Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Graft Survival; Graft vs Host Dis | 2007 |
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Topics: Adult; Bone Marrow Examination; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2007 |
Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; G | 2008 |
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.
Topics: Adult; Busulfan; Cell Count; Cord Blood Stem Cell Transplantation; Graft Survival; Graft vs Host Dis | 2008 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality T | 2008 |
In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.
Topics: Adolescent; Adult; Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal; Antibodies, Monoclon | 2008 |
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft | 2008 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclos | 1995 |
Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1995 |
Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therap | 1994 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1994 |
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bilirubin; Bone Marrow Transplantation; Busulfan; Child; Creatinine; Cyclophospha | 1994 |
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Child, Preschool; C | 1994 |
Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.
Topics: Administration, Oral; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Cyclophospham | 1994 |
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclopho | 1994 |
Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1993 |
Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cause of Deat | 1995 |
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1996 |
Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therap | 1995 |
Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Combine | 1996 |
Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Ch | 1996 |
Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey.
Topics: Adult; Body Weight; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Dose-Resp | 1997 |
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Drug Therapy, | 1997 |
An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
Topics: Alkylating Agents; Blood Specimen Collection; Bone Marrow Transplantation; Busulfan; Child; Child, P | 1997 |
Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cholagogues and Choleretics; Cyclophosphamide; Double- | 1998 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1997 |
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Catara | 1999 |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 1999 |
Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Topics: Aged; Aged, 80 and over; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survi | 1999 |
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-Up Studies; Graft Sur | 2000 |
Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies from HLA-matched siblings.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disea | 2001 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy P | 2001 |
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycloph | 2001 |
The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Gastric Muco | 2001 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graf | 2002 |
Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1992 |
Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Dose-Resp | 1992 |
Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft | 1992 |
Autologous and allogeneic bone marrow transplantation for childhood acute nonlymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cyclosporine; Fol | 1992 |
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1992 |
Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1992 |
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-U | 1992 |
Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin | 1991 |
Bone marrow transplantation with T-cell depleted allografts for the treatment of severe beta thalassemia major.
Topics: Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Cyclophosphamide; Graft Enhancement | 1989 |
Graft-versus-host disease: effects on long term disease free survival in marrow transplantation for haematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1989 |
Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1987 |
517 other studies available for busulfan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia-Lymphoma, | 2021 |
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow | 2021 |
Hand-foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients.
Topics: Busulfan; Female; Graft vs Host Disease; Hand-Foot Syndrome; Hematopoietic Stem Cell Transplantation | 2022 |
Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Data Mining; Electronic Health Records; Graft vs Host | 2021 |
Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell | 2022 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2022 |
Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cohort Studies; DN | 2022 |
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic St | 2022 |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Cocktail Conditioning Regimen for the Treatment of Pediatric Patients with Chronic Active Epstein-Barr Virus: A Retrospective Observational Study.
Topics: Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Epstein-Barr Virus Infections; | 2022 |
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans | 2022 |
Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults.
Topics: Adult; Busulfan; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Hematopoietic Stem Cel | 2022 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M | 2022 |
Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation.
Topics: Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2022 |
Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Topics: Busulfan; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2022 |
[Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].
Topics: Busulfan; Cladribine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2022 |
Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplanta | 2022 |
Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospecti | 2022 |
Radiation-free reduced-intensity hematopoietic stem cell transplantation with in vivo T-cell depletion from matched related and unrelated donors for Fanconi anemia: prognostic factor analysis.
Topics: Busulfan; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Pr | 2022 |
[Haploidentical stem cell transplantation for acute myeloid leukemia associated with adult-onset Shwachman-Diamond syndrome].
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2022 |
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplast | 2022 |
Role of therapeutic drug monitoring of intravenous Busulfan for prevention of sinusoidal obstructive syndrome in children.
Topics: Bayes Theorem; Busulfan; Child; Child, Preschool; Drug Monitoring; Female; Graft vs Host Disease; He | 2022 |
Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.
Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2022 |
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2022 |
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2022 |
Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retros | 2022 |
Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; M | 2022 |
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hu | 2022 |
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Primary Myelofibrosis; Retrospective Studies; Transp | 2022 |
Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft vs Host | 2022 |
Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency.
Topics: Adolescent; Adult; Busulfan; Child; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoi | 2022 |
A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospecti | 2022 |
Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
Topics: Bone Marrow; Busulfan; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem C | 2022 |
Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series.
Topics: Adult; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mal | 2022 |
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hu | 2022 |
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Topics: Busulfan; Child; Cyclophosphamide; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoieti | 2022 |
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group.
Topics: Busulfan; Child; Graft vs Host Disease; Hematology; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.
Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; H | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
[Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma].
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoieti | 2021 |
Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Topics: Adult; Aged; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2023 |
A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
Topics: Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Co | 2023 |
Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Co | 2023 |
Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Co | 2023 |
Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Co | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2023 |
Transplantation using targeted busulfan for Diamond-Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2023 |
Transplantation using targeted busulfan for Diamond-Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2023 |
Transplantation using targeted busulfan for Diamond-Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2023 |
Transplantation using targeted busulfan for Diamond-Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2023 |
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Bone Marrow; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic | 2023 |
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, N | 2023 |
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transp | 2023 |
Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome.
Topics: Busulfan; Child; Down Syndrome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
A single-center experience of haploidentical stem cell transplantation in hematological malignancies.
Topics: Busulfan; Child; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hemat | 2023 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan.
Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human | 2023 |
Improved Outcome Following Busulfan-Based Conditioning in Children with Functional Neutrophil Disorders Undergoing Hematopoietic Stem Cell Transplant from HLA-Matched Donors.
Topics: Busulfan; Child; Child, Preschool; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoie | 2023 |
Assessment of Stem Cell Transplant Eligibility in Recipients with Oral Foci of Infection: Appropriate Conditioning Regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Graft vs Host Disease; H | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Donor Age Influences Graft-Versus-Host Disease Relapse-Free Survival after Allogeneic Stem Cell Transplant in Elderly Patients in Two Countries from Latin America.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Latin Americ | 2023 |
The impact of Treosulfan-based conditioning for inborn errors of immunity: Is dose monitoring crucial?
Topics: Busulfan; Child; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantati | 2023 |
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients.
Topics: Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Synd | 2023 |
Outcome of first or second transplantation using unrelated umbilical cord blood without ATG conditioning regimen for pediatric bone marrow failure disorders.
Topics: Antilymphocyte Serum; Bone Marrow Failure Disorders; Busulfan; Child; Cyclophosphamide; Fetal Blood; | 2024 |
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus | 2023 |
Busulfan and subsequent malignancy: An evidence-based risk assessment.
Topics: Adult; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leuk | 2024 |
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
Topics: Aged; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
[Long-term outcome of hematopoietic stem cell transplantation in two children with Mucopolysaccharidosis].
Topics: Busulfan; Child; Child, Preschool; China; Female; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2023 |
The impact of low dose busulfan on gonodal function after allogeneic hematopoietic stem cell transplantation for aplastic anemia.
Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2020 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibro | 2020 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2019 |
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cy | 2019 |
Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Topics: Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2020 |
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosu | 2019 |
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up fro
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Follow-Up Studies; Graft vs Host Disease; Hematopoiet | 2020 |
Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.
Topics: Adult; Busulfan; Cytogenetic Analysis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantatio | 2020 |
Successful Salvage Haploidentical Alpha-Beta T Cell-Depleted Stem Cell Transplantation After Busulfan-Based Myeloablation in a Patient With IPEX Syndrome: A Case Report.
Topics: Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2019 |
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2020 |
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Femal | 2020 |
Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Busulfan; Cancer Survivors; Child; Chroni | 2020 |
Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Acetylcysteine; Adolescent; Adult; Busulfan; Capillaries; Child; Child, Preschool; Cholagogues and C | 2020 |
Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2020 |
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leuk | 2020 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2020 |
Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
Topics: Adolescent; Anemia, Diamond-Blackfan; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclo | 2019 |
Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thalassemia | 2020 |
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Nitriles; Pr | 2020 |
Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2020 |
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Sy | 2020 |
Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M | 2020 |
Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohisti | 2020 |
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cause of Death; Comorbidity; Cyclophosphamide; Female | 2020 |
Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2020 |
Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.
Topics: Busulfan; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Hematopoietic Stem Cell Trans | 2020 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; | 2021 |
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem | 2020 |
Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospecti | 2020 |
Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2020 |
Comparison of total body irradiation
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2021 |
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Topics: Aged; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2020 |
Splenomegaly May Increase the Risk of Rejection in Low-Risk Matched Related Donor Transplant for Thalassemia, This Risk Can Be Partially Overcome by Additional Immunosuppression during Conditioning.
Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; France; Germany; Graft vs Host Disease; Humans; Re | 2020 |
Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Chime | 2020 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human | 2020 |
Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2020 |
Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hema | 2020 |
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia
Topics: Adolescent; Adult; Bone Marrow; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplanta | 2020 |
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acut
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2021 |
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Hos | 2020 |
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middl | 2021 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2021 |
Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2021 |
Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Metabolomics; Prog | 2021 |
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2021 |
Second haploidentical stem cell transplantation for primary graft failure.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M | 2021 |
Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Graft vs Host Dis | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neopl | 2021 |
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cel | 2021 |
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppr | 2021 |
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality | 2021 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2021 |
Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Busulfan; Cyclophosphamide; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantati | 2021 |
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hum | 2021 |
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Successful Allogeneic Peripheral Blood Stem Cell Transplantation in 4 Wiskott-Aldrich Syndrome Patients.
Topics: Busulfan; Cyclosporine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Peri | 2022 |
Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Stud | 2021 |
Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults.
Topics: Adult; Blood Platelets; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Drug Admin | 2021 |
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2021 |
Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2022 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Dise | 2021 |
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2022 |
Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie
Topics: Busulfan; Cyclophosphamide; Feasibility Studies; Graft vs Host Disease; Hematologic Neoplasms; Hemat | 2021 |
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Su | 2021 |
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studi | 2017 |
Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan | 2017 |
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Gr | 2018 |
Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
Topics: Area Under Curve; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic St | 2018 |
A novel drug interaction between busulfan and blinatumomab.
Topics: Adult; Antibodies, Bispecific; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; D | 2019 |
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease | 2017 |
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclo | 2018 |
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; GATA2 Deficiency; Graft vs Host Disease; Hemat | 2018 |
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic | 2018 |
[Treatment of four cases of Fanconi anemia by allogeneic hematopoietic stem cell transplantation with low intensity conditional regimen].
Topics: Busulfan; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Tr | 2018 |
Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis.
Topics: Allografts; Antilymphocyte Serum; Busulfan; Child, Preschool; Cyclophosphamide; Disease-Free Surviva | 2018 |
A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Cystitis; Cytarabine; Cytomegalovirus Infections; Dru | 2018 |
Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Busulfan; China; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combinati | 2018 |
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; | 2019 |
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematop | 2018 |
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Gr | 2018 |
Haematopoietic stem cell transplant for hyper-IgM syndrome due to CD40 defects: a single-centre experience.
Topics: Antilymphocyte Serum; B-Lymphocytes; Busulfan; CD40 Antigens; Child, Preschool; Cyclophosphamide; Di | 2019 |
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combi | 2018 |
Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combinati | 2018 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2018 |
Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient.
Topics: Adult; Aged; Busulfan; Digestive System Diseases; Female; Graft vs Host Disease; Hematopoietic Stem | 2019 |
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera | 2019 |
[Treatment of 30 elderly patients with advanced myeloid neoplasm by allogeneic hematopoietic stem cell transplantation].
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2018 |
The study of engraftment after hematopoietic stem cell transplantation: From the presence of mixed chimerism to the development of immunological tolerance.
Topics: Antigens, CD; beta-Thalassemia; Busulfan; Cohort Studies; Cyclophosphamide; Gene Expression; Graft R | 2018 |
Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Granulomatous Disease, | 2019 |
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?
Topics: Adult; Aged; Busulfan; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic | 2019 |
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.
Topics: Adolescent; Adult; Aged; Busulfan; Female; Germany; Graft vs Host Disease; Hematopoietic Stem Cell T | 2019 |
Atypical cytological changes mimicking SIL of the uterine cervix in allogenic hematopoietic stem cell transplantation recipients treated with busulfan.
Topics: Adult; Busulfan; Cervix Uteri; Colposcopy; Diagnostic Errors; False Positive Reactions; Female; Foll | 2019 |
[Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Topics: Adult; Busulfan; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2019 |
Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide | 2013 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 2013 |
Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Gastrointestinal Tract; Gra | 2013 |
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; | 2013 |
A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Blood Group Incompatibility; Bronchiolitis Obliterans; Busulfan; Case-Contr | 2013 |
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; | 2013 |
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administ | 2013 |
Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.
Topics: Adolescent; beta-Thalassemia; Bone Marrow Cells; Busulfan; Cause of Death; Child; Child, Preschool; | 2013 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2014 |
Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia worki
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy | 2013 |
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Hos | 2014 |
An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neopla | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2013 |
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Bilirubin; Busulfan; Cell Line, Tumor; Cytokines; Female; Genotype; Glutathione T | 2014 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Specimen Collection; Busulfan; Child; Child, Pr | 2014 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Specimen Collection; Busulfan; Child; Child, Pr | 2014 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Specimen Collection; Busulfan; Child; Child, Pr | 2014 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Specimen Collection; Busulfan; Child; Child, Pr | 2014 |
Allogeneic hematopoietic stem cell transplantation for infants with idiopathic myelofibrosis.
Topics: Blood Platelets; Busulfan; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Follow-Up Stu | 2013 |
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Topics: Adult; Age Factors; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 2014 |
Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Female; Graft Surv | 2014 |
Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Cohort Studies; Cyclophosphamide; Cyclosporine; Cytome | 2014 |
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Fo | 2014 |
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft v | 2014 |
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Topics: Adolescent; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; France; Graft | 2014 |
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs | 2014 |
Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Topics: Adult; Allografts; Antilymphocyte Serum; Bronchiolitis Obliterans; Busulfan; Case-Control Studies; C | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2014 |
Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Busulfan; Databases, Factual; Disease-Free Sur | 2014 |
Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution.
Topics: Animals; B-Lymphocytes; Bone Marrow Transplantation; Busulfan; Cytostatic Agents; Female; Gastrointe | 2014 |
Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Feasibility Studies; Female; Graft vs Host Disease; Hem | 2014 |
Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Topics: Adolescent; Anemia, Sickle Cell; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; F | 2014 |
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.
Topics: Animals; Busulfan; Cyclophosphamide; Flow Cytometry; Freund's Adjuvant; Graft vs Host Disease; Hemat | 2014 |
Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neo | 2014 |
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Femal | 2014 |
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
Topics: Adolescent; Adult; Aged; BK Virus; Busulfan; Cystitis; Cytomegalovirus Infections; Female; Graft vs | 2014 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Si | 2014 |
Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cel | 2014 |
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation].
Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Ant | 2014 |
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug | 2015 |
Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child, Preschool; Gr | 2015 |
Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Diarr | 2015 |
Effectiveness and toxicity of high-dose cyclophosphamide in obese versus non-obese patients receiving allogeneic hematopoietic stem cell transplant.
Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2016 |
Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.
Topics: Adolescent; Adult; Busulfan; Cataract; Combined Modality Therapy; Dose Fractionation, Radiation; Dos | 2015 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myel | 2014 |
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Female; Graft Surviv | 2015 |
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Fe | 2015 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host D | 2015 |
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs | 2015 |
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality | 2015 |
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Dr | 2015 |
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.
Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; F | 2015 |
Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation.
Topics: Adult; Aged; Area Under Curve; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Tran | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Ch | 2015 |
[Establishment of a graft-versus-host disease mouse model for haplo-identical bone marrow transplantation with busulfan and fludarabine conditioning regimen].
Topics: Animals; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Drug Combinations; Graft vs | 2015 |
Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
Topics: Bone Marrow Cells; Busulfan; Child, Preschool; Chimerism; Combined Modality Therapy; Cyclophosphamid | 2015 |
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematopoiet | 2015 |
Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cohort Studies; Cross-Sectional Studies; Disease-Free Surviva | 2015 |
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hum | 2015 |
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantat | 2015 |
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution].
Topics: Adult; Aged; Allografts; Busulfan; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoieti | 2015 |
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclo | 2015 |
Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cel | 2015 |
HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; G | 2015 |
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Monitoring; Female; Graft vs Host Disease; Hematologic | 2016 |
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busul | 2016 |
Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Algorithms; Area Under Curve; Busulfan; Female; Gene Deletion; Genotype; Glutathi | 2015 |
Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulair
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chi-Square Distribut | 2016 |
A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.
Topics: Acute Disease; Allografts; Animals; Busulfan; Cyclophosphamide; Disease Models, Animal; Female; Graf | 2016 |
Treatment of childhood leukemia with haploidentical hematopoietic stem cell transplantation using parent as donor: a single-center study of 111 case.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft | 2015 |
[Establishment of a mouse model of acute graft-versus-host disease by busulfan combined with cyclophosphamide].
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease Models, Animal; Female; Gr | 2015 |
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survi | 2015 |
TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia.
Topics: Adolescent; Antigens, CD19; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Graft | 2016 |
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbi | 2016 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclopho | 2016 |
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male | 2016 |
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chimeri | 2016 |
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug T | 2016 |
Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Co | 2016 |
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopo | 2016 |
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hodgkin Disease; Human | 2016 |
Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update.
Topics: Adolescent; Adult; Busulfan; Child; Chimerism; Female; Graft vs Host Disease; Granulocyte Colony-Sti | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Gr | 2016 |
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclo | 2016 |
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem | 2016 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophospham | 2017 |
Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen.
Topics: Adolescent; Adult; Aged; Allografts; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; F | 2017 |
Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplanta
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 2017 |
Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.
Topics: Adolescent; Adrenoleukodystrophy; Busulfan; Child; Child, Preschool; Graft Rejection; Graft Survival | 2017 |
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Mye | 2017 |
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoieti | 2017 |
Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.
Topics: Adolescent; Adult; Busulfan; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplan | 2017 |
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Dru | 2017 |
Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2008 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chro | 2008 |
Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience.
Topics: Administration, Oral; Busulfan; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophospha | 2008 |
Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Granulocytes; Hematopoietic Stem Cell Transplantation; | 2008 |
GVHD after chemotherapy conditioning in allogeneic transplanted mice.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan | 2008 |
The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Topics: Bayes Theorem; Busulfan; Child; Computer Simulation; Cyclosporine; Drug Administration Schedule; Dru | 2008 |
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulf | 2009 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Drug Interactions; Graft vs Host Di | 2009 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Drug Interactions; Graft vs Host Di | 2009 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Drug Interactions; Graft vs Host Di | 2009 |
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Drug Interactions; Graft vs Host Di | 2009 |
Haploidentical in utero hematopoietic cell transplantation improves phenotype and can induce tolerance for postnatal same-donor transplants in the canine leukocyte adhesion deficiency model.
Topics: Animals; Busulfan; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dogs; Female; Fetal T | 2009 |
Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Evaluation; Female; Graft vs H | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine | 2009 |
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disea | 2010 |
Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran.
Topics: Acute Kidney Injury; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Prescho | 2010 |
Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2010 |
Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Chimerism; Combined Modality Therapy; Female; Graft Su | 2011 |
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
Topics: Adolescent; Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoies | 2010 |
Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclophos | 2011 |
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Foll | 2010 |
Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Case-Control Studies; | 2010 |
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; Busulfan; Child; Cyclophosphamide; Female; Fusion Proteins, bcr-abl; | 2011 |
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injec | 2011 |
Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.
Topics: Administration, Oral; Adult; Animals; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; Forc | 2011 |
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
Topics: Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Fema | 2011 |
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Dis | 2010 |
Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiet | 2010 |
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.
Topics: Age Factors; Aged; Antilymphocyte Serum; Busulfan; Comorbidity; Disease-Free Survival; Female; Graft | 2011 |
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2011 |
Effect of splenectomy on pancytopenia after a peripheral blood stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Dexamethasone; Female; Graft Survival; Graft vs Host Disease; Hem | 2011 |
Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Chronic Di | 2011 |
Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.
Topics: Busulfan; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Hematopoie | 2010 |
Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.
Topics: Animals; Antineoplastic Agents, Alkylating; Busulfan; CD8-Positive T-Lymphocytes; Cyclophosphamide; | 2010 |
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Chimerism; Cohort | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine | 2011 |
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplanta | 2011 |
Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.
Topics: Adolescent; Antigens, CD; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease | 2011 |
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chimerism; Female; Graft | 2011 |
Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chimerism; Combined Mod | 2012 |
Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cy | 2011 |
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosp | 2011 |
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
Topics: Adolescent; Age Factors; Anemia, Aplastic; Area Under Curve; Busulfan; Cyclophosphamide; Dose Fracti | 2011 |
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cohort Studies; Drug Therapy, Combination; | 2011 |
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell | 2012 |
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antily | 2011 |
[Conditioning regimen of allogeneic hematopoietic stem cell transplantation for aplastic anemia in Japan].
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; | 2011 |
Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.
Topics: Animals; Apoptosis; Bone Marrow Transplantation; Busulfan; Cell Transplantation; Cyclophosphamide; D | 2011 |
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoiet | 2012 |
Keratinocyte dysplasia in hematopoietic stem cell transplantation recipients in the day-28-to-84 posttransplantation period.
Topics: Biopsy; Busulfan; Case-Control Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Trans | 2012 |
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Hos | 2011 |
The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free | 2012 |
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
Topics: Adolescent; Adult; Busulfan; Chi-Square Distribution; Disease-Free Survival; Drug Therapy, Combinati | 2012 |
Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; H | 2012 |
Allo-SCT using BU, CY and melphalan for children with AML in second CR.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohor | 2013 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host | 2013 |
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host D | 2013 |
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; H | 2013 |
[Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hemato | 2002 |
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; G | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2002 |
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2003 |
BU-CTX(2) as conditioning regimen for allogeneic hematopoietic stem cell transplantation in sixty patients with leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Co | 2002 |
Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem | 2002 |
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive | 2002 |
Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follo | 2003 |
Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Fetal Blood; Gastroenteritis; Graft vs Host Disease; H | 2003 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi | 2003 |
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Dis | 2003 |
The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Busulfan; Drug Interactions; Female; Graft vs Host Disease; Hematopoietic Stem Ce | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Dis | 2003 |
Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic S | 2003 |
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Topics: Adult; Aged; Busulfan; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graf | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; | 2004 |
Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.
Topics: Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antig | 2003 |
Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.
Topics: Bone Marrow Transplantation; Busulfan; Chediak-Higashi Syndrome; Child, Preschool; Graft vs Host Dis | 2003 |
Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST).
Topics: Adenoviridae; Adolescent; Adult; Aged; Antibodies, Viral; Busulfan; Child; Child, Preschool; Cystiti | 2003 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Dis | 2004 |
Cyclosporin A-associated status epilepticus related to hematopoietic stem cell transplantation for thalassemia.
Topics: Anticonvulsants; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease Suscepti | 2003 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Thera | 2004 |
Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia.
Topics: Adolescent; Adult; Body Mass Index; Busulfan; Cyclophosphamide; Female; Genotype; Graft vs Host Dise | 2004 |
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosupp | 2004 |
Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Transplantation; Busulfan; Dose | 2004 |
[Reduced intensity stem cell transplantation for metastatic renal cell carcinoma].
Topics: Adult; Busulfan; Carcinoma, Renal Cell; Cyclosporine; Fatal Outcome; Female; Graft vs Host Disease; | 2004 |
Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease--comparison with a busulphan-cyclophosphamide regimen.
Topics: Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Graft vs Hos | 2004 |
Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre.
Topics: Adolescent; Airway Obstruction; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyto | 2004 |
Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: the preliminary experience in Taiwan.
Topics: Adolescent; Busulfan; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2004 |
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
Topics: Aged; Busulfan; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neop | 2004 |
Conditioning regimens including high-dose busulfan cause a high incidence of transplant-related mortality after myeloablative stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Healt | 2004 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follo | 2004 |
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Topics: Adult; Antilymphocyte Serum; Blood Transfusion, Autologous; Busulfan; Disease-Free Survival; Female; | 2005 |
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamid | 2005 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation.
Topics: Adolescent; Adult; Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Child; Child, Pr | 2005 |
Extracorporeal photo-chemotherapy for graft-versus-host disease.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pho | 2005 |
Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematologic | 2005 |
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Do | 2005 |
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Topics: Adolescent; Adult; Blast Crisis; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free S | 2006 |
Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2006 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical | 2005 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Th | 2006 |
Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation.
Topics: Antimetabolites, Antineoplastic; Busulfan; Cyclophosphamide; Graft vs Host Disease; Graft vs Leukemi | 2005 |
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2006 |
The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 2006 |
Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Topics: Acute Disease; Adolescent; Adult; Biomarkers; Busulfan; Child; Child, Preschool; Cyclophosphamide; F | 2006 |
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cycl | 2006 |
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Fibrosis; Graf | 2006 |
Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Disease-Free Survival; Evaluation Studies as Topic; Female; Graft | 2006 |
Serial transplantation resulting in tolerance to an unrelated cord blood graft.
Topics: Antilymphocyte Serum; B-Lymphocytes; Bone Marrow Transplantation; Busulfan; Chimerism; Cord Blood St | 2006 |
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; | 2006 |
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Fe | 2006 |
Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; C | 2006 |
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft S | 2006 |
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Di | 2006 |
Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Topics: Animals; Animals, Congenic; Antibodies, Monoclonal; Apoptosis; Bone Marrow Transplantation; Busulfan | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Su | 2006 |
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Surviv | 2007 |
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transp | 2006 |
Alloimmune hepatitis following peripheral stem cell transplantation.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Busulfan; Cyclophosphamide; Female; Graft vs Host Dis | 2007 |
Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2007 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antig | 2007 |
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Topics: Adolescent; Adult; Busulfan; Child; Disease-Free Survival; Female; Graft Survival; Graft vs Host Dis | 2007 |
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematol | 2007 |
Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Graft Survival; Graft vs Host Disease; H | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Prot | 2007 |
Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free | 2006 |
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cy | 2007 |
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neop | 2007 |
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infectio | 2007 |
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs | 2007 |
[Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hum | 2007 |
Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft vs Ho | 2007 |
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplas | 2007 |
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female | 2007 |
Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antilymphocyte Serum; Busulfan; Child; Disease-Free Survival; Female | 2007 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human | 2007 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Gr | 2008 |
Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; | 2007 |
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
Topics: Adolescent; Adult; Aged; Aspergillosis; Bacteremia; Busulfan; Catheterization, Central Venous; Chron | 2008 |
Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Topics: Acute Disease; Adolescent; beta-Thalassemia; Blood Platelets; Bone Marrow Transplantation; Busulfan; | 2008 |
Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Fibrinolytic Agents; Graft vs Host Disease; H | 2008 |
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survi | 2008 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Dis | 2008 |
Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Combine | 1983 |
Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Topics: Actuarial Analysis; Adolescent; Adult; Bleomycin; Bone Marrow Transplantation; Busulfan; Child; Chil | 1995 |
Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.
Topics: Adolescent; Adult; Alopecia; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, | 1995 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr | 1995 |
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantati | 1995 |
Treatment of Omenn syndrome by bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Reje | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycl | 1995 |
The effects of bone marrow transplantation on pulmonary function in children.
Topics: Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegalov | 1994 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; | 1994 |
Bone marrow transplantation in Iran.
Topics: Adolescent; Adult; Anemia, Aplastic; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child; | 1994 |
Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinop | 1994 |
Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulf | 1993 |
Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice.
Topics: Acute Disease; Animals; Busulfan; Cell Transplantation; Chronic Disease; Cyclophosphamide; Cytokines | 1994 |
Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, | 1994 |
Factors affecting hair regrowth after bone marrow transplantation.
Topics: Adolescent; Adult; Age Factors; Alopecia; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan | 1993 |
Bronchiolitis obliterans after bone marrow transplantation: the effect of preconditioning.
Topics: Adult; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Cyclophosphamide; Female; Gr | 1993 |
Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; | 1993 |
Bone marrow transplantation in thalassemia. The Cagliari team experience.
Topics: Adolescent; Adult; beta-Thalassemia; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Chi | 1993 |
Bone marrow transplantation in class 2 thalassemia patients.
Topics: Adolescent; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyc | 1993 |
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; | 1993 |
Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1993 |
Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Chromosome Aberra | 1993 |
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Pres | 1996 |
The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; B-Lymphocytes; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cell Survival; | 1996 |
Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Disease | 1996 |
Study of hematopoietic progenitor cells in thalassemia after bone marrow transplantation.
Topics: beta-Thalassemia; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cells, Cultured; Child; Child, | 1995 |
Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience.
Topics: Adolescent; Adult; Blood Donors; Busulfan; Child; Child, Preschool; Cyclosporine; Erythropoietin; Fe | 1996 |
Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topics: Actuarial Analysis; Acute Disease; Adult; Anti-Infective Agents; Bone Marrow Transplantation; Busulf | 1996 |
High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chimera; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; He | 1996 |
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood | 1996 |
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child, | 1996 |
Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
Topics: Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinophilia; Graft vs Hos | 1996 |
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow Transplanta | 1996 |
A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female | 1996 |
Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1996 |
Neurologic complications after allogeneic bone marrow transplantation.
Topics: Bone Marrow Transplantation; Brain Abscess; Busulfan; Cerebrovascular Disorders; Cyclosporine; Encep | 1996 |
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclophosphamide; Female; Graft Reject | 1997 |
Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Topics: Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Graft | 1998 |
Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1998 |
Big BU/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1998 |
Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1998 |
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin | 1998 |
Primary Sjögren's syndrome followed by chronic myelogenous leukemia: a case report with a ten year history.
Topics: Adult; Antibodies, Antinuclear; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Fatal Outco | 1998 |
High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; | 1998 |
Allogeneic BMT for haematological disorders: single centre experience of University Hospital Bratislava.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1998 |
Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cycloph | 1999 |
Impact of previous high-dose therapy on outcome after allografting for multiple myeloma.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Female; G | 1999 |
The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclo | 1999 |
Primary renal aspergillosis: extremely uncommon presentation in patients treated with bone marrow transplantation.
Topics: Aspergillosis; Aspergillus; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; F | 1999 |
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Combined Mo | 1999 |
Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antilymphocyte Serum; Bone Marrow Transplantati | 1999 |
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2000 |
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Topics: Adult; Antineoplastic Agents; Arthritis, Psoriatic; Autoimmunity; Busulfan; Graft vs Host Disease; G | 2000 |
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; G | 2000 |
Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Prescho | 2000 |
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; B | 2000 |
The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cycloph | 2000 |
Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2000 |
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow- | 2001 |
Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Antilymphocyte Serum; Busulfan; Cladribine; Cyclosporine; Graft Survival; Graft vs Host Disease; Hem | 2001 |
Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female | 2001 |
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell | 2001 |
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedu | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; | 2002 |
Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Bone Marrow Cells; Busulfan; Cell Count; Cyclophosphamide; Female; Graft vs Host Diseas | 2001 |
[The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
Topics: Acute Disease; Adult; Busulfan; Cyclophosphamide; Cystitis; Disease-Free Survival; Esophagitis; Fema | 2000 |
Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1992 |
Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1992 |
Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning.
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Fe | 1992 |
Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1992 |
Marrow transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cy | 1992 |
Marrow transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule | 1992 |
Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyc | 1992 |
Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cyclophosphamide | 1992 |
Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow T | 1992 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclopho | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Gr | 1991 |
Bone marrow transplantation in thalassemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1991 |
Bone marrow transplantation from unrelated donors for genetic diseases following conditioning with Busulphan and Cyclophosphamide.
Topics: Actuarial Analysis; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide | 1991 |
Bone marrow transplantation in sickle cell anaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Bone Marrow Transplantation; Busulfan; Child; Child, Prescho | 1991 |
Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth.
Topics: Adolescent; Adult; Alopecia; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; F | 1991 |
Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Bone Marrow Transplantation; Busulfan; Cyclophosphami | 1991 |
Busulfan disposition in children.
Topics: Administration, Oral; Bone Marrow Transplantation; Busulfan; Child, Preschool; Dose-Response Relatio | 1990 |
Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1990 |
CMV infections in thalassemia patients after BMT.
Topics: Adolescent; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclo | 1989 |
The role of busulfan/cyclophosphamide regimens in allogeneic and autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cycl | 1989 |
New conditioning regimens for high risk marrow transplants.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1989 |
Myeloablative conditioning for marrow transplantation in myelodysplastic syndromes and paroxysmal nocturnal haemoglobinuria.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Bone Marrow Transplantation; Busulfan | 1989 |
Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease.
Topics: Animals; Autoimmune Diseases; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporins; | 1989 |
Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Graft vs Host D | 1989 |
Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule | 1989 |
Bone marrow transplantation in thalassemia. The experience of Pesaro.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft | 1989 |
Bone marrow transplantation for thalassaemia--a preliminary report from the International Bone Marrow Transplant Registry.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Female; Graft vs Host | 1989 |
Bone marrow transplantation for thalassemia in Pescara.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Female; Graft vs Host Di | 1989 |
Bone marrow transplantation for thalassaemia: Westminster Children's Hospital and United Kingdom experience.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; England; Graft vs | 1989 |
Bone marrow transplantation (BMT) for thalassemia major (TM). The French experience.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; France; Graft Reje | 1989 |
Patterns of graft rejection after bone marrow transplant in thalassemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft | 1989 |
Liver iron stores before and after bone marrow transplantation for thalassemia.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Deferoxamine; Ferritins; Graft vs Ho | 1989 |
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1989 |
Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Dr | 1989 |
Immunologic recovery in thalassemic marrow graft recipients following high-dose busulfan and cyclophosphamide.
Topics: Antigens, Differentiation, T-Lymphocyte; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cy | 1988 |
Marrow transplantation for thalassaemia following busulphan and cyclophosphamide.
Topics: Actuarial Analysis; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Com | 1985 |
[Bone marrow transplantation in chronic myeloid leukemia. Influence of gnotobiotic measures, especially antiviral prophylaxis].
Topics: Acyclovir; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclos | 1986 |
Diminishing morbidity and mortality of bone marrow transplantation.
Topics: Administration, Oral; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophospha | 1986 |
Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 1988 |
Syngeneic graft-versus-host disease: failure of autoregulation in self/non-self discrimination.
Topics: Animals; Autoimmune Diseases; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Graft vs Host | 1988 |
Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Infa | 1988 |
Bone-marrow transplantation for thalassaemia.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Graft vs Host Disease; Humans; Infant; Info | 1986 |
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment.
Topics: Adult; Antilymphocyte Serum; Base Sequence; Blood Grouping and Crossmatching; Bone Marrow Transplant | 1985 |
Use of donors sharing one genetic haplotype for bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporins; Dose-Response Relationship, I | 1985 |
Runt diseases as a model of immunosuppressive therapy.
Topics: Aminopterin; Animals; Busulfan; Cyclophosphamide; Dactinomycin; Graft vs Host Disease; Immunosuppres | 1966 |
[The influence of age and experimentally-induced disease on the tolerance of cytostatically-active materials in mice].
Topics: Age Factors; Aminopterin; Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; | 1967 |